Mylan II B.V. 10-K 27 Feb 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 22, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	MYLAN N.V.
Entity Central Index Key	1,623,613
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 18,508,277,080
Entity Common Stock, Shares Outstanding		515,949,946
Entity Shell Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 388.1	$ 292.1
Accounts receivable, net	2,881	3,612.4
Inventories	2,580.2	2,542.7
Prepaid expenses and other current assets	518.4	766.1
Total current assets	6,367.7	7,213.3
Property, plant and equipment, net	2,170.2	2,339.1
Intangible assets, net	13,664.6	15,245.8
Goodwill	9,747.8	10,205.7
Deferred income tax benefit	572.2	496.8
Other assets	212.4	305.6
Total assets	32,734.9	35,806.3
Current liabilities:
Trade accounts payable	1,617	1,452.5
Short-term borrowings	1.9	46.5
Income taxes payable	121.5	112.9
Current portion of long-term debt and other long-term obligations	699.8	1,808.9
Other current liabilities	2,147.6	2,964.5
Total current liabilities	4,587.8	6,385.3
Long-term debt	13,161.2	12,865.3
Deferred income tax liability	1,722	2,012.4
Other long-term obligations	1,096.8	1,235.7
Total liabilities	20,567.8	22,498.7
Mylan N.V. shareholders’ equity
Ordinary shares — nominal value €0.01 per share as of December 31, 2016 and December 31, 2015	6	6
Additional paid-in capital	8,591.4	8,586
Accumulated other comprehensive loss	(1,441.3)	(361.2)
Retained earnings	6,010.7	5,644.5
Stockholders Equity Parent Before Treasury Stock	13,166.8	13,875.3
Less: Treasury stock — at cost	999.7	567.7
Total equity	12,167.1	13,307.6
Total liabilities and equity	$ 32,734.9	$ 35,806.3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Millions	Dec. 31, 2018USD ($)shares	Dec. 31, 2018€ / shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2017€ / shares
Ordinary shares, par value, in USD per share | € / shares		€ 0.01		€ 0.01
Ordinary shares, number of shares authorized | shares	1,200,000,000		1,200,000,000
Total equity | $	$ 12,167.1		$ 13,307.6
Common Stock
Shares issued | shares	539,289,665		537,902,426
Total equity | $	$ 6		$ 6
Treasury Stock
Shares issued | shares	23,490,867		13,695,251
Total equity | $	$ (999.7)		$ (567.7)

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Net sales	$ 11,268.7	$ 11,760	$ 10,967.1
Total revenues	11,433.9	11,907.7	11,076.9
Cost of sales	7,432.3	7,124.6	6,379.9
Gross profit	4,001.6	4,783.1	4,697
Operating expenses:
Research and development	704.5	783.3	826.8
Selling, general and administrative	2,441	2,575.7	2,498.5
Litigation settlements and other contingencies, net	(49.5)	(13.1)	672.5
Total operating expenses	3,096	3,345.9	3,997.8
Earnings from operations	905.6	1,437.2	699.2
Interest expense	542.3	534.6	454.8
Other expense (income), net	64.9	(0.4)	122.7
Earnings before income taxes and noncontrolling interest	298.4	903	121.7
Income tax provision	(54.1)	207	(358.3)
Net earnings	$ 352.5	$ 696	$ 480
Earnings per ordinary share attributable to Mylan N.V. ordinary shareholders
Basic (in USD per share)	$ 0.69	$ 1.30	$ 0.94
Diluted (in USD per share)	$ 0.68	$ 1.30	$ 0.92
Weighted average ordinary shares outstanding:
Basic	514.5	534.5	513
Diluted	516.5	536.7	520.5
Other
Revenues:
Total revenues	$ 165.2	$ 147.7	$ 109.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net earnings	$ 352.5	$ 696	$ 480
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(3.8)	3.8	21.4
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax (benefit) provision	(24.1)	12.8	5
Other comprehensive (loss) earnings, net of tax	(1,072.6)	1,902.5	(499.4)
Comprehensive earnings	(720.1)	2,598.5	(19.4)
Cash flow hedging relationships
Other comprehensive (loss) earnings, before tax:
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(79.2)	52.7	(31.2)
Net Investment Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	111.6	(238.4)	(1.8)
Mylan N.V.
Net earnings	352.5	696	480
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(3.8)	3.8	21.4
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax (benefit) provision	(24.1)	12.8	5
Other comprehensive (loss) earnings, net of tax	(1,072.6)	1,902.5	(499.4)
Comprehensive earnings	(720.1)	2,598.5	(19.4)
Mylan N.V. | Cash flow hedging relationships
Other comprehensive (loss) earnings, before tax:
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(79.2)	52.7	(31.2)
Mylan N.V. | Net Investment Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	111.6	(238.4)	(1.8)
Foreign Currency Translation Adjustment
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(1,125.2)		(507.4)
Defined Pension Plan Items
Other comprehensive (loss) earnings, before tax:
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans			(21.4)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Cash flow hedging relationships
Other comprehensive (loss) earnings, before tax:
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(79.2)		(31.2)
Gains and Losses on Marketable Securities
Other comprehensive (loss) earnings, before tax:
Net unrealized (loss) gain on marketable securities			24.6
AOCI Attributable to Parent [Member]
Other comprehensive (loss) earnings, before tax:
Other comprehensive (loss) earnings, before tax		1,915.3	(494.4)
Other comprehensive (loss) earnings, net of tax	(1,072.6)	1,902.5	(499.4)
Reclassification out of Accumulated Other Comprehensive Income | AOCI Attributable to Parent [Member]
Other comprehensive (loss) earnings, before tax:
Income tax (benefit) provision	$ (24.1)	$ 12.8	$ 5

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Loss	Noncontrolling Interest
Balance at Dec. 31, 2015	$ 9,765.8	$ 5.5	$ 7,128.6	$ 4,462.1	$ (67.5)	$ (1,764.3)	$ 1.4
Balance (in shares) at Dec. 31, 2015		491,928,095			1,311,193
Net earnings	480			480			0
Other comprehensive (loss) earnings, net of tax	(499.4)					(499.4)
Stock options exercised, net of shares tendered for payment	13.6		13.6		$ 0
Stock options exercised, net of shares tendered for payment (in shares)		1,283,580			0
Stock compensation expense	88.9		88.9
Issuance of restricted stock, net of shares withheld	(14.2)		(14.2)
Stock Issued During Period, Value, Other		$ 0.2	(0.2)
Issuance of restricted stock, net of shares withheld (in shares)					0
Tax benefit of stock option plans	1.2		1.2
Issuance of Ordinary Shares to Mylan N.V.		16,979,984
Stock Issued During Period, Shares, Acquisitions		26,447,632
Stock Issued During Period, Value, Acquisitions	1,281.7	$ 0.3	1,281.4
Other	5		0		$ 0
Balance at Dec. 31, 2016	11,117.6	$ 6	8,499.3	4,942.1	$ (67.5)	(2,263.7)	1.4
Balance (in shares) at Dec. 31, 2016		536,639,291			1,311,193
Net earnings	696			696			0
Other comprehensive (loss) earnings, net of tax	1,902.5					1,902.5
Common stock share repurchase	$ (500.2)				$ (500.2)
Common stock share repurchase (in shares)	(12,400,000)				(12,400,000)
Stock options exercised, net of shares tendered for payment	$ 17.8		17.8
Stock options exercised, net of shares tendered for payment (in shares)		1,263,135
Stock compensation expense	74.7		74.7
Tax benefit of stock option plans	(5.8)		(5.8)
Stock Issued During Period, Value, Acquisitions	0
Other				(6.4)			(1.4)
Balance at Dec. 31, 2017	13,307.6	$ 6	8,586	5,644.5	$ (567.7)	(361.2)	0
Balance (in shares) at Dec. 31, 2017		537,902,426			13,695,251
Net earnings	352.5			352.5
Other comprehensive (loss) earnings, net of tax	(1,072.6)					(1,072.6)
Common stock share repurchase	(432)				$ 432
Common stock share repurchase (in shares)					(9,800,000)
Stock options exercised, net of shares tendered for payment (in shares)		1,387,239
Stock compensation expense	(3.3)		(3.3)
Issuance of restricted stock, net of shares withheld	17.7		17.7
Tax benefit of stock option plans	(9)		(9)
Stock Issued During Period, Value, Acquisitions	0
Other	(6.2)			(13.7)		7.5
Balance at Dec. 31, 2018	$ 12,167.1	$ 6	$ 8,591.4	$ 6,010.7	$ (999.7)	$ (1,441.3)	$ 0
Balance (in shares) at Dec. 31, 2018		539,289,665			23,490,867

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net earnings	$ 352.5	$ 696	$ 480
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	2,109.9	1,805.8	1,523
Deferred income tax benefit	(264.3)	(111.4)	(609.5)
Litigation settlements and other contingencies, net	(31.6)	(40.1)	597.7
Unrealized losses on acquisition-related foreign currency derivatives	0	0	128.6
Loss from equity method investments	78.7	58	112.8
Stock-based compensation expense	(3.3)	74.7	88.9
Write off of financing fees	2.7	3.2	35.8
Other non-cash items	286.1	261	499.4
Changes in operating assets and liabilities:
Accounts receivable	340.1	(162.2)	(131.8)
Inventories	(547.6)	(129.5)	(279.3)
Trade accounts payable	220.3	14.4	87.7
Income taxes	(23.9)	15.2	37.5
Other operating assets and liabilities, net	(177.9)	(420.3)	(523.6)
Net cash provided by operating activities	2,341.7	2,064.8	2,047.2
Cash flows from investing activities:
Cash paid for acquisitions, net	(65.9)	(167)	(6,481.9)
Capital expenditures	(252.1)	(275.9)	(390.4)
Payments for product rights and other, net	(943.5)	(620.3)	(360.2)
Cash paid for Meda's unconditional deferred payment	0	0	(308)
Settlement of acquisition-related foreign currency derivatives	0	0	(128.6)
Proceeds from sale of assets and subsidiaries	29.3	86.7	0
Purchase of marketable securities	(63.4)	(96.5)	(30.2)
Proceeds from sale of marketable securities	85.2	96.6	21.5
Net cash used in investing activities	(1,210.4)	(976.4)	(7,677.8)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	2,577.9	876.1	11,752.2
Payment of long-term debt	(3,165.2)	(2,232.7)	(6,296.3)
Payment of financing fees	(21.4)	(10.1)	(112.6)
Change in short-term borrowings, net	(44.4)	(2.9)	40.8
Purchase of common stock	(432)	(500.2)	0
Proceeds from exercise of stock options	17.8	17.8	13.8
Taxes paid related to net share settlement of equity awards	(10.1)	(7.4)	(17.5)
Contingent consideration payments	(11.9)	(26.1)	(35.5)
Acquisition of noncontrolling interest	(0.6)	(7.5)	(1.1)
Other items, net	(1)	(0.1)	0.8
Net cash (used in) provided by financing activities	(1,090.9)	(1,893.1)	5,344.6
Effect on cash of changes in exchange rates	(21)	27.6	(9.6)
Net increase (decrease) in cash, cash equivalents and restricted cash	19.4	(777.1)	(295.6)
Cash, cash equivalents and restricted cash — beginning of period	369.9	1,147	1,442.6
Cash, cash equivalents and restricted cash — end of period	389.3	369.9	1,147
Non-cash transactions:
Contingent consideration		4	16
Ordinary shares issued for acquisition	0	0	1,281.7
Cash paid during the period for:
Income taxes	228.6	285.7	285.6
Interest	460.8	474	357.2
Other current liabilities
Non-cash transactions:
Contingent consideration	0	4	16
Retained Earnings [Member]
Cash flows from operating activities:
Net earnings	$ 352.5	$ 696	$ 480

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Mylan N.V. and its subsidiaries (collectively, the “Company,” “ Mylan ,” “our” or “we”) are engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (“OTC”) pharmaceutical products for resale by others and active pharmaceutical ingredients (“API”) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Our North America segment comprises our operations in the United States (“U.S.”) and Canada. Our Europe segment encompasses our operations across 35 countries within the region, including France, Italy, Germany, the United Kingdom (the “U.K.”) and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including our operations in Japan, Australia, China, Brazil, Russia, India, South Africa, and certain markets in the Middle East and Southeast Asia. Our API business is conducted through Mylan Laboratories Limited (“ Mylan India ”), which is included within our Rest of World segment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation. The Consolidated Financial Statements include the accounts of Mylan and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions. Noncontrolling interests in the Company’s subsidiaries are generally recorded net of tax as net earnings attributable to noncontrolling interests. Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates. Foreign Currencies. The Consolidated Financial Statements are presented in U.S. Dollars, the reporting currency of Mylan . Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the Consolidated Statements of Operations and Cash Flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the Consolidated Balance Sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the Consolidated Statements of Operations . Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase. Debt and Equity Securities. On January 1, 2018, the Company adopted Accounting Standards Update 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ ASU 2016-01”) which requires all equity securities to be measured at fair value with changes recognized through net income (loss). Debt securities classified as available-for-sale are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net , in the Consolidated Statements of Operations . Debt securities, and marketable equity securities prior to January 1, 2018, classified as trading securities are valued using quoted stock prices from public exchanges, the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date. Realized and unrealized gains and losses are included in other expense, net , in the Consolidated Statements of Operations . Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable. Mylan invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties. Inventories. Inventories are stated at the lower of cost or market, with cost principally determined by the first-in, first-out method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories. Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives ( 3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years . Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The cost to acquire a business is allocated to the underlying net assets of the acquired business in proportion to their respective fair values. Amounts allocated to acquired in-process research and development (“IPR&D”) are capitalized at the date of acquisition and are not amortized. As products in development are approved for sale, amounts are allocated to product rights and licenses and amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Purchases of developed products and licenses that are accounted for as an asset acquisition are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value then there is no impairment recognized. If the carrying value recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value is less than the carrying value of the assets being tested in an amount of the difference. Contingent Consideration. Mylan records contingent consideration resulting from business acquisitions at fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as a charge (credit) to litigation settlements and other contingencies, net within the Consolidated Statements of Operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations. Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on the discounted cash flows. Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations. Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. Mylan Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of the Company, also has a $400 million accounts receivable facility (“Receivables Facility”), which will expire in March 2019. Revenue Recognition. On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”) using the modified retrospective method applied to those contracts which were not completed as of the date of adoption. Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605 Revenue Recognition (“ASC 605”). Under ASC 605, the Company recognized net sales when title and risk of loss passed to its customers and when provisions for estimates, as described below, were reasonably determinable. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). The following briefly describes the nature of our provisions for variable consideration and how such provisions are estimated: • Chargebacks : the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Mylan will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels. • Rebates, promotional programs and other sales allowances : this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. • Returns : consistent with industry practice, Mylan maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. • Governmental rebate programs : government reimbursement programs include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. Also, this provision includes price reductions that are mandated by law outside of the U.S. Wholesaler and distributor inventory levels of our products can fluctuate throughout the year due to the seasonality of certain products, the timing of product demand and other factors. Such fluctuations may impact the comparability of our net sales between periods. Consideration received from licenses of intellectual property is recorded as revenue. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenue in the Consolidated Statements of Operations. Research and Development. Research and development (“R&D”) expenses are charged to operations as incurred. Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted. Earnings per Ordinary Share. Basic earnings per ordinary share is computed by dividing net earnings attributable to Mylan N.V. ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share is computed by dividing net earnings attributable to Mylan N.V. ordinary shareholders by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive. On August 5, 2016 , in conjunction with its acquisition of Meda AB (publ.) (“ Meda ”), the Company issued approximately 26.4 million Mylan N.V. ordinary shares to Meda shareholders. The impact of the issuance of these ordinary shares is included in the calculation of basic earnings per share. The weighted average impact for the year ended December 31, 2016, was approximately 10.8 million ordinary shares. The Company was authorized to repurchase up to $1 billion of the Company’s ordinary shares under its repurchase program that was previously approved by the Company's Board of Directors and announced on November 16, 2015, but was not obligated to acquire any particular amount of ordinary shares. During 2018 , the Company repurchased approximately 9.8 million ordinary shares at a cost of approximately $432.0 million . In 2017 , the Company repurchased approximately 12.4 million ordinary shares at a cost of approximately $500.2 million , and in 2016 , no ordinary shares were repurchased. On September 15, 2008, concurrent with the sale of $575 million aggregate principal amount of Cash Convertible Notes due 2015, Mylan Inc. entered into convertible note hedge and warrant transactions with certain counterparties. On April 15, 2016, in connection with the expiration and settlement of the warrants, the Company issued approximately 17.0 million Mylan N.V. ordinary shares. The impact of the issuance of these ordinary shares is included in the calculation of basic earnings per share from the date of issuance. The dilutive impact of the warrants, prior to settlement, is included in the calculation of diluted earnings per ordinary share based upon the average market value of the Company’s ordinary shares during the period as compared to the exercise price. For the year ended December 31, 2016, warrants included in the calculation of diluted earnings per ordinary share were 4.9 million . Basic and diluted earnings per ordinary share attributable to Mylan N.V. are calculated as follows: Year Ended December 31, (In millions, except per share amounts) 2018 2017 2016 Basic earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Basic earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.69 $ 1.30 $ 0.94 Diluted earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Share-based awards and warrants 2.0 2.2 7.5 Total dilutive shares outstanding 516.5 536.7 520.5 Diluted earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.68 $ 1.30 $ 0.92 Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2018 , 2017 and 2016 but were not included in the computation of diluted earnings per ordinary share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted ordinary shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 8.9 million , 8.5 million and 7.8 million shares for the years ended December 31, 2018 , 2017 and 2016 , respectively. Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the Consolidated Statements of Operations over the vesting period. Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the Consolidated Balance Sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the Consolidated Statements of Operations within other expense, net . Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions. The Company uses derivative financial instruments for the purpose of hedging foreign currency and interest rate exposures, which exist as part of ongoing business operations, or to hedge cash, and have been used to hedge share payments required on conversion of issued convertible notes. In addition, the Company has designated certain long-term debt instruments as net investment hedges. The Company carries derivative instruments on the Consolidated Balance Sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. Recent Accounting Pronouncements. Accounting Standards Issued Not Yet Adopted In November 2018, the FASB issued Accounting Standards Update 2018-18 (“ASU 2018-18”), Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606 . The amendments in ASU 2018-18 make targeted improvements to U.S. GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-14 (“ASU 2018-14”), Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 removes certain disclosures that are not considered cost beneficial, clarifies certain required disclosures and added additional disclosures. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2020 with early adoption in any interim period permitted. The amendments in ASU 2018-14 would need to be applied on a retrospective basis. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which modifies the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. The Company does not believe the impact of the adoption of this guidance will have a material impact on its consolidated financial statements and disclosures. In February 2018, the FASB issued Accounting Standards Update 2018-02, Income Statement - Reporting Comprehensive Income , (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the newly enacted federal corporate income tax rate under the comprehensive tax legislation enacted by the U.S. government on December 22, 2017 commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The amount of the reclassification would be the difference between the historical corporate income tax rate and the newly enacted 21% corporate income tax rate. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2018 with early adoption in any interim period permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (Topic 842) which supersedes FASB Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In July 2018, the FASB issued Accounting Standards Update 2018-10, Codification Improvements to Topic 842 (Leases) , and Accounting Standards Update 2018-11, Leases (Topic 842), Targeted Improvements , which provide (i) narrow amendments to clarify how to apply certain aspects of the new lease standard, (ii) entities with an additional transition method to adopt the new standard, and (iii) lessors with a practical expedient for separating components of a contract. In December 2018, the FASB issued Accounting Standards Update 2018-20, Leases (Topic 842): Narrow-Scope Improvements for Lessors, which provides certain narrow-scope improvements to Topic 842 as it relates to lessors. All Accounting Standards Updates related to Topic 842 will be effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is in the process of finalizing the analysis of its lease portfolio, implementing systems and processes and updating its accounting policies to comply with Topic 842. Based on work completed to date, the Company expects to recognize upon adoption an initial right-of-use asset and lease liability on its consolidated balance sheet of approximately $220 million to $260 million. Adoption of New Accounting Standards In October 2018, the FASB issued Accounting Standards Update 2018-16 (“ASU 2018-16”), Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. ASU 2018-16 permits the OIS rate based on SOFR as a U.S. benchmark interest rate for hedge accounting purposes under Topic 815. ASU 2018-16 will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and is required to be adopted in conjunction with ASU 2017-12 (as defined below) on a prospective basis. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures. In August 2017, the FASB issued Accounting Standards Update 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The objective of this update is to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The amendments in this update also make certain targeted improvements to simplify the application of the hedge accounting guidance in current U.S. GAAP based on feedback received from preparers, auditors, users, and other stakeholders. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted, including adoption in any interim period. The Company elected to early adopt this guidance as of January 1, 2018 and applied it on a prospective basis. Upon adoption, the Company recorded a cumulative effect adjustment. In May 2017, the FASB issued Accounting Standards Update 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”), which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions and classification of the awards are the same immediately before and after the

Acquisitions and Other Transact

Acquisitions and Other Transactions	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Acquisitions and Other Transactions	Acquisitions and Other Transactions Apicore Inc. On October 3, 2017, the Company completed the acquisition of Apicore, Inc. (“Apicore”), a U.S. based developer and manufacturer of API for approximately $174.9 million , net of cash acquired, which includes estimated contingent consideration of approximately $4.0 million related to the potential $15.0 million payment contingent on the achievement of certain 2017 financial results of the acquired business. As of December 31, 2017, the contingent consideration liability was zero as Apicore did not achieve the financial results that would have triggered the contingent consideration payment. The allocation of the $174.9 million purchase price to the assets acquired and liabilities assumed for this business is as follows: (In millions) Current assets (net of cash acquired) $ 6.5 Identified intangible assets 121.0 Goodwill 92.2 Other assets 1.9 Total assets acquired 221.6 Current liabilities (4.1 ) Deferred tax liabilities (40.9 ) Other non-current liabilities (1.7 ) Net assets acquired $ 174.9 The acquisition of Apicore added a diversified portfolio of API products to the Company’s existing portfolio. The identified intangible assets of $121.0 million are comprised of product rights and licenses with a weighted average useful life of seven years and includes IPR&D with a fair value of $9.0 million at the date of the acquisition. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $92.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was allocated to the North America segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the years ended December 31, 2017 and 2016. Meda AB On February 10, 2016 , the Company issued an offer announcement under the Nasdaq Stockholm’s Takeover Rules and the Swedish Takeover Act setting forth a public offer to the shareholders of Meda to acquire all of the outstanding shares of Meda (the “ Offer ”), with an enterprise value, including the net debt of Meda , of approximately Swedish krona (“SEK” or “kr”) 83.6 billion (based on a SEK/USD exchange rate of 8.4158 ) or $9.9 billion at announcement. On August 2, 2016 , the Company announced that the Offer was accepted by Meda shareholders holding an aggregate of approximately 343 million shares, representing approximately 94% of the total number of outstanding Meda shares, as of July 29, 2016 , and the Company declared the Offer unconditional. On August 5, 2016 , settlement occurred with respect to the Meda shares duly tendered by July 29, 2016 and, as a result, Meda became a controlled subsidiary of the Company. Pursuant to the terms of the Offer, each Meda shareholder that duly tendered Meda shares into the Offer received at settlement (1) in respect of 80% of the number of Meda shares tendered by such shareholder, 165kr in cash per Meda share, and (2) in respect of the remaining 20% of the number of Meda shares tendered by such shareholder, 0.386 of the Company’s ordinary shares per Meda share (subject to treatment of fractional shares as described in the offer document published on June 16, 2016). The non-tendered shares were required to be acquired for cash through a compulsory acquisition proceeding, in accordance with the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)). The compulsory acquisition proceeding price accrued interest as required by the Swedish Companies Act. Meda’s shares were delisted from the Nasdaq Stockholm exchange on August 23, 2016. On November 1, 2016, the Company made an offer to the remaining Meda shareholders to tender all their Meda shares for cash consideration of 161.31kr per Meda share to provide such remaining shareholders with an opportunity to sell their shares in Meda to the Company in advance of the automatic acquisition of their shares for cash in connection with the compulsory acquisition proceeding. At the end of November 2016, Mylan completed the acquisition of approximately 19 million Meda shares duly tendered for aggregate cash consideration of approximately $330.3 million . In March 2017, the Company received full legal ownership to the remaining non-tendered Meda shares in exchange for a cash payment of approximately $71.6 million , equal to the uncontested portion of the compulsory acquisition price plus statutory interest, and the Company’s arrangement of a customary bank guarantee to secure the payment of any additional cash consideration that may be awarded to the former Meda shareholders in the compulsory acquisition proceeding. In October 2017, the arbitration tribunal awarded a price of 163.07kr per Meda share, plus statutory interest of 1.5% per annum, to the former Meda shareholders subject to the compulsory acquisition proceeding. On November 15, 2017 Mylan paid an additional approximately $0.9 million plus interest to such former Meda shareholders and, in accordance with Swedish law, the fees of the arbitrators and costs of other parties to the compulsory acquisition proceeding. The bank guarantee was released on February 27, 2018, definitively concluding the compulsory acquisition proceeding. On August 5, 2016, the total purchase price was approximately $6.92 billion , net of cash acquired, which includes cash consideration paid of approximately $5.28 billion , the issuance of approximately 26.4 million Mylan N.V. ordinary shares at a fair value of approximately $1.28 billion based on the closing price of the Company’s ordinary shares on August 5, 2016, as reported by the NASDAQ Global Select Stock Market (“NASDAQ”), and an assumed liability of approximately $431.0 million related to the compulsory acquisition proceeding of the non-tendered Meda shares. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. Acquisition related costs of approximately $182 million were incurred during the year ended December 31, 2016, which were recorded as components of R&D expense, selling, general and administrative expense (“SG&A”), interest expense and other expense, net in the Consolidated Statements of Operations. These costs included approximately $128.6 million of losses on non-designated foreign currency forward and option contracts entered into in order to economically hedge the SEK purchase price of the Offer and approximately $45.2 million of financing fees related to the termination of a 2016 bridge credit agreement entered into in connection with the Meda acquisition. The allocation of the $6.92 billion purchase price to the assets acquired and liabilities assumed for Meda is as follows: (In millions) Current assets (excluding inventories and net of cash acquired) $ 473.3 Inventories 468.1 Property, plant and equipment 177.5 Identified intangible assets 8,060.7 Goodwill 3,684.6 Other assets 8.8 Total assets acquired 12,873.0 Current liabilities (1,110.8 ) Long-term debt, including current portion (2,864.6 ) Deferred tax liabilities (1,613.2 ) Pension and other postretirement benefits (322.3 ) Other noncurrent liabilities (41.0 ) Net assets acquired $ 6,921.1 The acquisition of Meda created a more diversified and expansive portfolio of branded and generic medicines along with a strong and growing portfolio of OTC products. The combined company has a balanced global footprint with significant scale in key geographic markets, particularly the U.S. and Europe. The acquisition of Meda also expanded our presence in key emerging markets, including, China, Russia, Turkey, and Mexico, and in countries in South East Asia, and the Middle East, which complemented Mylan’s existing presence in India, Brazil and Africa (including South Africa). The Company recorded a step-up in the fair value of inventory of approximately $107 million at the acquisition date, which was fully amortized as of December 31, 2016. The identified intangible assets of $8.06 billion are comprised of product rights and licenses that have a weighted average useful life of 20 years . Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $3.68 billion arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. Approximately $3.4 billion of goodwill recognized was allocated to the Europe segment, with approximately $290 million allocated to the North America segment, and approximately $6 million allocated to the Rest of World segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The settlement of the Offer constituted an Acceleration Event (as defined in the Rottapharm Agreement referred to below) under the Sale and Purchase Agreement, dated as of July 30, 2014 (the “Rottapharm Agreement”), among Fidim S.r.l., Meda Pharma S.p.A and Meda, the occurrence of which accelerated an unconditional deferred purchase price payment of approximately $308 million ( €275 million ) relating to Meda’s acquisition of Rottapharm S.p.A. which otherwise would have been payable in January 2017. The amount was paid during the year ended December 31, 2016. The operating results of Meda have been included in the Company’s Consolidated Statements of Operations since the acquisition date. The total revenues of Meda for the period from the acquisition date to December 31, 2016 were $833.9 million and the net loss, net of tax, was $208.7 million , which includes the effects of the purchase accounting adjustments and acquisition related costs. Renaissance Topicals Business On June 15, 2016 , the Company completed the acquisition of the non-sterile, topicals-focused business (the “ Topicals Business ”) of Renaissance Acquisition Holdings, LLC (“ Renaissance ”) for approximately $1.0 billion in cash at closing, including amounts deposited into escrow for potential contingent payments, subject to customary adjustments. The Topicals Business provided the Company with a complementary portfolio of commercial and pipeline products and an established U.S. sales and marketing infrastructure targeting dermatologists. The Topicals Business also provided an integrated manufacturing and development platform. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price was $972.7 million , which includes estimated contingent consideration of approximately $16 million related to the potential $50 million payment contingent on the achievement of certain 2016 financial targets. The contingent consideration was resolved in the fourth quarter of 2017 for a net payment of approximately $40 million and the Company recognized a charge of $23.5 million included as a component of litigation settlements and other contingencies, net in the Company’s Consolidated Statements of Operations for the year ended December 31, 2017 . The allocation of the $972.7 million purchase price to the assets acquired and liabilities assumed for the Topicals Business is as follows: (In millions) Current assets (excluding inventories) $ 57.7 Inventories 74.2 Property, plant and equipment 54.8 Identified intangible assets 467.0 In-process research and development 275.0 Goodwill 318.6 Other assets 0.1 Total assets acquired 1,247.4 Current liabilities (74.2 ) Deferred tax liabilities (194.6 ) Other noncurrent liabilities (5.9 ) Net assets acquired $ 972.7 The acquisition of the Topicals Business broadened the Company’s dermatological portfolio. The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $275.0 million was based on the excess earnings method, which utilizes forecasts of expected cash inflows (including estimates for ongoing costs) and other contributory charges. A discount rate of 12.5% was utilized to discount net cash inflows to present values. IPR&D is accounted for as an indefinite-lived intangible asset and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion and launch of each product, the Company will make a determination of the estimated useful life of the individual IPR&D asset and amounts will be allocated to product rights and licenses in intangible assets. The acquired IPR&D projects are in various stages of completion and the estimated costs to complete these projects total approximately $15 million , which is expected to be incurred through 2022. There are risks and uncertainties associated with the timely and successful completion of the projects included in IPR&D, and no assurances can be given that the underlying assumptions used to estimate the fair value of IPR&D will not change or the timely completion of each project to commercial success will occur. The identified intangible assets of $467.0 million are comprised of $454.0 million of product rights and licenses that have a weighted average useful life of 14 years and $13.0 million of contract manufacturing agreements that have a weighted average useful life of five years . Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $318.6 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the North America segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. Acquisition related costs of approximately $3.6 million were incurred during the year ended December 31, 2016 related to this transaction, which were recorded as a component of SG&A in the Consolidated Statements of Operations. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the year ended December 31, 2016. Unaudited Pro Forma Financial Results The following table presents supplemental unaudited pro forma information for the acquisition of Meda as if it had occurred on January 1, 2015. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable subsequent to acquisition of Meda. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred, nor are they indicative of the future operating results of Mylan N.V. (Unaudited, in millions, except per share amounts) Year Ended December 31, 2016 Total revenues $ 12,376.0 Net earnings $ 560.6 Earnings per ordinary share: Basic $ 1.06 Diluted $ 1.05 Weighted average ordinary shares outstanding: Basic 528.7 Diluted 536.2 Other Transactions On December 1, 2018, the Company and certain subsidiaries of Aspen Pharmacare Holdings Limited entered into an agreement for Mylan to distribute a portfolio of prescription and OTC products in Australia and New Zealand. The agreement includes an option for Mylan to purchase the rights to the portfolio for approximately $135 million . On August 31, 2018, the Company completed an agreement with certain subsidiaries of Novartis AG (“Novartis”) to purchase the worldwide rights to their global cystic fibrosis products consisting of the TOBI Podhaler® and TOBI® solution. Tobramycin is the standard of care for treatment of pseudomonas aeruginosa, a leading driver of infection in cystic fibrosis. These products further strengthen our existing presence in cystic fibrosis, especially with our Creon Franchise in Europe, Australia, Japan and Canada. The asset acquisition allows us to further extend our respiratory franchise into rare/orphan disease indications and broaden our portfolio into dry powdered inhalers and nebulized products. Tobi Podhaler™ is manufactured using a proprietary Pulmosphere technology for which we have acquired exclusive rights for use, hence we expect a high barrier for generic entry. Under the terms of the agreement, Novartis is owed fixed consideration of $463.0 million which consists of $240.0 million which was paid at closing and deferred payments of $130.0 million included in other current liabilities and $93.0 million included in other long-term obligations, due in 2019 and 2020, respectively. Novartis is also eligible to receive a contingent payment of up to $20 million . The Company also entered into a supply agreement with Novartis to purchase the products for up to three years from the date of closing. The Company has recorded a liability of approximately $91 million related to supply obligations. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset for the product rights of $574.8 million . The intangible asset is being amortized over a useful life of 10 years . On February 28, 2018, the Company and Revance Therapeutics, Inc. (“Revance”) entered into a collaboration agreement (the “Revance Collaboration Agreement”) pursuant to which the Company and Revance will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. Under the Revance Collaboration Agreement, the Company will be primarily responsible for (a) clinical development activities outside of North America (excluding Japan) (the “ex-U.S. Mylan territories”), (b) regulatory activities, and (c) commercialization for any approved product. Revance will be primarily responsible for (a) non-clinical development activities, (b) clinical development activities in North America, and (c) manufacturing and supply of clinical drug substance and drug product; Revance will be solely responsible for an initial portion of non-clinical development costs. The remaining portion of any non-clinical development costs and clinical development costs for obtaining approval in the U.S. and Europe will be shared equally between the parties, and the Company will be responsible for all other clinical development costs and commercialization expenses. Upon closing, Revance received a non-refundable upfront payment of $25.0 million . In addition, under the Revance Collaboration Agreement, Revance can receive potential development milestone payments of up to $100.0 million , in the aggregate, upon the achievement of specified clinical and regulatory milestones and potential tiered sales milestones of up to $225.0 million . In addition, Mylan will pay Revance royalties on sales of the biosimilar in the ex-U.S. Mylan territories. The Company accounted for this transaction as an asset acquisition of IPR&D and the total upfront payment was expensed as a component of R&D expense during the year ended December 31, 2018. During the year ended December 31, 2018, the Company completed four agreements to acquire certain intellectual property rights and marketing authorizations for products that were in the development stage, including agreements with Fujifilm Kyowa Kirin Biologics Co., Ltd. (“FKB”), Mapi Pharma Ltd., and Lupin Limited. The Company also completed the acquisition of intellectual property rights and marketing authorizations related to a commercialized product in certain rest of world markets for $220.0 million , of which $160.0 million was paid at closing and $20 million was paid in the fourth quarter of 2018, with the remaining amount due in 2019 and included in other current liabilities. The Company is accounting for these transactions as asset acquisitions and a useful life of five years is being used to amortize the asset related to the commercialized product. The Company recorded expense of approximately $53.7 million as a component of R&D expense related to non-refundable upfront payments for agreements for products in development during the year ended December 31, 2018. Certain of the agreements include additional development and commercial milestones. As part of the Meda acquisition, the Company acquired the in-licensed rights to Betadine in certain European markets. These rights were set to expire on December 31, 2017. Under the licensing agreement, Meda had a binding option to acquire a perpetual license for the rights to Betadine under certain conditions. In October 2017, the Company finalized an agreement to acquire the perpetual license. An estimated liability of approximately $300 million for the purchase of these rights was accrued for on the Meda acquisition opening balance sheet. On January 2, 2018, the Company paid the amounts due to acquire the perpetual license. On December 25, 2017, the Company entered into an agreement to reacquire certain intellectual property rights and marketing authorizations related to a product commercialized in Japan for $90.0 million , which was paid in 2018. The Company accounted for this transaction as an asset acquisition and the asset is being amortized over a useful life of five years . On November 30, 2017, the Company entered into an exclusive license and supply agreement with Natco Pharma Limited for API related to the Company’s Glatiramer Acetate Injection 40 mg/mL product for $22.5 million paid at closing and $29.5 million due through 2020. The license grants the Company the exclusive right to license, market and sell the product in North America and certain other territories. The intangible asset recognized totaled $52 million and was amortized over a useful life of 15 months . On September 29, 2017, the Company completed the acquisition of intellectual property rights and marketing authorizations related to a product in certain markets for $40 million . The Company accounted for this transaction as an asset acquisition and the asset is being amortized over a useful life of five years . On June 19, 2017, the Company completed the acquisition of a portfolio of four generic pharmaceutical products in the U.S. The acquisition price was $256.7 million and the Company accounted for this transaction as an asset acquisition. The intangible asset recognized totaled $252.5 million with the remaining assets primarily consisting of receivables. The intangible asset was being amortized over a useful life of seven years through December 31, 2018. Subsequently, the Company has revised the remaining useful life to four years . On June 2, 2017, the Company completed the acquisition of additional intellectual property rights and marketing authorizations in certain rest of world markets for a product that the Company previously licensed in certain European markets. The acquisition price was $128.0 million and the Company accounted for this transaction as an asset acquisition. The intangible asset is being amortized over a useful life of five years . On March 29, 2017, the Company announced that it had completed its acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. for approximately $50 million in cash. The Company accounted for this transaction as an asset acquisition and the asset is being amortized over a useful life of 15 years . On February 14, 2017, the Company entered into a joint development and marketing agreement for a respiratory product that resulted in approximately $50 million in R&D expense during the year ended December 31, 2017. During the year ended December 31, 2016, the Company entered into an agreement to acquire a marketed pharmaceutical product for an upfront payment of approximately $57.9 million in cash. The Company accounted for this transaction as an asset acquisition and is amortizing the product over a weighted useful life of five years .

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	Revenue from Contracts with Customers Revenue Disaggregation The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the years ended December 31, 2018 , 2017 , and 2016 : (In millions) North America Europe Rest of World Total Year Ended December 31, 2018 Central Nervous System & Anesthesia $ 718.5 $ 877.5 $ 340.7 $ 1,936.7 Infectious Disease 260.8 441.8 826.4 1,529.0 Respiratory & Allergy 643.2 399.9 208.9 1,252.0 Cardiovascular 342.4 567.9 170.6 1,080.9 Gastroenterology 136.4 614.0 364.7 1,115.1 Diabetes & Metabolism 416.5 252.3 121.3 790.1 Dermatology 352.2 330.6 95.8 778.6 Women’s Health 350.7 253.2 104.4 708.3 Oncology 543.4 78.4 137.1 758.9 Immunology 49.5 18.7 38.6 106.8 Other (1) 282.0 323.0 607.3 1,212.3 Total $ 4,095.6 $ 4,157.3 $ 3,015.8 $ 11,268.7 (In millions) North America Europe Rest of World Total Year Ended December 31, 2017 Central Nervous System & Anesthesia $ 1,057.1 $ 862.7 $ 317.0 $ 2,236.8 Infectious Disease 200.0 343.2 921.7 1,464.9 Respiratory & Allergy 709.8 446.3 206.2 1,362.3 Cardiovascular 454.5 579.8 170.3 1,204.6 Gastroenterology 183.5 581.0 357.9 1,122.4 Diabetes & Metabolism 577.7 266.2 103.6 947.5 Dermatology 529.4 295.3 106.0 930.7 Women’s Health 331.2 282.7 94.4 708.3 Oncology 487.4 71.2 148.6 707.2 Immunology 83.5 10.3 37.6 131.4 Other (1) 355.5 219.6 368.8 943.9 Total $ 4,969.6 $ 3,958.3 $ 2,832.1 $ 11,760.0 (In millions) North America Europe Rest of World Total Year Ended December 31, 2016 Central Nervous System & Anesthesia $ 1,105.0 $ 699.5 $ 198.9 $ 2,003.4 Infectious Disease 184.0 270.4 884.0 1,338.4 Respiratory & Allergy 1,348.1 261.4 198.2 1,807.7 Cardiovascular 564.3 473.5 129.6 1,167.4 Gastroenterology 244.5 485.1 293.8 1,023.4 Diabetes & Metabolism 638.3 237.7 95.1 971.1 Dermatology 207.8 134.6 53.8 396.2 Women’s Health 367.9 151.4 70.9 590.2 Oncology 613.6 53.0 120.1 786.7 Immunology 93.6 8.2 32.1 133.9 Other (1) 262.4 179.0 307.3 748.7 Total $ 5,629.5 $ 2,953.8 $ 2,383.8 $ 10,967.1 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales. Variable Consideration The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2018 , 2017 and 2016 , respectively: Year Ended December 31, (In millions) 2018 2017 2016 Gross sales $ 19,588.1 $ 22,206.1 $ 21,058.9 Gross to net adjustments: Chargebacks (3,352.2 ) (4,239.5 ) (4,277.9 ) Rebates, promotional programs and other sales allowances (4,235.6 ) (5,281.1 ) (5,147.9 ) Returns (261.6 ) (390.7 ) (301.7 ) Governmental rebate programs (470.0 ) (534.8 ) (364.3 ) Total gross to net adjustments $ (8,319.4 ) $ (10,446.1 ) $ (10,091.8 ) Net sales $ 11,268.7 $ 11,760.0 $ 10,967.1 The following is a rollforward of the categories of variable consideration during 2018 : (In millions) Balance at December 31, 2017 Current Provision Related to Sales Made in the Current Period Checks/ Credits Issued to Third Parties Effects of Foreign Exchange Balance at December 31, 2018 Chargebacks $ 574.3 $ 3,352.2 $ (3,447.1 ) $ (1.2 ) $ 478.2 Rebates, promotional programs and other sales allowances 1,508.1 4,235.6 (4,526.0 ) (15.3 ) 1,202.4 Returns 472.5 261.6 (292.1 ) (2.5 ) 439.5 Governmental rebate programs 240.3 470.0 (486.6 ) (1.5 ) 222.2 Total $ 2,795.2 $ 8,319.4 $ (8,751.8 ) $ (20.5 ) $ 2,342.3 Accruals for these provisions are presented in the Consolidated Financial Statements as reductions in determining net revenues and in accounts receivable and other current liabilities. Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2018 and 2017 , respectively: (In millions) December 31, December 31, Accounts receivable $ 1,715.6 $ 1,977.2 Other current liabilities 626.7 818.0 Total $ 2,342.3 $ 2,795.2 We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2018
Balance Sheet Components [Abstract]
Balance Sheet Components	Balance Sheet Components Selected balance sheet components consist of the following: Cash and restricted cash (In millions) December 31, December 31, Cash and cash equivalents $ 388.1 $ 292.1 Restricted cash, included in prepaid expenses and other current assets 1.2 77.8 Cash, cash equivalents and restricted cash $ 389.3 $ 369.9 Accounts receivable, net (In millions) December 31, 2018 December 31, 2017 Trade receivables, net $ 2,416.5 $ 3,173.1 Other receivables 464.5 439.3 Accounts receivable, net $ 2,881.0 $ 3,612.4 Total allowances for doubtful accounts were $98.2 million and $75.3 million at December 31, 2018 and 2017 , respectively. Mylan performs ongoing credit evaluations of its customers and generally does not require collateral. Approximately 21% and 35% of the accounts receivable balances represent amounts due from three customers at December 31, 2018 and 2017 , respectively. Inventories (In millions) December 31, 2018 December 31, 2017 Raw materials $ 955.7 $ 895.5 Work in process 369.9 384.7 Finished goods 1,254.6 1,262.5 Inventories $ 2,580.2 $ 2,542.7 Inventory reserves totaled $228.2 million and $171.0 million at December 31, 2018 and 2017 , respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $300.5 million , $229.3 million and $195.7 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Prepaid expenses and other current assets (In millions) December 31, 2018 December 31, 2017 Prepaid expenses $ 130.6 $ 119.8 Restricted cash 1.2 77.8 Available-for-sale fixed income securities 25.0 31.5 Fair value of financial instruments 33.8 88.9 Equity securities 32.5 79.1 Other current assets 295.3 369.0 Prepaid expenses and other current assets $ 518.4 $ 766.1 Prepaid expenses consists primarily of prepaid rent, insurance and other individually insignificant items. At December 31, 2017, restricted cash principally related to amounts deposited in escrow for contingent consideration payments related to the Company’s acquisition of Agila Specialties Private Limited (“Agila”). During the year ended December 31, 2018 , approximately $51.0 million of restricted cash was remitted to Strides Arcolab Limited (“Strides Arcolab”) as part of the final settlement of the Agila contingent consideration and $23.5 million to Merck KGaA for the remittance of certain income tax refunds. Property, plant and equipment, net (In millions) December 31, 2018 December 31, 2017 Machinery and equipment $ 2,421.2 $ 2,414.5 Buildings and improvements 1,182.3 1,191.7 Construction in progress 239.7 252.9 Land and improvements 131.3 143.1 Gross property, plant and equipment 3,974.5 4,002.2 Accumulated depreciation 1,804.3 1,663.1 Property, plant and equipment, net $ 2,170.2 $ 2,339.1 Capitalized software costs included on our Consolidated Balance Sheets were $112.0 million and $143.0 million , net of accumulated depreciation, at December 31, 2018 and 2017 , respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $279.5 million , $287.6 million and $259.4 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Other assets (In millions) December 31, 2018 December 31, 2017 Equity method investments, clean energy investments $ 138.7 $ 226.0 Other long-term assets 73.7 79.6 Other assets $ 212.4 $ 305.6 Accounts payable (In millions) December 31, 2018 December 31, 2017 Trade accounts payable $ 1,123.2 $ 976.0 Other payables 493.8 476.5 Accounts payable $ 1,617.0 $ 1,452.5 Other current liabilities (In millions) December 31, 2018 December 31, 2017 Accrued sales allowances $ 626.7 $ 818.0 Payroll and employee benefit liabilities 399.7 404.6 Legal and professional accruals, including litigation accruals 128.1 241.1 Contingent consideration 158.3 167.8 Restructuring 62.3 91.5 Equity method investments, clean energy investments 45.1 56.7 Accrued interest 62.4 42.3 Fair value of financial instruments 29.4 31.1 Other 635.6 1,111.4 Other current liabilities $ 2,147.6 $ 2,964.5 In the fourth quarter of 2018, the Company announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of an impurity, N-nitrosodiethylamine (“NDEA”) contained in the API valsartan, USP, manufactured by Mylan India. The impact of this recall on the Company’s consolidated financial statements for the year ended December 31, 2018 was approximately $22.6 million , primarily related to recall costs and inventory reserves. Depending on the scope of regulatory actions, and severity of the impurity, the Company may face additional loss of revenues and profits and incur contractual or other litigation costs. There can be no assurance that future costs related to the recall will not exceed amounts recorded. Other long-term obligations (In millions) December 31, 2018 December 31, 2017 Employee benefit liabilities $ 397.7 $ 408.2 Equity method investments, clean energy investments 100.3 171.8 Contingent consideration 197.0 285.9 Tax contingencies 162.1 237.7 Other 239.7 132.1 Other long-term obligations $ 1,096.8 $ 1,235.7

Equity Method Investments

Equity Method Investments	12 Months Ended
	Dec. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Equity Method Investments The Company has three equity method investments in limited liability companies that own refined coal production plants (the “clean energy investments”), whose activities qualify for income tax credits under Section 45 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Company does not consolidate these entities as we have determined that we are not the primary beneficiary of these entities and do not have the power to individually direct the activities of these entities. Accordingly, these investments are accounted for under the equity method of accounting. For each of the clean energy investments, the Company has entered into notes payable with the respective project sponsor, which in part will be paid to the sponsor as certain production levels are met. During 2018, the Company and a project sponsor agreed to terminate two previous investments. Under the termination agreements, the Company returned its ownership interest in the projects to the sponsor and in exchange the Company will have no further obligations with respect to the notes payable for these projects. Also, during 2018, the Company entered into amended agreements related to the three remaining investments. These amendments effectively reduce the amount of expected future variable debt payments to the respective project sponsor. During the year ended December 31, 2017 as a result of a decline in the current and expected future production levels at certain of the facilities, the Company impaired its investment balance and other assets by approximately $47.0 million and reduced the related long-term obligations for these investments by approximately $89.0 million resulting in a net gain of $42.0 million which was recognized as a component of other expense, net in the Consolidated Statement of Operations. The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2018 and 2017 , respectively: (In millions) December 31, 2018 December 31, 2017 Other assets $ 138.7 $ 226.0 Total liabilities 145.4 228.5 Included in other current liabilities 45.1 56.7 Included in other long-term obligations 100.3 171.8 Summarized financial information, in the aggregate, of the Company’s equity method investments on a 100% basis as of December 31, 2018 and 2017 and for the years ended December 31, 2018 , 2017 and 2016 are as follows: (In millions) December 31, 2018 December 31, 2017 Current assets $ 36.6 $ 56.4 Noncurrent assets 2.3 18.2 Total assets 38.9 74.6 Current liabilities 32.8 56.1 Noncurrent liabilities 1.7 3.6 Total liabilities 34.5 59.7 Net assets $ 4.4 $ 14.9 Year Ended December 31, (In millions) 2018 2017 2016 Total revenues $ 483.3 $ 473.0 $ 589.4 Gross (loss) profit (21.1 ) (12.8 ) (13.2 ) Operating and non-operating expense 21.9 22.3 22.2 Net loss $ (43.0 ) $ (35.1 ) $ (35.4 ) The Company’s net losses from equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment to the underlying assets of each individual investee. For the years ended December 31, 2018 , 2017 and 2016 , the Company’s share of the net loss of the equity method investments was $78.7 million , $58.0 million , and $112.8 million , respectively, which was recognized as a component of other expense, net in the Consolidated Statements of Operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2016: Goodwill $ 3,990.4 $ 3,859.1 $ 1,767.4 $ 9,616.9 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,605.4 3,859.1 1,767.4 9,231.9 Acquisitions 92.2 — — 92.2 Reclassifications (1) (200.1 ) 382.2 (182.1 ) — Measurement period adjustments — 7.7 — 7.7 Divestiture — (1.3 ) — (1.3 ) Foreign currency translation 52.1 719.4 103.7 875.2 3,549.6 4,967.1 1,689.0 10,205.7 Balance at December 31, 2017: Goodwill 3,934.6 4,967.1 1,689.0 10,590.7 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,549.6 4,967.1 1,689.0 10,205.7 Foreign currency translation (41.7 ) (309.7 ) (106.5 ) (457.9 ) 3,507.9 4,657.4 1,582.5 9,747.8 Balance at December 31, 2018 Goodwill 3,892.9 4,657.4 1,582.5 10,132.8 Accumulated impairment losses (385.0 ) — — (385.0 ) $ 3,507.9 $ 4,657.4 $ 1,582.5 $ 9,747.8 ____________ (1) The reclassifications relate to the allocation of goodwill for the Meda acquisition. Intangible assets consist of the following components at December 31, 2018 and 2017 : (In millions) Weighted Average Life (Years) Cost Accumulated Amortization Net Book Value December 31, 2018 Product rights, licenses and other (1) 15 $ 20,264.1 $ 7,225.1 $ 13,039.0 In-process research and development 625.6 — 625.6 $ 20,889.7 $ 7,225.1 $ 13,664.6 December 31, 2017 Product rights, licenses and other (1) 15 $ 20,338.7 $ 5,906.1 $ 14,432.6 In-process research and development 813.2 — 813.2 $ 21,151.9 $ 5,906.1 $ 15,245.8 ____________ (1) Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights. Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic franchise, is as follows: (In millions) December 31, 2018 December 31, 2017 Central Nervous System and Anesthesia $ 2,148.9 $ 2,453.7 Dermatology 2,125.7 2,393.0 Gastroenterology 1,790.9 2,050.0 Diabetes and Metabolism 1,232.4 1,425.6 Cardiovascular 1,541.9 1,779.5 Respiratory and Allergy 2,084.1 1,769.5 Infectious Disease 596.0 494.8 Oncology 206.0 380.1 Women's Healthcare 315.1 371.4 Immunology 258.8 301.5 Other (1) 694.9 970.1 $ 12,994.7 $ 14,389.2 ____________ (1) Other consists of numerous therapeutic classes, none of which individually exceeds 5% of total product rights and licenses. Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the Consolidated Statements of Operations, for the years ended December 31, 2018 , 2017 and 2016 was as follows: Year ended December 31, (In millions) 2018 2017 2016 Intangible asset amortization expense $ 1,606.4 $ 1,437.4 $ 1,195.3 IPR&D intangible asset impairment charges 117.7 74.6 49.9 Finite-lived intangible asset impairment charges 106.3 6.2 18.4 Total intangible asset amortization expense (including impairment charges) $ 1,830.4 $ 1,518.2 $ 1,263.6 The assessment for impairment of finite-lived intangibles is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of book value over fair value based on the discounted cash flows. Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. The fair value of finite-lived intangible assets was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated future cash flows include, among other things, the impact of the current competitive environment and future market expectations. Discount rates ranging between 9.0% and 10.0% were utilized in the valuations performed during the years ended December 31, 2018 , 2017 and 2016 . At December 31, 2018 and 2017 , the Company’s finite-lived intangible assets totaled $13.04 billion and $14.43 billion , respectively. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations. The Company’s IPR&D assets are tested at least annually for impairment, but they may be tested whenever certain impairment indicators are present. Impairment is determined to exist when the fair value of IPR&D assets, which was based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested. The fair value of IPR&D was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated future cash flows include, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment. Discount rates ranging between 9.5% and 13.0% , 8.4% and 10.5% , and 8.5% and 11.9% were utilized in the valuations performed during the years ended December 31, 2018 , 2017 and 2016 respectively. The fair value of both IPR&D and finite-lived intangible assets was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 8 Financial Instruments and Risk Management . Changes to any of the Company’s assumptions including changes to or abandonment of development programs, regulatory timelines, discount rates or the competitive environment related to the assets could lead to future material impairment charges. In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus and Seretide® Diskus incorporating Pfizer Inc.’s (“Pfizer”) proprietary dry powder inhaler delivery platform (the “respiratory delivery platform”). The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. As of December 31, 2018 , the Company has an IPR&D asset of $347.2 million and related contingent consideration liability of $336.5 million . The Company performed an analysis and valuation of the IPR&D asset and the fair value of the related contingent consideration liability using a discounted cash flow model. The model contained certain key assumptions including: the expected product launch date, the number of competitors, the timing of competition and a discount factor based on an industry specific weighted average cost of capital. Based on the analysis performed, the Company determined that the fair value of the IPR&D asset was substantially in excess of its carrying value, and the asset was not impaired at December 31, 2018 . Additionally, a fair value adjustment was required for the related contingent consideration liability resulting in a gain of approximately $44.0 million for the year ended December 31, 2018 based upon changes to assumptions relating to the timing of the product launch along with other competitive and market factors. The fair value of the contingent consideration liability was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 8 - Financial Instruments and Risk Management . On January 30, 2019, the Company received FDA approval of Wixela TM Inhub TM (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus ® . The commercial launch of the Wixela TM Inhub TM occurred in February 2019. The Company expects to reclassify the IPR&D asset of $347.2 million to product rights and licenses in the first quarter of 2019. Market conditions and other factors may result in significant future changes in the projections and assumptions utilized in the discounted cash flow model, which could lead to material adjustments to the amounts recorded for intangible assets and contingent consideration. The Company has performed its annual goodwill impairment test as of April 1, 2018 on a quantitative basis for its four reporting units, North America Generics, North America Brands, Europe and Rest of World. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches, except for the North America Brands reporting unit where the fair value was estimated utilizing the income approach. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts. Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as it relates to the key assumptions detailed, could have a significant impact on the fair value of the reporting units. As of the date of our annual impairment test, the allocation of the Company’s total goodwill was as follows: North America Generics $2.89 billion , North America Brands $0.66 billion , Europe $4.97 billion and Rest of World $1.80 billion . The fair value of the North America Generics, North America Brands and Rest of World reporting units was substantially in excess of the respective unit’s carrying value. For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $800.0 million or 6.0% . The excess fair value for the Europe reporting unit is consistent with the result of the Company’s 2017 annual impairment test. As it relates to the income approach for the Europe reporting unit at April 1, 2018 , the Company forecasted cash flows for the next 5 years . During the forecast period, the revenue compound annual growth rate was approximately 3.5% . A terminal value year was calculated with a 2.0% revenue growth rate applied. The discount rate utilized was 9.0% and the estimated tax rate was 24.0% . Under the market-based approach, we utilized an estimated range of market multiples of 9.0 to 10.5 times EBITDA plus a control premium of 15.0% . If all other assumptions are held constant, a reduction in the terminal value growth rate by 2.0% or an increase in discount rate by 1.5% would result in an impairment charge for the Europe reporting unit. Intangible asset amortization expense for the years ended December 31, 2019 through 2023 is estimated to be as follows: (In millions) 2019 $ 1,703 2020 1,544 2021 1,462 2022 1,392 2023 967

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments And Risk Management	Financial Instruments and Risk Management The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk. Foreign Currency Risk Management In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities on the Consolidated Balance Sheets . Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the Consolidated Statements of Operations. The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities on the Consolidated Balance Sheets . Any changes in the fair value of designated cash flow hedges are deferred in accumulated other comprehensive earnings (“AOCE”) and are reclassified into earnings when the hedged item impacts earnings. Net Investment Hedges The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments. The Company designated certain Euro borrowings as a hedge of its investment in certain Euro-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro borrowings not designated as net investment hedges through certain Euro denominated financial assets and forward currency swaps. The following table summarizes the principal amounts of the Company’s outstanding Euro borrowings and the notional amounts of the Euro borrowings designated as net investment hedges: Notional Amount Designated as a Net Investment Hedge (in millions) Principal Amount December 31, December 31, 2.250% Euro Senior Notes due 2024 € 1,000.0 € 1,000.0 € 1,000.0 3.125% Euro Senior Notes due 2028 750.0 750.0 750.0 1.250% Euro Senior Notes due 2020 750.0 104.0 104.0 2.125% Euro Senior Notes due 2025 500.0 500.0 — Floating Rate Euro Notes due 2020 500.0 — — Total € 3,500.0 € 2,354.0 € 1,854.0 Interest Rate Risk Management The Company enters into interest rate swaps in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the Consolidated Balance Sheets . For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings. Cash Flow Hedging Relationships The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the Consolidated Statements of Operations . Following the acquisition of Meda, the Company designated certain interest rate swaps with a notional amount of €750 million as cash flow hedges. In the fourth quarter of 2016, the Company repaid the related debt instrument and terminated these swaps. In anticipation of issuing fixed-rate debt, the Company may use treasury rate locks or forward starting interest rate swaps that are designated as cash flow hedges. In September 2015, the Company entered into a series of forward starting swaps to hedge against changes in interest rates related to future debt issuances. These swaps were designated as cash flow hedges of expected future issuances of long-term bonds. The Company executed $500 million of notional value swaps with an effective date of June 2016 and an additional $500 million of notional value swaps with an effective date of November 2016. Both sets of swaps had a maturity of ten years . During the second quarter of 2016, the Company issued $2.25 billion in an aggregate principal amount of 3.950% Senior Notes due 2026 (the “2026 Senior Notes”) and the Company terminated these swaps. As a result of this termination, the Company recorded losses of $64.9 million in AOCE, which are being amortized over the life of the 2026 Senior Notes. Fair Value Hedging Relationships The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. In December 2013, the Company entered into interest rate swaps with a notional value of $750 million that were designated as hedges of the Company’s 3.125% Senior Notes due 2023. The variable rate was 2.86% at December 31, 2018 . The total notional amount of the Company’s interest rate swaps on fixed-rate debt was $750 million as of December 31, 2018 and 2017 . Credit Risk Management The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the Consolidated Balance Sheets . Accordingly, there are no offsetting amounts that net assets against liabilities. The Effect of Derivative Instruments on the Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Designated as Hedging Instruments Asset Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ 3.6 Prepaid expenses and other current assets $ 16.2 Foreign currency forward contracts Prepaid expenses and other current assets — Prepaid expenses and other current assets 63.4 Total $ 3.6 $ 79.6 Liability Derivatives December 31, 2018 December 31, 2017 Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 12.1 Other current liabilities $ — $ 12.1 $ — The Effect of Derivative Instruments on the Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments Asset Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 30.2 Prepaid expenses and other current assets $ 9.3 Total $ 30.2 $ 9.3 Liability Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 17.3 Other current liabilities $ 31.1 Total $ 17.3 $ 31.1 The Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships Location of Loss Recognized in Earnings on Derivatives Amount of Loss Recognized in Earnings on Derivatives Year Ended December 31, (In millions) 2018 2017 2016 Interest rate swaps Interest expense $ (12.6 ) $ (10.0 ) $ (10.0 ) Total $ (12.6 ) $ (10.0 ) $ (10.0 ) Location of Gain Recognized in Earnings on Hedged Items Amount of Gain Recognized in Earnings on Hedging Items Year Ended December 31, (In millions) 2018 2017 2016 2023 Senior Notes (3.125% coupon) Interest expense $ 12.6 $ 10.0 $ 10.0 Total $ 12.6 $ 10.0 $ 10.0 The Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationships Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivatives (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency borrowings and forward contracts $ 108.9 $ (238.4 ) $ (1.4 ) Total $ 108.9 $ (238.4 ) $ (1.4 ) The Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships Amount of (Loss) or Gain Recognized in AOCE (Net of Tax) on Derivatives (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts $ (46.6 ) $ 28.1 $ (27.5 ) Interest rate swaps — — (38.7 ) Total $ (46.6 ) $ 28.1 $ (66.2 ) The Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion) Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts Net sales $ 6.2 $ 1.1 $ (44.3 ) Interest rate swaps Interest expense (7.7 ) (7.3 ) (8.7 ) Total $ (1.5 ) $ (6.2 ) $ (53.0 ) Location of Loss Excluded from the Assessment of Hedge Effectiveness Amount of Loss Excluded from the Assessment of Hedge Effectiveness Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts Other expense, net $ — $ (3.3 ) $ 33.5 Total $ — $ (3.3 ) $ 33.5 At December 31, 2018 , the Company expects that approximately $58.0 million of pre-tax net losses on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months . The Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments Location of Gain or (Loss) Recognized in Earnings on Derivatives Amount of Gain or (Loss) Recognized in Earnings on Derivatives Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency option and forward contracts Other expense, net $ 34.8 $ 47.7 $ (104.5 ) Total $ 34.8 $ 47.7 $ (104.5 ) Fair Value Measurement Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: December 31, 2018 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 71.0 $ — $ — $ 71.0 Total cash equivalents 71.0 — — 71.0 Equity securities: Exchange traded funds 31.7 — — 31.7 Marketable securities 0.8 — — 0.8 Total equity securities 32.5 — — 32.5 Available-for-sale fixed income investments: Corporate bonds — 9.9 — 9.9 U.S. Treasuries — 9.4 — 9.4 Agency mortgage-backed securities — 1.6 — 1.6 Asset backed securities — 3.2 — 3.2 Other — 0.9 — 0.9 Total available-for-sale fixed income investments — 25.0 — 25.0 Foreign exchange derivative assets — 30.2 — 30.2 Interest rate swap derivative assets — 3.6 — 3.6 Total assets at recurring fair value measurement $ 103.5 $ 58.8 $ — $ 162.3 Financial Liabilities Foreign exchange derivative liabilities $ — $ 29.4 $ — $ 29.4 Contingent consideration — — 355.3 355.3 Total liabilities at recurring fair value measurement $ — $ 29.4 $ 355.3 $ 384.7 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 8.4 $ — $ — $ 8.4 Total cash equivalents 8.4 — — 8.4 Equity securities: Exchange traded funds 33.9 — — 33.9 Marketable securities 45.2 — — 45.2 Total equity securities 79.1 — — 79.1 Available-for-sale fixed income investments: Corporate bonds — 16.5 — 16.5 U.S. Treasuries — 7.4 — 7.4 Agency mortgage-backed securities — 4.1 — 4.1 Asset backed securities — 2.1 — 2.1 Other — 1.4 — 1.4 Total available-for-sale fixed income investments — 31.5 — 31.5 Foreign exchange derivative assets — 72.7 — 72.7 Interest rate swap derivative assets — 16.2 — 16.2 Total assets at recurring fair value measurement $ 87.5 $ 120.4 $ — $ 207.9 Financial Liabilities Foreign exchange derivative liabilities $ — $ 31.1 $ — $ 31.1 Contingent consideration — — 453.7 453.7 Total liabilities at recurring fair value measurement $ — $ 31.1 $ 453.7 $ 484.8 For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2018 and 2017 , there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities: • Cash equivalents — valued at observable net asset value prices. • Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the Consolidated Statements of Operations . • Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the Consolidated Statements of Operations . • Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity. • Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions. • Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions. Contingent Consideration The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for the respiratory delivery platform, the acquisitions of Agila , certain female healthcare businesses from Famy Care Limited (such businesses “ Jai Pharma Limited ”) and the Topicals Business and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions. For the respiratory delivery platform, Jai Pharma Limited and certain other acquisitions, significant unobservable inputs in the valuation include the probability and timing of future development and commercial milestones and future profit sharing payments. When valuing the contingent consideration related to the respiratory delivery platform and Jai Pharma Limited, the value of the obligations is derived from a probability assessment based on expectations of when certain milestones or profit share payments occur which are discounted using a market rate of return. At December 31, 2018 and 2017 , discount rates ranging from 2.1% to 11.0% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability. A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2016 to December 31, 2018 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2016 $ 256.9 $ 307.7 $ 564.6 Payments (77.3 ) (0.2 ) (77.5 ) Reclassifications 27.0 (27.0 ) — Accretion — 25.9 25.9 Fair value gain (3) (38.8 ) (20.5 ) (59.3 ) Balance at December 31, 2017 $ 167.8 $ 285.9 $ 453.7 Payments (82.9 ) — (82.9 ) Reclassifications 62.1 (62.1 ) — Accretion — 19.8 19.8 Fair value loss (gain) (3) 11.3 (46.6 ) (35.3 ) Balance at December 31, 2018 $ 158.3 $ 197.0 $ 355.3 ____________ (1) Included in other current liabilities on the Consolidated Balance Sheets. (2) Included in other long-term obligations on the Consolidated Balance Sheets. (3) Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations. 2017 Changes to Contingent Consideration: During the year ended December 31, 2017, the Company recorded a fair value gain of $93.5 million related to the respiratory delivery platform contingent consideration partially offset by fair value losses of $9.9 million related to Jai Pharma Limited contingent consideration and $23.5 million related to the Topicals Business contingent consideration. In addition, the Company made payments of approximately $13.7 million related to the Agila contingent consideration, a net payment of $40 million to resolve the Topicals Business contingent consideration and a payment of approximately $20.0 million related to the Jai Pharma Limited contingent consideration. 2018 Changes to Contingent Consideration: During the year ended December 31, 2018 , the Company recorded a fair value gain of $44.0 million related to the respiratory delivery platform contingent consideration partially offset by fair value losses of $8.6 million related to the Jai Pharma Limited contingent consideration. In addition, the Company made payments of approximately $51.0 million to resolve the Agila contingent consideration and a net payment of $30.0 million to resolve the Jai Pharma Limited contingent consideration. The Company expects to incur approximately $15 million to $20 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2019 . Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election. Available-for-Sale Securities The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows: (In millions) Cost Gross Gross Fair December 31, 2018 (1) Debt securities $ 24.8 $ 0.2 $ — $ 25.0 $ 24.8 $ 0.2 $ — $ 25.0 December 31, 2017 Debt securities $ 31.5 $ — $ — $ 31.5 Equity securities 29.5 16.9 (1.2 ) 45.2 $ 61.0 $ 16.9 $ (1.2 ) $ 76.7 (1) Equity securities are no longer classified as available-for-sale as of January 1, 2018 as a result of the adoption of ASU 2016-01. Refer to Note 2 Summary of Significant Accounting Policies for additional information. Maturities of available-for-sale debt securities at fair value as of December 31, 2018 , were as follows: (In millions) Mature within one year $ 3.1 Mature in one to five years 13.4 Mature in five years and later 8.5 $ 25.0

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt Short-Term Borrowings (In millions) December 31, December 31, Receivables Facility $ — $ 45.0 Other 1.9 1.5 Short-term borrowings $ 1.9 $ 46.5 Receivables Facility The Company has a $400 million Receivables Facility, which expires on March 25, 2019 . Under the terms of the Receivables Facility, our subsidiary, MPI, sells certain accounts receivable to Mylan Securitization LLC (“Mylan Securitization”), a wholly-owned special purpose entity which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. MPI is the servicer of the receivables under the Receivables Facility. Purchases under the Receivables Facility will be repaid as accounts receivable are collected, with new purchases being advanced as new accounts receivable are originated by MPI. Mylan Securitization’s assets have been pledged to The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent, in support of its obligations under the Receivables Facility. Any amounts outstanding under the facility are recorded as borrowings and the underlying receivables will continue to be included in accounts receivable, net, in the Consolidated Balance Sheets of the Company. The Receivables Facility contains requirements relating to the performance of the accounts receivable and covenants related to the Company with which the Company was compliant as of December 31, 2018 . As of December 31, 2018 and 2017 , the Company had $322.0 million and $1.04 billion , respectively, of accounts receivable balances sold to Mylan Securitization. Commercial Paper Program On July 27, 2018, the Company established an unsecured commercial paper program (the “Commercial Paper Program”) pursuant to which Mylan Inc. may issue short-term, unsecured commercial paper notes (the “CP Notes”) that are guaranteed by the Company pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), which replaced Mylan N.V.’s existing commercial paper program established June 8, 2017 (the “Existing Commercial Paper Program”) on substantially identical terms to the Existing Commercial Paper Program. Amounts available under the Commercial Paper Program may be borrowed, repaid and re-borrowed from time to time, with the aggregate principal amount of the commercial paper notes outstanding under the Commercial Paper Program at any time not to exceed $1.65 billion . The Company’s 2018 Revolving Facility (as defined below) will be available to pay the CP Notes, if necessary. The maturities of the CP Notes will vary but will not exceed 364 days from the date of issue. The Company uses net proceeds from its Commercial Paper Program and the Receivables Facility as a source of liquidity for general corporate purposes, including for business development transactions, working capital and share repurchases. Commercial paper borrowings and the Receivables Facility may vary during a particular period, as a result of fluctuations in working capital requirements and timing of cash receipts. Long-Term Debt A summary of long-term debt is as follows: (In millions) Coupon December 31, December 31, Current portion of long-term debt: 2016 Term Facility (a) ** 3.897 % $ 100.0 $ — 2018 Senior Notes * 2.600 % — 649.9 2018 Floating Rate Euro Notes (b) ** — 600.2 2018 Senior Notes ** 3.000 % — 499.8 2019 Senior Notes ** 2.500 % 549.9 — Other 6.2 2.4 Deferred financing fees (0.9 ) (3.1 ) Current portion of long-term debt $ 655.2 $ 1,749.2 Non-current portion of long-term debt: 2016 Term Facility (a) ** 3.897 % $ — $ 100.0 2019 Senior Notes ** 2.500 % — 999.5 2019 Senior Notes * 2.550 % — 499.7 2020 Floating Rate Euro Notes (c) ** 573.3 600.2 2020 Euro Senior Notes ** 1.250 % 858.1 897.6 2020 Senior Notes ** 3.750 % 499.9 499.9 2021 Senior Notes ** 3.150 % 2,248.7 2,248.2 2023 Senior Notes * 3.125 % 752.9 765.4 2023 Senior Notes * 4.200 % 498.9 498.8 2024 Euro Senior Notes ** 2.250 % 1,144.2 1,197.7 2025 Euro Senior Notes * 2.125 % 572.0 — 2026 Senior Notes ** 3.950 % 2,236.5 2,235.0 2028 Euro Senior Notes ** 3.125 % 852.5 892.0 2028 Senior Notes * 4.550 % 748.2 — 2043 Senior Notes * 5.400 % 497.2 497.1 2046 Senior Notes ** 5.250 % 999.8 999.8 2048 Senior Notes * 5.200 % 747.6 — Other 5.1 6.3 Deferred financing fees (73.7 ) (71.9 ) Long-term debt $ 13,161.2 $ 12,865.3 ____________ (a) The 2016 Term Facility bears interest at LIBOR plus a base rate, which margins can fluctuate based on the Company’s credit ratings. (b) Interest rate of the instrument was three-month EURIBOR plus 0.870% per annum, reset quarterly. (c) Instrument bears interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V. 2016 Revolving Facility, 2018 Revolving Facility and 2016 Term Facility On November 22, 2016, the Company entered into a revolving credit facility among the Company, as borrower, Mylan Inc., as a guarantor, certain lenders and issuing banks and Bank of America, N.A., as the administrative agent, pursuant to which the Company may obtain extensions of credit in an aggregate principal amount not to exceed $2.0 billion (the “ 2016 Revolving Facility ”). On the same day, the Company entered into a term credit facility among the Company, as borrower, Mylan Inc., as a guarantor, certain lenders and Goldman Sachs Bank USA, as administrative agent, pursuant to which the Company has $100.0 million outstanding in term loans (the “ 2016 Term Facility ”) at December 31, 2018 . On July 27, 2018, the Company entered into a revolving credit facility among Mylan Inc., as borrower, the Company, as a guarantor, certain lenders and issuing banks and Bank of America, N.A., as the administrative agent, which replaced the 2016 Revolving Facility on substantially identical terms to the 2016 Revolving Facility and pursuant to which Mylan Inc. may obtain extensions of credit in an aggregate principal amount not to exceed $2.0 billion (the “ 2018 Revolving Facility ”). The 2016 Term Facility and the 2018 Revolving Facility each contain customary affirmative covenants for facilities of this type, including among others, covenants pertaining to the delivery of financial statements, notices of default and certain material events, maintenance of corporate existence and rights, property, and insurance and compliance with laws, as well as customary negative covenants for facilities of this type, including limitations on the incurrence of subsidiary indebtedness, liens, mergers and certain other fundamental changes, investments and loans, acquisitions, transactions with affiliates, payments of dividends and other restricted payments and changes in our lines of business. The 2016 Term Facility and 2018 Revolving Facility contain a maximum consolidated leverage ratio financial covenant requiring maintenance of a maximum ratio of 3.75 to 1.00 for consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters as defined in the related credit agreements (“leverage ratio”). The 2016 Term Facility was amended in November 2017 to allow a leverage ratio of 4.25 to 1.00 through the December 31, 2018 reporting period and a leverage ratio of 3.75 to 1.00 thereafter. The 2018 Revolving Facility similarly provides for a leverage ratio of 4.25 to 1.00 through the December 31, 2018 reporting period and a leverage ratio of 3.75 to 1.00 thereafter. On February 22, 2019, the Company, as a guarantor, and Mylan Inc., as borrower, entered into an amendment (the "Revolving Loan Amendment") to the 2018 Revolving Facility. In addition, on February 22, 2019, the Company entered into an amendment (the "Term Loan Amendment") to the 2016 Term Facility. The Revolving Loan Amendment and the Term Loan Amendment extended the leverage ratio covenant of 4.25 to 1.00 through the December 31, 2019 reporting period, with a leverage ratio of 3.75 to 1.00 thereafter. The Company is in compliance at December 31, 2018 and expects to remain in compliance for the next twelve months. Senior Notes Issuance of 2018 Senior Notes The following table provides the amounts of senior unsecured debt issued by Mylan Inc. and guaranteed by Mylan N.V., on April 9, 2018 (the “ April 2018 Senior Notes ”). The April 2018 Senior Notes were issued pursuant to an indenture dated April 9, 2018. The April 2018 Senior Notes were issued in a private offering exempt from the registration requirements of the Securities Act to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. The Company has entered into a registration rights agreement, dated as of April 9, 2018 pursuant to which Mylan Inc. and Mylan N.V. are required to use commercially reasonable efforts to file a registration statement with respect to an offer to exchange each series of the April 2018 Senior Notes for new notes with the same aggregate principal amount and terms substantially identical in all material respects. (In millions) Interest Rate Principal Amount 2028 Senior Notes (1) 4.550 % $ 750.0 2048 Senior Notes (1) 5.200 % 750.0 Total April 2018 Senior Notes $ 1,500.0 ____________ (1) Redeemable, in whole or in part, at our option at any time prior to three months (in the case of the 2028 Senior Notes) or six months (in the case of the 2048 Senior Notes) of the maturity date at the greater of 100% of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread of 0.30% (in the case of the 2028 Senior Notes) or 0.35% (in the case of the 2048 Senior Notes), plus, in each case, accrued and unpaid interest. On April 28, 2018, the Company redeemed all of the outstanding $650 million principal amount of Mylan Inc.’s 2.600% senior notes due 2018, all of the outstanding $500 million principal amount of Mylan N.V.’s 3.000% senior notes due 2018 and $350 million of the outstanding $500 million principal amount of Mylan Inc.’s 2.550% senior notes due 2019. The redemption of these notes was funded with the net proceeds from the April 2018 Senior Notes offering. In November 2018, Mylan N.V. and Mylan Inc. filed a registration statement with the Securities and Exchange Commission (“SEC”) with respect to an offer to exchange these notes for registered notes with the same aggregate principal amount and terms substantially identical in all material respects, which was declared effective on December 11, 2018. The exchange offer expired on January 9, 2019 and settled on January 10, 2019. 100% of each of the 4.550% Senior Notes due 2028 and the 5.200% Senior Notes due 2048 were exchanged. Issuance of 2018 Euro Senior Notes On May 23, 2018, Mylan Inc. completed the offering of €500 million aggregate principal amount of its 2.125% Euro Senior Notes due 2025 (the “ May 2018 Euro Senior Notes ”). The May 2018 Euro Senior Notes were issued pursuant to an indenture dated May 23, 2018. The May 2018 Euro Senior Notes are guaranteed by Mylan N.V. and were issued in a private offering exempt from the registration requirements of the Securities Act, to persons outside of the U.S. pursuant to Regulation S under the Securities Act. The May 2018 Euro Senior Notes are redeemable, in whole or in part, at our option at any time prior to three months of the maturity date at the greater of 100% of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the applicable Bund Rate plus an incremental spread of 0.30% , plus, in each case, accrued and unpaid interest. On June 15, 2018, the Company redeemed the remaining $150 million outstanding principal amount of Mylan Inc.’s 2.550% Senior Notes due 2019 and $450 million of the outstanding $1.0 billion principal amount of Mylan N.V.’s 2.500% Senior Notes due 2019. The redemption of these notes was funded with the net proceeds from the May 2018 Euro Senior Notes offering. Issuance of 2017 Euro Senior Notes On May 24, 2017, the Company completed its offering of €500 million aggregate principal amount of Floating Rate Senior Notes due 2020 (the “May 2017 Floating Rate Euro Senior Notes”), issued pursuant to the indenture dated May 24, 2017 (the “2017 Euro Notes Indenture”). The May 2017 Floating Rate Euro Senior Notes will mature on May 24, 2020 and cannot be redeemed prior to maturity at the option of the Company. The May 2017 Floating Rate Euro Senior Notes were issued in a private offering exempt from the registration requirements of the Securities Act to persons outside of the U.S. pursuant to Regulation S under the Securities Act. The May 2017 Floating Rate Euro Senior Notes are the Company’s senior unsecured indebtedness and are guaranteed on a senior unsecured basis by Mylan Inc. The May 2017 Floating Rate Euro Senior Notes bear interest at a rate per annum, reset quarterly, equal to the sum of (i) three-month EURIBOR (as defined in the 2017 Euro Notes Indenture) plus (ii) 0.50% , provided, however, that the minimum interest rate is zero . Interest on the May 2017 Floating Rate Euro Senior Notes is payable quarterly in arrears on each February 24, May 24, August 24 and November 24. The interest rate at December 31, 2018 was approximately 0.17% per annum. The Company utilized the net proceeds from the May 2017 Floating Rate Euro Senior Notes offering to repay a portion of the term loans under the 2016 Term Facility and to pay associated fees and expenses. Fair Value At December 31, 2018 and 2017 , the aggregate fair value of the Company’s outstanding notes was approximately $13.10 billion and $14.93 billion , respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy. Based on quoted market rates of interest and maturity schedules of similar debt issues, the fair value of the Company’s 2016 Term Facility determined based on Level 2 inputs, approximates its carrying value at December 31, 2018 and 2017 . Mandatory minimum repayments remaining on the outstanding long-term debt at December 31, 2018 , excluding the discounts and premiums, are as follows for each of the periods ending December 31: (In millions) Total 2019 $ 650 2020 1,933 2021 2,250 2022 — 2023 1,250 Thereafter 7,830 Total $ 13,913

Comprehensive Earnings

Comprehensive Earnings	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Comprehensive Earnings	Comprehensive Earnings Accumulated other comprehensive loss , as reflected on the Consolidated Balance Sheets , is comprised of the following: (In millions) December 31, 2018 December 31, 2017 Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ — $ 10.1 Net unrecognized gains and prior service cost related to defined benefit plans, net of tax 1.7 6.0 Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax (53.1 ) (3.7 ) Net unrecognized losses on derivatives in net investment hedging relationships, net of tax (130.9 ) (239.8 ) Foreign currency translation adjustment (1,259.0 ) (133.8 ) $ (1,441.3 ) $ (361.2 ) Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following: Year Ended December 31, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Other comprehensive (loss) earnings before reclassifications, before tax (80.7 ) 111.6 (0.1 ) (3.0 ) (1,125.2 ) (1,097.4 ) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (6.2 ) (6.2 ) (6.2 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 7.7 7.7 7.7 Amortization of prior service costs included in SG&A (0.4 ) (0.4 ) Amortization of actuarial loss included in SG&A (0.4 ) (0.4 ) Net other comprehensive (loss) earnings, before tax (79.2 ) 111.6 (0.1 ) (3.8 ) (1,125.2 ) (1,096.7 ) Income tax (benefit) provision (27.3 ) 2.7 — 0.5 — (24.1 ) Cumulative effect of the adoption of new accounting standards $ 2.5 $ — $ (10.0 ) $ — $ — $ (7.5 ) Balance at December 31, 2018, net of tax $ (53.1 ) $ (130.9 ) $ — $ 1.7 $ (1,259.0 ) $ (1,441.3 ) Year Ended December 31, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 ) Other comprehensive (loss) earnings before reclassifications, before tax 46.5 (238.4 ) (6.7 ) 2.9 2,103.9 1,908.2 Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (1.1 ) (1.1 ) (1.1 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 7.3 7.3 7.3 Amortization of prior service costs included in SG&A 0.2 0.2 Amortization of actuarial gain included in SG&A 0.7 0.7 Net other comprehensive (loss) earnings, before tax 52.7 (238.4 ) (6.7 ) 3.8 2,103.9 1,915.3 Income tax (benefit) provision 17.8 — (2.3 ) (2.7 ) — 12.8 Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Year Ended December 31, 2016 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2015, net of tax $ (18.1 ) $ — $ (1.0 ) $ (14.9 ) $ (1,730.3 ) $ (1,764.3 ) Other comprehensive earnings (loss) before reclassifications, before tax (84.2 ) (1.8 ) 24.6 20.0 (507.4 ) (548.8 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (44.3 ) 44.3 44.3 Loss on interest rate swaps classified as cash flow hedges, included in interest expense (8.7 ) 8.7 8.7 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial gain included in SG&A 1.1 1.1 Net other comprehensive loss, before tax (31.2 ) (1.8 ) 24.6 21.4 (507.4 ) (494.4 ) Income tax provision (benefit) (10.7 ) (0.4 ) 9.1 7.0 — 5.0 Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 )

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the Code including, but not limited to, reducing the U.S. federal corporate income tax rate and requiring a one-time transition tax on certain unrepatriated earnings of non-U.S. corporate subsidiaries of large U.S. shareholders that may electively be paid over eight years. While the Tax Act reduces the U.S. federal corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017, ASC Topic 740 required the Company to remeasure its deferred tax balances at December 31, 2017 in accordance with the 2018 rate reduction. The Tax Act also puts in place new tax laws that impact our taxable income beginning in 2018, which include, but are not limited to (1) creating a Base Erosion Anti-Abuse Tax (“BEAT”), which is a new minimum tax, (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries, (3) a new provision designed to tax currently global intangible low-taxed income (“GILTI”) earned by non-U.S. corporate subsidiaries of large U.S. shareholders and a deduction generally equal to 50 percent of GILTI ( 37.5 percent for tax years beginning after December 31, 2025) to offset the income tax liability, (4) a provision limiting the amount of deductible interest expense in the U.S., (5) the repeal of the domestic manufacturing deduction, (6) limitations on the deductibility of certain executive compensation, and (7) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability. Shortly after the Tax Act was enacted, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) which provided guidance on accounting for the Tax Act’s impact. SAB 118 provides a measurement period, which in no case should extend beyond one year from the Tax Act enactment date, during which a company acting in good faith may complete the accounting for the impacts of the Tax Act under ASC Topic 740. To the extent that the accounting for certain income tax effects of the Tax Act is incomplete, a company can determine a reasonable estimate for those effects and record a provisional estimate in the financial statements in the first reporting period in which a reasonable estimate can be determined. The Company recorded a provisional net tax charge of $128.6 million related to the Tax Act in the year ended December 31, 2017. This net charge primarily consisted of a net expense of $15.0 million due to the remeasurement of our net deferred tax accounts to reflect the U.S. federal corporate income tax rate reduction to 21% and a net expense for the transition tax of $113.6 million . The transition tax is a 2017 tax on the previously untaxed accumulated and current earnings and profits of certain of our foreign subsidiaries, which the Company expects to pay, net of certain tax attributes and credit carryforwards, over eight years beginning in 2018. Proposed regulations issued by the U.S. Department of the Treasury on August 1, 2018, provided further interpretive guidance on the transition tax. During the year ended December 31, 2018 , the Company revised its estimated liability for the transition tax from $113.6 million to $99.1 million . The $14.5 million benefit was recorded as a component of the Company’s tax provision during the year ended December 31, 2018. The Tax Act includes a provision designed to currently tax GILTI earned by non-U.S. corporate subsidiaries of large U.S. shareholders starting in 2018. The Company has elected, as permitted in FASB Staff Q&A - Topic 740 - No. 5, to treat any future GILTI tax liabilities as period costs and will expense those liabilities in the period incurred. The Company has not recorded deferred taxes associated with the GILTI provision of the Tax Act. As of December 31, 2018 , the Company’s practice and intention was to reinvest the earnings in our non-U.S. subsidiaries outside of the U.S., and no U.S. deferred income taxes or foreign withholding taxes were recorded. The transition tax noted above resulted in the previously untaxed foreign earnings of U.S. subsidiaries being included in the federal and state taxable income. We analyze on an ongoing basis our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries repatriate cash, which include potential local country withholding taxes and U.S. state taxation. The Company’s accounting for the impact of the 2017 Tax Act was completed during the year ended December 31, 2018. However, the Company continues to analyze the provisions of the Tax Act. Subsequent to the enactment of the Tax Act, additional guidance was issued by the U.S. Department of the Treasury, including Notices, Proposed Regulations, and Final Regulations. Further guidance may be issued in 2019 which could impact our interpretations of the Tax Act and materially impact the amounts recorded related to the Tax Act. The income tax provision (benefit) consisted of the following components: Year Ended December 31, (In millions) 2018 2017 2016 U.S. Federal: Current $ (68.2 ) $ 39.5 $ 86.8 Deferred (112.9 ) 28.2 (303.8 ) (181.1 ) 67.7 (217.0 ) U.S. State: Current 6.8 3.9 13.8 Deferred (12.3 ) (0.6 ) (14.8 ) (5.5 ) 3.3 (1.0 ) Non-U.S.: Current 271.6 275.0 150.6 Deferred (139.1 ) (139.0 ) (290.9 ) 132.5 136.0 (140.3 ) Income tax (benefit) provision $ (54.1 ) $ 207.0 $ (358.3 ) Earnings before income taxes: United Kingdom $ 1,259.8 $ 89.7 $ (129.4 ) United States (1,000.5 ) (414.5 ) (187.4 ) Foreign - Other 39.1 1,227.8 438.5 Total earnings before income taxes $ 298.4 $ 903.0 $ 121.7 For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis. Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows: (In millions) December 31, 2018 December 31, 2017 Deferred tax assets: Employee benefits $ 184.8 $ 215.0 Litigation reserves 15.7 45.3 Accounts receivable allowances 217.7 251.7 Tax credit and loss carry-forwards 891.4 849.9 Interest expense 373.5 151.7 Intangible assets 104.1 114.9 Other 182.4 212.4 1,969.6 1,840.9 Less: Valuation allowance (806.0 ) (662.8 ) Total deferred tax assets 1,163.6 1,178.1 Deferred tax liabilities: Plant and equipment 105.6 120.7 Intangible assets and goodwill 2,189.2 2,538.2 Other 18.7 34.8 Total deferred tax liabilities 2,313.5 2,693.7 Deferred tax liabilities, net $ (1,149.9 ) $ (1,515.6 ) For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the amount by which the investment in those subsidiaries, as recorded for U.S. GAAP purposes, exceeds the tax basis. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such temporary differences is approximately $1.8 billion at December 31, 2018 . Determination of the amount of any unrecognized deferred income tax liability on this temporary difference is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes. No deferred taxes have been recorded on the instances whereby the Company’s investment in foreign subsidiaries is currently greater for tax purposes than for U.S. GAAP purposes, as management has no current plans that would cause that temporary difference to reverse in the foreseeable future. A reconciliation of the UK statutory tax rate of 19% to the effective tax rate is as follows: Year Ended December 31, 2018 2017 2016 Statutory tax rate 19.0 % 19.0 % 20.0 % United States Operations Clean energy and research credits (33.1 )% (10.1 )% (85.9 )% U.S. rate differential (5.4 )% 7.4 % (36.9 )% Tax Act - transition tax & deferred tax rate change (4.9 )% 8.4 % — % Uncertain tax positions (22.5 )% 1.0 % 2.2 % State income taxes and credits (3.2 )% (0.6 )% (8.1 )% Valuation allowance 54.2 % 10.3 % 4.4 % Global intangible low-taxed income 8.6 % — % — % Other U.S. items 7.5 % 0.2 % 1.3 % Other Foreign Operations Luxembourg (28.3 )% (10.1 )% (52.6 )% Luxembourg — U.S. Branch — % — % (28.8 )% Gibraltar (19.2 )% (6.5 )% (49.2 )% India (0.6 )% (0.5 )% (13.0 )% Ireland (3.5 )% (1.4 )% (7.2 )% Other 9.0 % 2.7 % 2.0 % Deferred tax rate change (5.2 )% (2.6 )% (5.2 )% Valuation allowance (4.3 )% 3.9 % 79.9 % Withholding taxes 4.1 % 1.3 % 14.3 % Merger of foreign subsidiaries — % — % (123.5 )% Other foreign items 9.7 % 0.5 % (8.1 )% Effective tax rate (18.1 )% 22.9 % (294.4 )% During 2016, the Company merged its wholly owned subsidiary, Jai Pharma Limited, into Mylan India. The merger resulted in the recognition of a deferred tax asset of approximately $150 million for the tax deductible goodwill in excess of the book goodwill with a corresponding benefit to income tax provision for the year ended December 31, 2016. Valuation Allowance A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2018 , a valuation allowance has been applied to certain deferred tax assets in the amount of $806.0 million . When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations. Net Operating Losses As of December 31, 2018 , the Company has U.S. federal net operating loss carry-forwards of $44.0 million , and U.S. state income tax loss carry-forwards of approximately $2.80 billion . The Company also has non-U.S. net operating loss carryforwards of approximately $1.69 billion , of which $1.39 billion can be carried forward indefinitely, with the remaining $300.0 million expiring in years 2019 through 2037. Most of the net operating losses have a full valuation allowance. The Company also has $71.0 million of foreign deductible attributes that can be carried forward indefinitely. The Company has $73.4 million of foreign capital loss carry-forwards expiring in 2019 through 2022. A full valuation allowance is recorded against these losses. The Company also has $211.0 million of U.S. and foreign credit carryovers, expiring in various amounts through 2038. Tax Examinations The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation. Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. Mylan is subject to ongoing U.S. Internal Revenue Service (“IRS”) examinations and is a voluntary participant in the IRS Compliance Assurance Process (“CAP”), which allows Mylan to work collaboratively with the IRS to identify and review tax matters on an ongoing basis. The years 2015, 2016 and 2017 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition has been filed regarding the matter and a trial was held in December 2018. On February 27, 2015, Mylan N.V. acquired Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business (collectively, the “EPD Business Acquisition”). In connection with the EPD Business Acquisition, we entered into intercompany transactions with our affiliates that affect our U.S. tax liability. Mylan N.V. is not incorporated in the U.S. and expects to be treated as a non-U.S. corporation for U.S. federal income tax purposes. As part of our ongoing participation and cooperation in the CAP, we have received and responded to various IRS requests for information about, among other matters, the EPD Business Acquisition, including the interest rates used for intercompany loans and our status as a non-U.S. corporation for U.S. federal income tax purposes. As previously disclosed, the IRS may challenge our positions on the EPD Business Acquisition. We remain confident in our positions and, should the IRS choose to challenge our positions, we would vigorously defend our positions through all available channels. If the IRS chooses to challenge our positions, and if the IRS succeeds, we would be subject to significantly greater U.S. tax liability, beginning February 27, 2015, than currently contemplated as a non-U.S. corporation, which would have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price. The Company’s major state taxing jurisdictions remain open from fiscal year 2008 through 2017, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2011 through 2017, some of which are indemnified by Strides Arcolab for tax assessments. Tax Court Proceeding The Company's U.S. federal income tax returns for 2007 through 2011 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether the proceeds received by the Company in connection with the 2008 sale of its rights in nebivolol constituted a capital gain or ordinary income. The Company and the IRS filed a joint stipulation of settled issues with the Tax Court that resolved all issues in this dispute and the Tax Court issued the final order closing the case during 2018. Accounting for Uncertainty in Income Taxes The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained. As of December 31, 2018 and 2017 , the Company’s Consolidated Balance Sheets reflect net liabilities for unrecognized tax benefits of $96.3 million and $185.7 million , of which $96.3 million and $138.4 million , respectively, would affect the Company’s effective tax rate if recognized. Accrued interest and penalties included in the Consolidated Balance Sheets were $72.6 million and $90.9 million as of December 31, 2018 and 2017 , respectively. For the year ended December 31, 2018 , 2017 and 2016 , Mylan recognized $18.3 million of interest income and $11.1 million and $6.9 million , respectively, of interest expense related to uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision. A reconciliation of the unrecognized tax benefits is as follows: Year Ended December 31, (In millions) 2018 2017 2016 Unrecognized tax benefit — beginning of year $ 185.7 $ 190.9 $ 174.1 Additions for current year tax positions — 4.4 2.1 Additions for prior year tax positions 20.0 5.5 — Reductions for prior year tax positions (5.8 ) (0.8 ) (1.8 ) Settlements (32.9 ) (0.4 ) — Reductions due to expirations of statute of limitations (70.7 ) (13.9 ) (7.7 ) Addition due to acquisition — — 24.2 Unrecognized tax benefit — end of year $ 96.3 $ 185.7 $ 190.9 The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $40.0 million , involving federal and state audits and settlements and expirations of certain state, federal, and foreign statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months .

Share-Based Incentive Plan

Share-Based Incentive Plan	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Incentive Plan	Share-Based Incentive Plan The Company’s shareholders have approved the 2003 Long-Term Incentive Plan (as amended, the “2003 Plan”). Under the 2003 Plan, 55,300,000 ordinary shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, stock appreciation rights (“SAR”), restricted ordinary shares and units, performance awards (“PSU”), other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the ordinary shares underlying the options at the date of the grant, generally become exercisable over periods ranging from three to four years , and generally expire in ten years . The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2015 7,732,499 $ 31.85 Granted 876,397 45.51 Exercised (612,477 ) 23.13 Forfeited (296,978 ) 50.70 Outstanding at December 31, 2016 7,699,441 $ 33.38 Granted 964,475 42.48 Exercised (902,041 ) 20.06 Forfeited (563,191 ) 47.36 Outstanding at December 31, 2017 7,198,684 $ 35.17 Granted 905,265 40.38 Exercised (820,603 ) 21.75 Forfeited (468,068 ) 47.86 Outstanding at December 31, 2018 6,815,278 $ 36.61 Vested and expected to vest at December 31, 2018 6,603,247 $ 36.41 Exercisable at December 31, 2018 5,134,445 $ 34.76 As of December 31, 2018 , stock awards outstanding, stock awards vested and expected to vest, and stock awards exercisable had average remaining contractual terms of 5.3 years , 5.2 years and 4.2 years , respectively. Also at December 31, 2018 , stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had aggregate intrinsic values of $15.9 million . A summary of the status of the Company’s nonvested restricted ordinary shares and restricted stock unit awards, including PSUs (collectively, “restricted stock awards”) as of December 31, 2017 and the changes during the year ended December 31, 2018 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2017 5,964,207 $ 41.92 Granted 1,542,727 41.00 Released (762,561 ) 49.11 Forfeited (351,292 ) 43.70 Nonvested at December 31, 2018 6,393,081 $ 40.75 Of the 1,542,727 restricted stock awards granted during the year ended December 31, 2018 , 757,433 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining restricted stock awards granted, 668,878 are subject to market conditions and will cliff vest in three years or less and 116,416 are not subject to market or performance conditions and will cliff vest in one year or less. As of December 31, 2018 , the Company had $80.6 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to be recognized over the remaining weighted average vesting period of 1.5 years . The total intrinsic value of stock-based awards exercised and restricted stock awards released during the years ended December 31, 2018 and 2017 was $46.3 million and $39.1 million , respectively. With respect to options granted under the Company’s 2003 Plan, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors. The assumptions used for options granted under the 2003 Plan are as follows: Year Ended December 31, 2018 2017 2016 Volatility 35.8% 33.2% 38.1% Risk-free interest rate 2.8% 2.2% 1.4% Expected term (years) 6.5 6.4 6.3 Forfeiture rate 5.5% 5.5% 5.5% Weighted average grant date fair value per option $16.51 $15.88 $17.90 In February 2014, Mylan ’s Compensation Committee and the independent members of the Board of Directors adopted the One-Time Special Performance-Based Five-Year Realizable Value Incentive Program (the “2014 Program”) under the 2003 Plan. Under the 2014 Program, certain key employees received a one-time, performance-based incentive award (the “Awards”) either in the form of a grant of SARs or PSUs. The initial Awards were granted in February 2014 and contain a five -year cliff-vesting feature based on the achievement of various performance targets, external market conditions and the employee’s continued services. Additional Awards were granted in 2016 and 2017 and are subject to the same performance conditions as the Awards granted in February 2014 and with a service vesting condition of between two and six years. The market condition was met on June 10, 2015. During the year ended December 31, 2018 , the Company determined that it was no longer probable that the minimum performance condition would be met and therefore reversed all of the cumulative expense related to the Awards resulting in a reduction in share-based compensation expense of approximately $70.6 million . In addition, during the year ended December 31, 2018 , the Company recorded $20.0 million of compensation expense as an additional discretionary bonus for a certain group of employees. None of the employees who are eligible for this bonus are named executive officers. As of December 31, 2018 , there are approximately 2.6 million Awards outstanding under the 2014 Program, which are expected to be canceled in the first quarter of 2019.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefit Plans Defined Benefit Plans The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. The Company maintains two fully frozen defined benefit pension plans in the U.S., and employees in the U.S. and Puerto Rico are provided retirement benefits through defined contribution plans rather than through a defined benefit plan. The Company also sponsors other postretirement benefit plans. There are plans that provide for postretirement supplemental medical coverage. Benefits from these plans are paid to certain employees and their spouses and dependents who meet various minimum age and service requirements. In addition, there are plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees. Accounting for Defined Benefit Pension and Other Postretirement Plans The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive income. Included in accumulated other comprehensive loss as of December 31, 2018 and 2017 are: Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2018 2017 Unrecognized actuarial (gains) losses $ (10.3 ) $ (8.6 ) $ 1.1 $ 2.0 Unrecognized prior service costs 12.1 2.0 0.7 0.7 Total $ 1.8 $ (6.6 ) $ 1.8 $ 2.7 Of the December 31, 2018 amount, the Company expects to recognize approximately $0.9 million of unrecognized actuarial gains and $1.0 million of unrecognized prior service costs in net periodic benefit cost during 2019 . The unrecognized net actuarial losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants. The increase in accumulated other comprehensive income in 2018 relating to pension benefits and other postretirement benefits consists of: (In millions) Pension Benefits Other Postretirement Benefits Unrecognized actuarial (gain)/loss $ (2.1 ) $ (0.6 ) Amortization of actuarial (gain)/loss (0.1 ) (0.3 ) Unrecognized prior service costs 6.6 — Amortization of prior service costs (0.4 ) — Impact of foreign currency translation 0.7 — Net change $ 4.7 $ (0.9 ) Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans. Net Periodic Benefit Cost Components of net periodic benefit cost for the years ended December 31, 2018 , 2017 and 2016 were as follows: Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2016 2018 2017 2016 Service cost $ 19.2 $ 20.1 $ 17.4 $ 0.6 $ 0.7 $ 0.6 Interest cost 13.0 13.6 8.2 1.5 1.6 1.3 Expected return on plan assets (14.4 ) (14.3 ) (10.9 ) — — — Plan curtailment, settlement and termination (0.1 ) (1.7 ) (2.4 ) — — — Amortization of prior service costs 0.3 0.2 0.3 — — — Recognized net actuarial (gains) losses (0.1 ) 0.3 0.8 0.2 0.4 0.3 Net periodic benefit cost $ 17.9 $ 18.2 $ 13.4 $ 2.3 $ 2.7 $ 2.2 Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2018 and 2017 . Pension Benefits Other Postretirement Benefits (In millions) 2018 2017 2018 2017 Change in Projected Benefit Obligation Projected benefit obligation, beginning of year $ 665.2 $ 632.9 $ 35.1 $ 38.0 Service cost 19.2 20.1 0.7 0.7 Interest cost 13.0 13.6 1.3 1.6 Participant contributions 1.0 1.0 0.2 0.2 Transferred liabilities 16.1 0.5 — — Plan settlements and terminations (7.6 ) (28.4 ) — — Actuarial losses (gains) (27.4 ) 9.3 (0.6 ) (2.7 ) Benefits paid (24.9 ) (24.5 ) (2.7 ) (2.5 ) Impact of foreign currency translation (19.2 ) 40.7 — (0.2 ) Projected benefit obligation, end of year $ 635.4 $ 665.2 $ 34.0 $ 35.1 Change in Plan Assets Fair value of plan assets, beginning of year $ 296.1 $ 291.7 $ — $ — Actual return on plan assets (11.0 ) 21.7 — — Company contributions 28.9 31.5 2.5 2.3 Participant contributions 1.0 1.0 0.2 0.2 Transferred assets 16.1 0.5 — — Plan settlements (16.5 ) (28.0 ) — — Benefits paid (24.9 ) (24.5 ) (2.7 ) (2.5 ) Other (1.6 ) (0.4 ) — — Impact of foreign currency translation (4.6 ) 2.6 — — Fair value of plan assets, end of year 283.5 296.1 — — Funded status of plans $ (351.9 ) $ (369.1 ) $ (34.0 ) $ (35.1 ) Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s Consolidated Balance Sheets at December 31, 2018 and 2017 : Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2018 2017 Noncurrent assets $ 5.9 $ 6.0 $ — $ — Current liabilities (11.9 ) (11.7 ) (1.7 ) (1.6 ) Noncurrent liabilities (345.9 ) (363.4 ) (32.3 ) (33.5 ) Net accrued benefit costs $ (351.9 ) $ (369.1 ) $ (34.0 ) $ (35.1 ) The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $592.5 million and $598.5 million at December 31, 2018 and 2017 , respectively. The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2018 and 2017 were as follows: December 31, (In millions) 2018 2017 Plans with accumulated benefit obligation in excess of plan assets: Projected benefit obligation $ 502.9 $ 530.1 Accumulated benefit obligation 483.1 506.0 Fair value of plan assets 154.8 164.8 Fair Value of Plan Assets The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 8 Financial Instruments and Risk Management . The table below presents total plan assets by investment category as of December 31, 2018 and 2017 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value: December 31, 2018 (In millions) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 3.5 $ 0.4 $ — $ 3.9 Equity securities 58.5 66.0 — 124.5 Fixed income securities 65.4 58.4 — 123.8 Assets held by insurance companies and other 0.1 7.2 24.0 31.3 Total $ 127.5 $ 132.0 $ 24.0 $ 283.5 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 2.5 $ 0.3 $ — $ 2.8 Equity securities 65.2 71.8 — 137.0 Fixed income securities 45.2 57.6 — 102.8 Assets held by insurance companies and other 10.4 23.9 19.2 53.5 Total $ 123.3 $ 153.6 $ 19.2 $ 296.1 Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met. Assumptions The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2018 and 2017 : Pension Benefits Other Postretirement Benefits 2018 2017 2018 2017 Discount rate 2.3 % 2.0 % 4.3 % 3.7 % Expected return on plan assets 4.9 % 4.9 % — % — % Rate of compensation increase 2.9 % 2.8 % — % — % The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2018 : Pension Benefits Other Postretirement Benefits 2018 2017 2016 2018 2017 2016 Discount rate 2.0 % 2.2 % 2.1 % 3.7 % 4.2 % 4.2 % Expected return on plan assets 4.9 % 5.0 % 4.9 % — % — % — % Rate of compensation increase 2.9 % 2.8 % 3.2 % — % — % — % The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated. The weighted-average healthcare cost trend rate used for 2018 was 7.5% declining to a projected 5.0% in the year 2022 . For 2019 , the assumed weighted-average healthcare cost trend rate used will be 5.6% declining to a projected 4.5% in the year 2023 . In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates. If these 2019 healthcare cost trend rates were increased or decreased by one percentage point per year, such increase or decrease would have the following effects: (In millions) Increase Decrease Increase (decrease) in the aggregate of service and interest cost components of annual expense $ 0.1 $ (0.1 ) Increase (decrease) in the projected benefit obligation 1.2 (1.0 ) Estimated Future Benefit Payments The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the nonqualified plans are paid as they come due. Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows: (In millions) Pension Benefits Other Postretirement Benefits 2019 $ 32.0 $ 1.7 2020 34.2 1.7 2021 35.7 2.0 2022 34.0 2.3 2023 36.4 2.2 Thereafter 192.1 11.6 Total $ 364.4 $ 21.5 Defined Contribution Plans The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a 401(k) retirement plan with a profit sharing component for non-union represented employees (the “Profit Sharing 401(k) Plan”) and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the Consolidated Statements of Operations when they are earned. The Company adopted a 401(k) Restoration Plan (the “Restoration Plan”), which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code. The Company adopted an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted. Total employer contributions to defined contribution plans were approximately $85.2 million , $95.9 million and $95.6 million for the years ended December 31, 2018 , 2017 and 2016 , respectively. Other Benefit Arrangements The Company participated in a multi-employer pension plan under previous collective bargaining agreements. The PACE Industry Union-Management Pension Fund (the “Plan”) provides defined benefits to certain retirees and certain production and maintenance employees at the Company’s manufacturing plant in Morgantown, West Virginia who were covered by the previous collective bargaining agreements. Pursuant to a collective bargaining agreement entered into on April 16, 2012, the Company withdrew from the Plan effective May 10, 2012. In 2013, the Plan trustee notified the Company that its withdrawal liability was approximately $27.3 million , which was accrued by the Company in 2013. The withdrawal liability is being paid over a period of approximately nine years; payments began in March 2014 . The withdrawal liability was approximately $15.1 million and $18.1 million at December 31, 2018 and 2017 , respectively. The Employee Identification Number for the Plan is 11-6166763.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Segment Information	ment Information Mylan reports segment information on a geographic basis. This approach reflects the company’s focus on bringing its broad and diversified portfolio of generic, branded generic, brand-name and OTC products to people in markets everywhere. Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment encompasses our operations in 35 countries, including France, Italy, Germany, the U.K. and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle East and Southeast Asia. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct R&D and direct SG&A. Certain general and administrative and R&D expenses not allocated to the segments, including certain special items, net charges for litigation settlements and other contingencies, amortization of intangible assets, impairment charges and other expenses not directly attributable to the segments are reported separately or outside of segment profitability. Items below the earnings from operations line on the Company’s Consolidated Statements of Operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company has revised segment profitability for Rest of World to conform with the current presentation by reclassifying approximately $78.2 million of net gains to litigation settlements and other contingencies for the year ended December 31, 2017. The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies . Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level. Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2018 Net sales $ 4,095.6 $ 4,157.3 $ 3,015.8 $ — $ 11,268.7 Other revenue 112.4 27.1 25.7 — 165.2 Intersegment revenue 85.2 107.8 343.9 (536.9 ) — Total $ 4,293.2 $ 4,292.2 $ 3,385.4 $ (536.9 ) $ 11,433.9 Segment profitability $ 1,838.4 $ 1,089.5 $ 692.0 $ — $ 3,619.9 Intangible asset amortization expense (1,606.4 ) Intangible asset impairment charges (224.0 ) Globally managed research and development costs (250.3 ) Corporate costs and special items (683.1 ) Litigation settlements & other contingencies 49.5 Earnings from operations $ 905.6 North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2017 Net sales $ 4,969.6 $ 3,958.3 $ 2,832.1 $ — $ 11,760.0 Other revenue 86.5 36.5 24.7 — 147.7 Intersegment revenue 74.6 112.4 379.2 (566.2 ) — Total $ 5,130.7 $ 4,107.2 $ 3,236.0 $ (566.2 ) $ 11,907.7 Segment profitability $ 2,497.1 $ 1,082.8 $ 572.7 $ — $ 4,152.6 Intangible asset amortization expense (1,437.4 ) Intangible asset impairment charges (80.8 ) Globally managed research and development costs (356.4 ) Corporate costs and special items (853.9 ) Litigation settlements & other contingencies 13.1 Earnings from operations $ 1,437.2 North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2016 Net sales $ 5,629.5 $ 2,953.8 $ 2,383.8 $ — $ 10,967.1 Other revenue 88.4 12.6 8.8 — 109.8 Intersegment revenue 45.4 106.3 407.6 (559.3 ) — Total $ 5,763.3 $ 3,072.7 $ 2,800.2 $ (559.3 ) $ 11,076.9 Segment profitability $ 2,921.2 $ 669.4 $ 423.5 $ — $ 4,014.1 Intangible asset amortization expense (1,195.3 ) Intangible asset impairment charges (68.3 ) Globally managed research and development costs (423.7 ) Corporate costs and special items (955.1 ) Litigation settlements & other contingencies (672.5 ) Earnings from operations $ 699.2 The following table represents the percentage of consolidated net sales to Mylan’s major customers during the years ended December 31, 2018 , 2017 , and 2016 : Percentage of Consolidated Net Sales 2018 2017 2016 McKesson Corporation 12 % 13 % 16 % AmerisourceBergen Corporation 8 % 8 % 14 % Cardinal Health, Inc. 8 % 10 % 11 % Sales by Country Information Net sales by country are presented on the basis of geographic location of our subsidiaries: Year Ended December 31, (In millions) 2018 2017 2016 United States $ 3,865.2 $ 4,683.7 $ 5,385.6 India 1,164.8 1,082.6 985.8 The Netherlands (1) 132.2 117.5 88.3 Other countries (2) 6,106.5 5,876.2 4,507.4 $ 11,268.7 $ 11,760.0 $ 10,967.1 ____________ (1) Mylan N.V. has its corporate seat in the Netherlands. (2) No other country’s net sales represents more than 10% of consolidated net sales for the years ended December 31, 2018 , 2017 and 2016 , respectively.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2018
Commitments [Abstract]
Commitments	Commitments Operating Leases The Company leases certain property under various operating lease arrangements. These leases generally provide the Company with the option to renew the lease at the end of the lease term. For the years ended December 31, 2018 , 2017 and 2016 , the Company had operating lease expense of approximately $78.9 million , $83.8 million and $70.8 million , respectively. Future minimum lease payments under operating lease commitments are as follows: (In millions) December 31, 2019 $ 73.7 2020 54.7 2021 40.2 2022 28.5 2023 18.3 Thereafter 54.2 $ 269.6 Other Commitments The Company has also entered into employment and other agreements with certain executives and other employees that provide for compensation, retirement and certain other benefits. These agreements provide for severance payments under certain circumstances. Additionally, the Company has split-dollar life insurance agreements with certain retired executives. In the normal course of business, Mylan periodically enters into employment, legal settlement and other agreements which incorporate indemnification provisions. While the maximum amount to which Mylan may be exposed under such agreements cannot be reasonably estimated, the Company maintains insurance coverage, which management believes will effectively mitigate the Company’s obligations under these indemnification provisions. No amounts have been recorded in the Consolidated Financial Statements with respect to the Company’s obligations under such agreements.

Subsidiary Guarantors

Subsidiary Guarantors	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	idiary Guarantors The following tables present condensed consolidating financial information for (a) Mylan N.V., the issuer of the 2.500% Senior Notes due 2019, 3.750% Senior Notes due 2020, 3.150% Senior Notes due 2021, 3.950% Senior Notes due 2026 and 5.250% Senior Notes due 2046 (collectively, the “Mylan N.V. Senior Notes”), which are guaranteed on a senior unsecured basis by Mylan Inc.; (b) Mylan Inc., the issuer of the 3.125% Senior Notes due 2023, 4.200% Senior Notes due 2023, 4.550% Senior Notes due 2028, 5.400% Senior Notes due 2043 and 5.200% Senior Notes due 2048 (collectively, the “Mylan Inc. Senior Notes”), which are guaranteed on a senior unsecured basis by Mylan N.V.; and (c) all other subsidiaries of the Company on a combined basis, none of which guarantee the Mylan N.V. Senior Notes or guarantee the Mylan Inc. Senior Notes (“Non-Guarantor Subsidiaries”). The consolidating adjustments primarily relate to eliminations of investments in subsidiaries and intercompany balances and transactions. The condensed consolidating financial statements present investments in subsidiaries using the equity method of accounting. The following financial information presents the related Condensed Consolidating Balance Sheets as of December 31, 2018 and 2017 and the related Condensed Consolidating Statements of Operations, Condensed Consolidating Statements of Comprehensive Earnings and Condensed Consolidating Statements of Cash Flows for each of the three years in the period ended December 31, 2018 . This condensed consolidating financial information has been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The Company has revised its consolidating balance sheet as previously presented in the 2017 Annual Report on Form 10-K to appropriately present intercompany activity relating to certain subsidiaries which were included in the Mylan Inc. column. The Company overstated the line items investment in subsidiaries and total equity within the Mylan Inc. column with a corresponding offset to the elimination column. Specifically, the balance sheet caption investment in subsidiaries has been revised from the previously reported amount of $15.3 billion as of December 31, 2017 to $13.7 billion with an offset to total equity. There is no impact to the consolidated financial statements of Mylan N.V. as previously filed in the 2017 Annual Report on Form 10-K. CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 18.2 $ — $ 369.9 $ — $ 388.1 Accounts receivable, net — 24.3 — 2,856.7 — 2,881.0 Inventories — — — 2,580.2 — 2,580.2 Intercompany receivables 342.9 518.7 — 13,107.1 (13,968.7 ) — Prepaid expenses and other current assets 5.6 71.3 — 441.5 — 518.4 Total current assets 348.5 632.5 — 19,355.4 (13,968.7 ) 6,367.7 Property, plant and equipment, net — 259.7 — 1,910.5 — 2,170.2 Investments in subsidiaries 18,995.9 13,129.5 — — (32,125.4 ) — Intercompany notes and interest receivable 6,287.4 10,732.6 — 2,519.8 (19,539.8 ) — Intangible assets, net — — — 13,664.6 — 13,664.6 Goodwill — 17.1 — 9,730.7 — 9,747.8 Other assets 0.3 68.9 — 715.4 — 784.6 Total assets $ 25,632.1 $ 24,840.3 $ — $ 47,896.4 $ (65,633.9 ) $ 32,734.9 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 70.6 $ — $ 1,546.4 $ — $ 1,617.0 Short-term borrowings — — — 1.9 — 1.9 Income taxes payable — — — 121.5 — 121.5 Current portion of long-term debt and other long-term obligations 649.0 0.2 — 50.6 — 699.8 Intercompany payables 1,618.8 12,326.4 — 23.5 (13,968.7 ) — Other current liabilities 21.0 216.0 — 1,910.6 — 2,147.6 Total current liabilities 2,288.8 12,613.2 — 3,654.5 (13,968.7 ) 4,587.8 Long-term debt 9,370.1 3,786.2 — 4.9 — 13,161.2 Intercompany notes payable 1,806.1 3,094.2 — 14,639.5 (19,539.8 ) — Other long-term obligations — 48.6 — 2,770.2 — 2,818.8 Total liabilities 13,465.0 19,542.2 — 21,069.1 (33,508.5 ) 20,567.8 Total equity 12,167.1 5,298.1 — 26,827.3 (32,125.4 ) 12,167.1 Total liabilities and equity $ 25,632.1 $ 24,840.3 $ — $ 47,896.4 $ (65,633.9 ) $ 32,734.9 CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Accounts receivable, net — 1.0 — 3,611.4 — 3,612.4 Inventories — — — 2,542.7 — 2,542.7 Intercompany receivables 317.2 462.1 — 11,828.5 (12,607.8 ) — Prepaid expenses and other current assets 5.6 171.1 — 589.4 — 766.1 Total current assets 322.8 634.4 — 18,863.9 (12,607.8 ) 7,213.3 Property, plant and equipment, net — 294.1 — 2,045.0 — 2,339.1 Investments in subsidiaries 19,736.5 13,683.3 — — (33,419.8 ) — Intercompany notes and interest receivable 7,822.6 10,271.2 — 2,186.3 (20,280.1 ) — Intangible assets, net — — — 15,245.8 — 15,245.8 Goodwill — 17.1 — 10,188.6 — 10,205.7 Other assets 4.9 56.5 — 741.0 — 802.4 Total assets $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 45.3 $ — $ 1,407.2 $ — $ 1,452.5 Short-term borrowings — — — 46.5 — 46.5 Income taxes payable — — — 112.9 — 112.9 Current portion of long-term debt and other long-term obligations 1,097.8 649.1 — 62.0 — 1,808.9 Intercompany payables 664.7 11,911.5 — 31.6 (12,607.8 ) — Other current liabilities 35.5 397.0 — 2,532.0 — 2,964.5 Total current liabilities 1,798.0 13,002.9 — 4,192.2 (12,607.8 ) 6,385.3 Long-term debt 10,614.3 2,244.5 — 6.5 — 12,865.3 Intercompany notes payable 2,166.9 3,312.7 — 14,800.5 (20,280.1 ) — Other long-term obligations — 57.3 — 3,190.8 — 3,248.1 Total liabilities 14,579.2 18,617.4 — 22,190.0 (32,887.9 ) 22,498.7 Total equity 13,307.6 6,339.2 — 27,080.6 (33,419.8 ) 13,307.6 Total liabilities and equity $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 11,268.7 $ — $ 11,268.7 Other revenues — — — 165.2 — 165.2 Total revenues — — — 11,433.9 — 11,433.9 Cost of sales — — — 7,432.3 — 7,432.3 Gross profit — — — 4,001.6 — 4,001.6 Operating expenses: Research and development — — — 704.5 — 704.5 Selling, general and administrative 40.7 517.3 — 1,883.0 — 2,441.0 Litigation settlements and other contingencies, net — 7.1 — (56.6 ) — (49.5 ) Total operating expenses 40.7 524.4 — 2,530.9 — 3,096.0 (Losses) earnings from operations (40.7 ) (524.4 ) — 1,470.7 — 905.6 Interest expense 349.0 154.6 — 38.7 — 542.3 Other (income) expense, net (316.4 ) (273.3 ) — 654.6 — 64.9 (Losses) earnings before income taxes (73.3 ) (405.7 ) — 777.4 — 298.4 Income tax (benefit) provision (28.7 ) (27.4 ) — 2.0 — (54.1 ) Earnings of equity interest subsidiaries 397.1 328.8 — — (725.9 ) — Net earnings (loss) $ 352.5 $ (49.5 ) $ — $ 775.4 $ (725.9 ) $ 352.5 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 11,760.0 $ — $ 11,760.0 Other revenues — — — 147.7 — 147.7 Total revenues — — — 11,907.7 — 11,907.7 Cost of sales — — — 7,124.6 — 7,124.6 Gross profit — — — 4,783.1 — 4,783.1 Operating expenses: Research and development — — — 783.3 — 783.3 Selling, general and administrative 45.5 650.9 — 1,879.3 — 2,575.7 Litigation settlements and other contingencies, net — 17.0 — (30.1 ) — (13.1 ) Total operating expenses 45.5 667.9 — 2,632.5 — 3,345.9 (Losses) earnings from operations (45.5 ) (667.9 ) — 2,150.6 — 1,437.2 Interest expense 378.0 104.1 — 52.5 — 534.6 Other (income) expense, net (484.9 ) (264.6 ) — 749.1 — (0.4 ) Earnings (losses) before income taxes and noncontrolling interest 61.4 (507.4 ) — 1,349.0 — 903.0 Income tax (benefit) provision (21.1 ) (14.0 ) — 242.1 — 207.0 Earnings of equity interest subsidiaries 613.5 886.4 — — (1,499.9 ) — Net earnings $ 696.0 $ 393.0 $ — $ 1,106.9 $ (1,499.9 ) $ 696.0 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 10,967.1 $ — $ 10,967.1 Other revenues — — — 109.8 — 109.8 Total revenues — — — 11,076.9 — 11,076.9 Cost of sales — — — 6,379.9 — 6,379.9 Gross profit — — — 4,697.0 — 4,697.0 Operating expenses: Research and development — — — 826.8 — 826.8 Selling, general and administrative 71.6 664.1 — 1,762.8 — 2,498.5 Litigation settlements and other contingencies, net — — — 672.5 — 672.5 Total operating expenses 71.6 664.1 — 3,262.1 — 3,997.8 (Losses) earnings from operations (71.6 ) (664.1 ) — 1,434.9 — 699.2 Interest expense 198.4 161.3 — 95.1 — 454.8 Other (income) expense, net (55.6 ) (193.2 ) — 371.5 — 122.7 (Losses) earnings before income taxes and noncontrolling interest (214.4 ) (632.2 ) — 968.3 — 121.7 Income tax benefit (19.5 ) (18.2 ) — (320.6 ) — (358.3 ) Earnings of equity interest subsidiaries 674.9 1,360.2 — — (2,035.1 ) — Net earnings $ 480.0 $ 746.2 $ — $ 1,288.9 $ (2,035.1 ) $ 480.0 CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 352.5 $ (49.5 ) $ — $ 775.4 $ (725.9 ) $ 352.5 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (1,125.2 ) — — (1,125.2 ) 1,125.2 (1,125.2 ) Change in unrecognized gain and prior service cost related to defined benefit plans (3.8 ) 0.6 — (4.4 ) 3.8 (3.8 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (79.2 ) 7.7 — (86.9 ) 79.2 (79.2 ) Net unrecognized gain on derivatives in net investment hedging relationships 111.6 11.6 — (11.6 ) 111.6 Net unrealized loss on marketable securities (0.1 ) — — (0.1 ) 0.1 (0.1 ) Other comprehensive (loss) earnings, before tax (1,096.7 ) 19.9 — (1,216.6 ) 1,196.7 (1,096.7 ) Income tax benefit (24.1 ) (4.7 ) — (19.4 ) 24.1 (24.1 ) Other comprehensive (loss) earnings, net of tax (1,072.6 ) 24.6 — (1,197.2 ) 1,172.6 (1,072.6 ) Comprehensive loss $ (720.1 ) $ (24.9 ) $ — $ (421.8 ) $ 446.7 $ (720.1 ) CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 696.0 $ 393.0 $ — $ 1,106.9 $ (1,499.9 ) $ 696.0 Other comprehensive earnings, before tax: Foreign currency translation adjustment 2,103.9 — — 2,103.9 (2,103.9 ) 2,103.9 Change in unrecognized gain and prior service cost related to defined benefit plans 3.8 3.0 — 0.8 (3.8 ) 3.8 Net unrecognized gain on derivatives 52.7 7.3 — 45.4 (52.7 ) 52.7 Net unrecognized loss on derivatives in net investment hedging relationships (238.4 ) — — — — (238.4 ) Net unrealized loss on marketable securities (6.7 ) (6.4 ) — (0.3 ) 6.7 (6.7 ) Other comprehensive earnings, before tax 1,915.3 3.9 — 2,149.8 (2,153.7 ) 1,915.3 Income tax provision (benefit) 12.8 (1.6 ) — 14.4 (12.8 ) 12.8 Other comprehensive earnings, net of tax 1,902.5 5.5 — 2,135.4 (2,140.9 ) 1,902.5 Comprehensive earnings $ 2,598.5 $ 398.5 $ — $ 3,242.3 $ (3,640.8 ) $ 2,598.5 CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 480.0 $ 746.2 $ — $ 1,288.9 $ (2,035.1 ) $ 480.0 Other comprehensive loss, before tax: Foreign currency translation adjustment (507.4 ) — — (507.4 ) 507.4 (507.4 ) Change in unrecognized gain (loss) and prior service cost related to defined benefit plans 21.4 (1.1 ) — 22.5 (21.4 ) 21.4 Net unrecognized (loss) gain on derivatives (31.2 ) (47.7 ) — 16.5 31.2 (31.2 ) Net unrecognized loss on derivatives in net investment hedging relationships (1.8 ) — — (1.8 ) 1.8 (1.8 ) Net unrealized gain on marketable securities 24.6 24.6 — — (24.6 ) 24.6 Other comprehensive loss, before tax (494.4 ) (24.2 ) — (470.2 ) 494.4 (494.4 ) Income tax provision (benefit) 5.0 (9.1 ) — 4.1 5.0 5.0 Other comprehensive loss, net of tax (499.4 ) (15.1 ) — (474.3 ) 489.4 (499.4 ) Comprehensive (loss) earnings $ (19.4 ) $ 731.1 $ — $ 814.6 $ (1,545.7 ) $ (19.4 ) CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (230.4 ) $ (1,551.7 ) $ — $ 4,123.8 $ — $ 2,341.7 Cash flows from investing activities: Capital expenditures — (28.6 ) — (223.5 ) — (252.1 ) Cash paid for acquisitions, net of cash acquired — — — (65.9 ) — (65.9 ) Proceeds from sale of assets and subsidiaries — — — 29.3 — 29.3 Purchase of marketable securities — — — (63.4 ) — (63.4 ) Proceeds from the sale of marketable securities — 36.3 — 48.9 — 85.2 Investments in affiliates — (28.8 ) — — 28.8 — Dividends from affiliates 118.6 — — — (118.6 ) — Loans to affiliates (492.2 ) — — (5,687.8 ) 6,180.0 — Repayments of loans from affiliates 2,615.4 — — 4,066.8 (6,682.2 ) — Payments for product rights and other, net — (0.5 ) — (943.0 ) — (943.5 ) Net cash provided by (used in) investing activities 2,241.8 (21.6 ) — (2,838.6 ) (592.0 ) (1,210.4 ) Cash flows from financing activities: Payments of financing fees (0.6 ) (20.8 ) — — — (21.4 ) Purchase of ordinary shares (432.0 ) — — — — (432.0 ) Change in short-term borrowings, net — — — (44.4 ) — (44.4 ) Proceeds from issuance of long-term debt 496.5 2,079.2 — 2.2 — 2,577.9 Payments of long-term debt (2,012.5 ) (1,150.0 ) — (2.7 ) — (3,165.2 ) Proceeds from exercise of stock options 17.8 — — — — 17.8 Taxes paid related to net share settlement of equity awards (10.1 ) — — — — (10.1 ) Contingent consideration payments — — — (11.9 ) — (11.9 ) Capital contribution from affiliates — — — 28.8 (28.8 ) — Capital payments to affiliates — — — (118.6 ) 118.6 — Payments on borrowings from affiliates (1,454.2 ) (3,691.6 ) — (1,536.4 ) 6,682.2 — Proceeds from borrowings from affiliates 1,383.7 4,350.9 — 445.4 (6,180.0 ) — Acquisition of noncontrolling interest — — — (0.6 ) — (0.6 ) Other items, net — — — (1.0 ) — (1.0 ) Net cash (used in) provided by financing activities (2,011.4 ) 1,567.7 — (1,239.2 ) 592.0 (1,090.9 ) Effect on cash of changes in exchange rates — — — (21.0 ) — (21.0 ) Net (decrease) increase in cash, cash equivalents and restricted cash — (5.6 ) — 25.0 — 19.4 Cash, cash equivalents and restricted cash — beginning of period — 23.8 — 346.1 — 369.9 Cash, cash equivalents and restricted cash — end of period $ — $ 18.2 $ — $ 371.1 $ — $ 389.3 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (326.6 ) $ (381.1 ) $ — $ 2,772.5 $ — $ 2,064.8 Cash flows from investing activities: Capital expenditures — (54.8 ) — (221.1 ) — (275.9 ) Cash paid for acquisitions, net of cash acquired (71.6 ) — — (95.4 ) — (167.0 ) Proceeds from sale of assets and subsidiaries — — — 86.7 — 86.7 Purchase of marketable securities — — — (96.5 ) — (96.5 ) Proceeds from the sale of marketable securities — — — 96.6 — 96.6 Investments in affiliates — (30.2 ) — — 30.2 — Dividends from affiliates 261.3 — — — (261.3 ) — Loans to affiliates (322.7 ) (98.0 ) — (3,493.7 ) 3,914.4 — Repayments of loans from affiliates 1,258.8 0.3 — 1,630.9 (2,890.0 ) — Payments for product rights and other, net — (0.9 ) — (619.4 ) — (620.3 ) Net cash provided by (used in) investing activities 1,125.8 (183.6 ) — (2,711.9 ) 793.3 (976.4 ) Cash flows from financing activities: Payments of financing fees (9.7 ) (0.4 ) — — — (10.1 ) Purchase of ordinary shares (500.2 ) — — — — (500.2 ) Change in short-term borrowings, net — — — (2.9 ) — (2.9 ) Proceeds from issuance of long-term debt 874.5 — — 1.6 — 876.1 Payments of long-term debt (1,820.0 ) — — (412.7 ) — (2,232.7 ) Proceeds from exercise of stock options 17.8 — — — — 17.8 Taxes paid related to net share settlement of equity awards (7.4 ) — — — — (7.4 ) Contingent consideration payments — — — (26.1 ) — (26.1 ) Capital contribution from affiliates — — — 30.2 (30.2 ) — Capital payments to affiliates — — — (261.3 ) 261.3 — Payments on borrowings from affiliates — (2,447.2 ) — (442.8 ) 2,890.0 — Proceeds from borrowings from affiliates 645.5 2,966.7 — 302.2 (3,914.4 ) — Acquisition of noncontrolling interest — — — (7.5 ) — (7.5 ) Other items, net — (16.0 ) — 15.9 — (0.1 ) Net cash (used in) provided by financing activities (799.5 ) 503.1 — (803.4 ) (793.3 ) (1,893.1 ) Effect on cash of changes in exchange rates — — — 27.6 — 27.6 Net decrease in cash, cash equivalents and restricted cash (0.3 ) (61.6 ) — (715.2 ) — (777.1 ) Cash, cash equivalents and restricted cash — beginning of period 0.3 85.4 — 1,061.3 — 1,147.0 Cash, cash equivalents and restricted cash — end of period $ — $ 23.8 $ — $ 346.1 $ — $ 369.9 Supplemental disclosures of cash flow information — Non-cash transactions: Contingent consideration $ — $ — $ — $ 4.0 $ — $ 4.0 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (0.3 ) $ (518.3 ) $ — $ 2,565.8 $ — $ 2,047.2 Cash flows from investing activities: Capital expenditures — (94.4 ) — (296.0 ) — (390.4 ) Cash paid for acquisitions, net of cash acquired (5,608.8 ) (931.3 ) — 58.2 — (6,481.9 ) Cash paid for Meda's unconditional deferred payment — — — (308.0 ) — (308.0 ) Settlement of acquisition-related foreign currency derivatives (128.6 ) — — — — (128.6 ) Purchase of marketable securities — (4.3 ) — (25.9 ) — (30.2 ) Proceeds from the sale of marketable securities — — — 21.5 — 21.5 Investments in affiliates — (49.6 ) — — 49.6 — Dividends from affiliates 135.6 — — — (135.6 ) — Loans to affiliates (14,073.5 ) (530.2 ) — (3,185.0 ) 17,788.7 — Repayments of loans from affiliates 8,539.6 793.0 — 1,914.1 (11,246.7 ) — Payments for product rights and other, net — 3.3 — (363.5 ) — (360.2 ) Net cash used in investing activities (11,135.7 ) (813.5 ) — (2,184.6 ) 6,456.0 (7,677.8 ) Cash flows from financing activities: Payments of financing fees (112.6 ) — — — — (112.6 ) Change in short-term borrowings, net — — — 40.8 — 40.8 Contingent consideration payments — — — (35.5 ) — (35.5 ) Proceeds from issuance of long-term debt 11,652.6 — — 99.6 — 11,752.2 Payments of long-term debt (400.0 ) (3,400.0 ) — (2,496.3 ) — (6,296.3 ) Proceeds from exercise of stock options 13.8 — — — — 13.8 Taxes paid related to net share settlement of equity awards (17.5 ) — — — — (17.5 ) Capital payments to affiliates — — — (135.6 ) 135.6 — Capital contribution from affiliates — — — 49.6 (49.6 ) — Proceeds from borrowings from affiliates — 6,961.2 — 10,827.6 (17,788.8 ) — Payments on borrowings from affiliates — (3,021.9 ) — (8,224.9 ) 11,246.8 — Acquisition of noncontrolling interest — — (1.1 ) — (1.1 ) Other items, net — (16.2 ) — 17.0 — 0.8 Net cash provided by financing activities 11,136.3 523.1 — 141.2 (6,456.0 ) 5,344.6 Effect on cash of changes in exchange rates — — — (9.6 ) — (9.6 ) Net increase (decrease) in cash, cash equivalents and restricted cash 0.3 (808.7 ) — 512.8 — (295.6 ) Cash, cash equivalents and restricted cash — beginning of period — 894.1 — 548.5 — 1,442.6 Cash, cash equivalents and restricted cash — end of period $ 0.3 $ 85.4 $ — $ 1,061.3 $ — $ 1,147.0 Supplemental disclosures of cash flow information — Non-cash transactions: Contingent consideration $ — $ — $ — $ 16.0 $ — $ 16.0 Ordinary shares issued for acquisition $ 1,281.7 $ — $ — $ — $ — $ 1,281.7 The following tables provide a reconciliation of cash and cash equivalents, as reported on our Condensed Consolidating Balance Sheets, to cash, cash equivalents and restricted cash, as reported on our Condensed Consolidating Statements of Cash Flows (in millions): December 31, 2018 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 18.2 $ — $ 369.9 $ — $ 388.1 Restricted cash, included in prepaid expenses and other current assets — — — 1.2 — 1.2 Cash, cash equivalents and restricted cash $ — $ 18.2 $ — $ 371.1 $ — $ 389.3 December 31, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Restricted cash, included in prepaid expenses and other current assets — 23.6 — 54.2 — 77.8 Cash, cash equivalents and restricted cash $ — $ 23.8 $ — $ 346.1 $ — $ 369.9

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	17. Restructuring On December 5, 2016, the Company announced a restructuring program representing initial steps of a series of actions in certain locations that are anticipated to further streamline its operations globally. Since 2015, the Company has made a number of significant acquisitions, and as part of the holistic, global integration of these acquisitions, the Company is focused on how to best optimize and maximize all of its assets across the organization and across all geographies. Charges for restructuring and ongoing cost reduction initiatives are recorded in the period the Company commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. During the second quarter of 2018, the Company commenced comprehensive restructuring and remediation activities, which are aimed at reducing the complexity at the Morgantown, West Virginia plant and include the discontinuation and transfer to other manufacturing sites of a number of products, a reduction of the workforce and extensive process and facility remediation. The restructuring actions other than for this plant were substantially complete as of December 31, 2018. At this time, the expenses related to the additional restructuring activities at the Morgantown, West Virginia plant cannot be reasonably estimated. The following table summarizes the restructuring charges and the reserve activity from December 31, 2016 to December 31, 2018 : (In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2016: $ 138.6 $ 1.6 $ 140.2 Charges 107.4 80.6 188.0 Cash payment (150.0 ) (2.4 ) (152.4 ) Reclassifications (8.3 ) 8.3 — Utilization — (74.4 ) (74.4 ) Foreign currency translation $ 5.2 $ 0.4 $ 5.6 Balance at December 31, 2017: $ 92.9 $ 14.1 $ 107.0 Charges (1) 71.6 168.6 240.2 Cash payment (100.8 ) (26.1 ) (126.9 ) Utilization — (144.5 ) (144.5 ) Foreign currency translation (2.9 ) (0.3 ) (3.2 ) Balance at December 31, 2018 $ 60.8 $ 11.8 $ 72.6 ____________ (1) For the year ended December 31, 2018 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $129.1 million , $73.4 million , $16.2 million and $21.5 million , respectively. For the year ended December 31, 2017 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $48.0 million , $70.1 million , $36.5 million and $33.4 million respectively. At December 31, 2018 and 2017 , accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities on the Consolidated Balance Sheets.

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	18. Collaboration and Licensing Agreements We periodically enter into collaboration and licensing agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant collaboration agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds, insulin analog products and respiratory products, among other complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the Consolidated Balance Sheets, except for milestone and royalty obligations reflected as acquisition related contingent consideration. Refer to Note 8 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at December 31, 2018 totaled approximately $425 million . We estimate that the amounts that may be paid in the next twelve months to be approximately $35 million . These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty obligations may be significant depending upon the level of commercial sales for each product. Respiratory Delivery Platform On December 23, 2011, the Company completed the acquisition of the respiratory delivery platform. Under the agreement, the development program for the respiratory delivery platform was transferred to the Company along with exclusive licenses and assignments of the intellectual property effective from the closing date. The Company is responsible for all development costs after the closing date. The Company will also lead the commercialization efforts in certain territories, including the U.S. and Europe. Pfizer is eligible to receive milestone payments, which are contingent upon the future product development achievements including regulatory approvals, market launches, sales targets and profitability. On January 30, 2019, the Company received FDA approval of Wixela TM Inhub TM (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus ® . The commercial launch of the Wixela TM Inhub TM occurred in February 2019. In accordance with U.S. GAAP guidance regarding business combinations, the Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at the date of acquisition at the estimate of their respective fair values. The fair value of the contingent consideration liability related to the estimate of future profit sharing and milestone payments was $336.5 million at December 31, 2018 . These payments are contingent upon the occurrence of certain future events and the ultimate success of the respective projects. We estimate the amount of development milestones that may be paid in the next twelve months to be approximately $60 million , a portion of which is accrued as contingent consideration. Given the inherent uncertainty of these events, it is unclear when we may be required to pay such amounts or pay amounts in excess of those accrued. Momenta On January 8, 2016 , the Company entered into an agreement with Momenta Pharmaceuticals, Inc. (“Momenta”) to develop, manufacture and commercialize up to six of Momenta ’s current biosimilar candidates, including Momenta ’s biosimilar candidate, ORENCIA® (abatacept) (“ORENCIA®”). Mylan paid an up-front cash payment of $45 million to Momenta. Under the terms of the agreement, the Company and Momenta are jointly responsible for product development and equally share in the costs and profits of the products with Mylan leading the worldwide commercialization efforts. Under the terms of the agreement, Momenta was eligible to receive additional contingent milestone payments for the development of biosimilar candidates. The Company paid $60 million related to certain milestones in 2016. There were no milestone payments in 2017 or 2018 . On November 1, 2017, the Company and Momenta announced that M834 did not meet its primary pharmacokinetic (PK) endpoints in the Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834 to U.S.- and European Union (“EU”)-sourced ORENCIA® in normal healthy volunteers. On January 3, 2018, the Company and Momenta announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) (“EYLEA®”) injection. EYLEA® is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema. On October 1, 2018, Momenta announced that it had initiated discussions with Mylan to exit its participation in the development of five biosimilar programs including M834, a proposed biosimilar to ORENCIA®. The parties have agreed to the termination of all collaboration activities, except for the continued development of M710, a proposed biosimilar to EYLEA®. The Company remains committed to invest strategically in biosimilar programs through the evaluation of regulatory data and market dynamics. The Company does not anticipate making any additional continuation payments to Momenta. In accordance with ASC 730 , Research and Development and based upon the cost sharing provisions of the agreement, the Company accounted for the contingent milestone payments related to the Momenta collaboration as non-refundable advance payments for services to be used in future R&D activities, which were required to be capitalized until the related services have been performed. More specifically, as costs were incurred within the scope of the collaboration, the Company recorded its share of the costs as R&D expense. In addition to the upfront cash payment, during the years ended December 31, 2018 , 2017 , and 2016 , the Company incurred R&D expense related to this collaboration of approximately $13.4 million , $31.9 million and $29.2 million , respectively. To the extent the contingent milestone payments made by the Company exceeded the liability incurred, a prepaid asset was reflected on the Company’s Consolidated Balance Sheets. To the extent the contingent milestone payments made by the Company were less than the expense incurred, the difference between the payment and the expense was recorded as a liability on the Company’s Consolidated Balance Sheets. At December 31, 2018 , there was no significant recorded prepaid asset or accrued liability on the Consolidated Balance Sheet. Theravance On January 30, 2015 , the Company entered into a development and commercialization collaboration with Theravance Biopharma, Inc. (“Theravance Biopharma”) for the development and, subject to FDA approval, commercialization of Revefenacin (“TD-4208”). Under the terms of the agreement, Mylan and Theravance Biopharma are co-developing nebulized TD-4208 for chronic obstructive pulmonary disease (“COPD”) and other respiratory diseases. Theravance Biopharma is leading the U.S. registrational development program and Mylan was responsible for the reimbursement of Theravance Biopharma ’s development costs for that program up until the approval of the first new drug application (“NDA”). On November 9, 2018, Mylan announced that the FDA approved the NDA for YUPELRI TM (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the U.S. The commercial launch of YUPELRI occurred in the fourth quarter of 2018. Mylan is responsible for commercial manufacturing and commercialization. Theravance Biopharma is co-promoting the product in the hospital channel under a profit-sharing arrangement. Under the terms of the agreement, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling $220 million in the aggregate. As of December 31, 2018 , Mylan has paid a total of $30 million in milestone payments to Theravance Biopharma . Biocon The Company has entered into exclusive collaborations with Biocon Limited (“Biocon”) on the development, manufacturing, supply and commercialization of multiple, high value biosimilar compounds and three insulin analog products for the global marketplace. Under the agreements with Biocon, Mylan has exclusive commercialization rights for the products under the collaborations in the U.S., Canada, Japan, Australia, New Zealand and in the EU and European Free Trade Association countries. Biocon has co-exclusive commercialization rights with Mylan for the products in the rest of the world. In December 2017, the FDA approved Mylan's Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri has been approved for all indications included in the label of the reference product, Herceptin, including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the U.S. Mylan anticipates potentially being the first company to commercialize a biosimilar to Herceptin. In December 2018, the Company received final approval from the European Commission to market Ogivri in all 28 EU member states and the European Economic Area. On June 4, 2018, Mylan and Biocon announced that the FDA approved Mylan's Fulphila™ (pegfilgrastim-jmdb), a biosimilar to Neulasta ® (pegfilgrastim). Fulphila has been approved to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of neutrophils, a type of white blood cells) in patients treated with chemotherapy in certain types of cancer. The commercial launch of Fulphila occurred in the second quarter of 2018. The Company continues to provide development funding related to this collaboration. As the timing of cash expenditures is dependent upon a number of factors, many of which are out of the Company’s control, it is difficult to forecast the amount of payments to be made over the next few years, which could be significant. FKB On February 22, 2018, the Company entered into a collaboration license and distribution agreement with FKB for the distribution of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab). Under the agreement, Mylan has exclusive commercialization rights for the product in the EU and the European Economic Area countries and FKB is responsible for development, manufacturing and supply of the product. On September 20, 2018, the Company received final approval from the European Commission (the “Commission”) to market Hulio for all adalimumab indications in all 28 EU member states and the European Economic Area. Under the agreement, FKB received an upfront payment of $25.0 million , an approval milestone of $10.0 million and is eligible for a royalty based upon net sales. We are actively pursuing, and are currently involved in, joint projects related to the development, distribution and marketing of both generic and branded products. Many of these arrangements provide for payments by us upon the attainment of specified milestones. While these arrangements help to reduce the financial risk for unsuccessful projects, fulfillment of specified milestones or the occurrence of other obligations may result in fluctuations in cash flows and R&D expense.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Litigation The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. The Company is also party to certain proceedings and litigation matters for which it may be entitled to indemnification under the respective sale and purchase agreements relating to the acquisitions of the former Merck Generics business, Agila, Abbott Laboratories’ (“Abbott”) non-U.S. developed markets specialty and branded generics business, and certain other acquisitions. While the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters or the inability or denial of Merck KGaA, Strides Arcolab, Abbott, or another indemnitor or insurer to pay an indemnified claim, could have a material effect on the Company’s business, financial condition, results of operations, cash flows and/or ordinary share price. Some of these governmental inquiries, investigations, proceedings and litigation matters with which the Company is involved are described below, and unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is also involved in other pending proceedings for which, in the opinion of the Company based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s business, financial position, results of operations, cash flows and/or ordinary share price. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in the opinion of the Company, become material, the Company will disclose such matters. Legal costs are recorded as incurred and are classified in SG&A in the Company’s Consolidated Statements of Operations . Lorazepam and Clorazepate On June 1, 2005, a jury verdict was rendered against Mylan, MPI, and co-defendants Cambrex Corporation and Gyma Laboratories in the U.S. District Court for the District of Columbia in the amount of approximately $12.0 million in an antitrust case brought by four health insurers who opted out of earlier class action settlements agreed to by the Company in 2001. The Court entered final judgment on August 30, 2017 in the amount of approximately $67.0 million (not including post-judgment interest and fees and costs). Mylan filed a notice of appeal on September 15, 2017 with the United States Court of Appeals for the District of Columbia Circuit. This matter has been resolved by way of settlement and the case is closed. The Company paid approximately $34.5 million during 2018 related to this matter. The Company maintained a surety bond underwritten by a third-party insurance company in the amount of $66.6 million which has been released. Pricing and Medicaid Litigation Dey L.P. (now known as Mylan Specialty L.P. and herein as “Mylan Specialty”), a wholly owned subsidiary of the Company, was named in 1997 as a defendant in a case brought by the U.S. as well as in later filed class actions brought by consumers and third-party payors. All of the cases and claims brought against Mylan Specialty have been fully resolved and dismissed. Under the terms of the purchase agreement with Merck KGaA, Mylan is fully indemnified for the claims in the preceding paragraph and Merck KGaA is entitled to any income tax benefit the Company realizes for any deductions of amounts paid for such pricing litigation. The Company paid approximately $65.7 million in 2018. No further amounts are owed by the Company. Modafinil Antitrust Litigation Beginning in April 2006, Mylan and four other drug manufacturers were named as defendants in civil lawsuits filed in or transferred to the U.S. District Court for the Eastern District of Pennsylvania (“EDPA”) by a variety of plaintiffs purportedly representing direct and indirect purchasers of the drug modafinil and in a lawsuit filed by Apotex, Inc., a manufacturer of generic drugs. These actions alleged violations of federal antitrust and state laws in connection with the generic defendants’ settlement of patent litigation with Cephalon relating to modafinil. Mylan entered into a settlement agreement with the putative indirect purchasers for approximately $16.0 million , which is subject to court approval. Mylan has settled with the putative direct purchaser class and the retailer opt-out plaintiffs for $165 million , a portion of which was paid by the Company prior to 2018, and a final amount of approximately $89.2 million was paid in April 2018. Mylan and Apotex have also settled Apotex’s claims. The Company has also received subpoenas from certain state attorneys general requesting documents related to the modafinil patent litigation. On July 10, 2015, the Louisiana Attorney General filed in the 19th Judicial District Court in Louisiana a petition against Mylan and three other drug manufacturers asserting state law claims based on the same underlying allegations as those made in the litigation then pending in the EDPA. On December 8, 2016, Mylan’s peremptory exceptions of no cause of action with respect to the supplemental and amended petition were granted in their entirety and with prejudice. The State of Louisiana appealed this decision. The First Circuit Court of Appeal subsequently returned the case to the District Court with instructions to include certain decretal language in order to make the District Court’s decision final and appealable. On July 28, 2016, United Healthcare filed a complaint against Mylan Inc. and four other drug manufacturers in the United States District Court for the District of Minnesota, asserting state law claims based on the same underlying allegations as those made in the litigation then pending in the EDPA. On January 6, 2017, the case was transferred to the EDPA and is still pending. MPI has since been included as an additional party. A trial date has been scheduled for July 2019. The Company believes that it has strong defenses to these remaining cases. Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. The Company has a total accrual of approximately $16.0 million related to this matter at December 31, 2018 , which is included in other current liabilities in the Consolidated Balance Sheets. Pioglitazone Beginning in December 2013, Mylan, Takeda, and several other drug manufacturers have been named as defendants in civil lawsuits consolidated in the U.S. District Court for the Southern District of New York by plaintiffs which purport to represent direct and indirect purchasers of branded or generic Actos® and Actoplus Met®. These actions allege violations of state and federal competition laws in connection with the defendants’ settlements of patent litigation in 2010 related to Actos® and Actoplus Met®. Mylan’s motion to dismiss the indirect purchasers’ complaint was granted and no appeal was filed as to Mylan. Following the appellate decision relating to other defendants, the direct purchasers filed an amended complaint against Mylan and the other manufacturers. Mylan’s motion to dismiss the amended complaint is pending. SEC Investigation On September 10, 2015, Mylan N.V. received a subpoena from the SEC’s Division of Enforcement seeking documents with regard to certain related party matters. Mylan subsequently received additional requests for information. The SEC’s Division of Enforcement has informed the Company that it has completed its investigation with no recommended further action. Trade Agreements Act (“TAA”) On April 9, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Commercial Litigation Branch of the U.S. Department of Justice (“DOJ”) concerning its TAA compliance for certain products. The company fully cooperated with DOJ. On September 14, 2018, the United States District Court for the Southern District of Ohio unsealed a qui tam lawsuit filed against the Mylan N.V. subsidiary concerning its TAA compliance for the same products identified in DOJ’s civil investigative demand. DOJ has declined to intervene in the lawsuit and has closed its investigation. The lawsuit has been stayed and we believe that its claims are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector and Certain Congressional Matters Classification of EpiPen® Auto-Injector and EpiPen Jr® Auto-Injector In November 2014, the Company received a subpoena from the DOJ related to the classification of the EpiPen® Auto-Injector for purposes of the Medicaid Drug Rebate Program (“MDRP”). On August 17, 2017, two of Mylan’s subsidiaries - Mylan Inc. and Mylan Specialty - signed an agreement for a $465 million settlement, plus interest, with the DOJ, state government agencies and two relators (the “MDRP Settlement”). The settlement with the DOJ, two relators and all 50 states plus the District of Columbia has been completed and both the federal and state matters have been dismissed through stipulations of dismissal. In connection with the settlement, Mylan Inc. and Mylan Specialty entered into a Corporate Integrity Agreement (the “CIA”) with the Office of Inspector General of the Department of Health and Human Services. The CIA has a five-year term and requires, among other things, that an independent review organization annually review various matters relating to the MDRP. Neither the settlement agreement nor the CIA contains an admission or finding of wrongdoing. In connection with the settlement, Mylan Specialty has reclassified EpiPen® Auto-Injector as an innovator product for purposes of the MDRP effective April 1, 2017. The Company recorded an accrual for the full settlement amount during the year ended December 31, 2016 and recorded an additional accrual for interest related to the settlement amount prior to the payment made in 2017. Department of Veterans Affairs Request for Information On June 30, 2017, the Company responded to a request for information from the Department of Veterans Affairs (“VA”) (acting on behalf of itself and other government agencies) requesting certain historical pricing data related to the EpiPen® Auto-Injector. The Company and the VA are engaged in a continuing dialogue regarding the classification of the EpiPen® Auto-Injector as a covered drug under Section 603 of the Veterans Health Care Act of 1992, Public Law 102-585. The EpiPen® Auto-Injector has been classified as a non covered drug with the VA based upon long standing written guidance from the federal government. The Company is fully cooperating with the VA. SEC Request for Information/Subpoenas On October 7, 2016, Mylan received a document request from the SEC’s Division of Enforcement seeking communications with the Centers for Medicare and Medicaid Services and documents concerning Mylan products sold and related to the MDRP, and any related complaints. On November 15, 2016, Mylan received a follow-up letter, modifying the initial document request, seeking information on and public disclosures regarding the MDRP Settlement and the classification of the EpiPen® Auto-Injector under the MDRP. Mylan has received subpoenas and additional requests for information in this matter and will continue to fully cooperate with the SEC. On April 25, 2017, Mylan received a comment letter from the staff of the SEC’s Division of Corporation Finance (“Corporation Finance”) with respect to Mylan’s Annual Report on Form 10-K for the year ended December 31, 2016, requesting information regarding Mylan’s accounting treatment of the MDRP Settlement, including with respect to the determinations that the settlement amount should be recorded as a charge against earnings in the third quarter of 2016 rather than against any earlier periods, and that the settlement amount should be classified as an expense rather than a reduction of revenue. The Company responded to the comment letter in May 2017 and we will continue to respond to any additional correspondence from Corporation Finance. We believe that our accounting treatment for the aforementioned settlement is appropriate and consistent with all applicable accounting standards. FTC Request for Information On November 18, 2016, Mylan received a request from the U.S. Federal Trade Commission (“FTC”) Bureau of Competition seeking documents and information relating to its preliminary investigation into potential anticompetitive practices relating to epinephrine auto-injectors. Mylan is fully cooperating with the FTC. Federal Securities Litigation Purported class action complaints were filed in October 2016 against Mylan N.V., Mylan Inc. and certain of their current and former directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the United States District Court for the Southern District of New York on behalf of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ. The complaints alleged that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to Mylan N.V. and Mylan Inc.’s classification of their EpiPen® Auto-Injector as a non-innovator drug for purposes of the MDRP. The complaints sought damages, as well as the plaintiffs’ fees and costs. On March 20, 2017, after the actions were consolidated, a consolidated amended complaint was filed, alleging substantially similar claims and seeking substantially similar relief, but adding allegations that defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both federal securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ) and Israeli securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. on the Tel Aviv Stock Exchange). On March 28, 2018, defendants’ motion to dismiss the consolidated amended complaint was granted in part (including the dismissal of claims arising under Israeli securities laws) and denied in part. On July 6, 2018, the Plaintiffs filed a second amended complaint, including certain current and former directors and officers and additional allegations in connection with purportedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs. On August 6, 2018, defendants filed a motion to dismiss the second amended complaint, which is currently pending. We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. Israeli Securities Litigation On October 13, 2016, a purported shareholder of Mylan N.V. filed a lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, against Mylan N.V. and four of its directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the Tel Aviv District Court (Economic Division) (the “Friedman Action”). The plaintiff alleges that the defendants made false or misleading statements and omissions of purportedly material fact in Mylan N.V.’s reports to the Tel Aviv Stock Exchange regarding Mylan N.V.’s classification of its EpiPen® Auto-Injector for purposes of the MDRP, in violation of both U.S. and Israeli securities laws, the Israeli Companies Law and the Israeli Torts Ordinance. The plaintiff seeks damages, among other remedies. On April 30, 2017, another purported shareholder of Mylan N.V. filed a separate lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, in the Tel Aviv District Court (Economic Division), alleging substantially similar claims and seeking substantially similar relief against the defendants and other directors and officers of Mylan N.V., but alleging also that this group of defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both U.S. federal securities laws and Israeli law (the “IEC Fund Action”). On April 10, 2018, the Tel Aviv District Court granted the motion filed by plaintiffs in both the Friedman Action and the IEC Fund Action, voluntarily dismissing the Friedman Action and staying the IEC Fund Action until a judgment is issued in the securities litigation pending in the U.S. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector Civil Litigation Mylan Specialty and other Mylan-affiliated entities have been named as defendants in putative class actions relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The plaintiffs in these cases assert violations of various federal and state antitrust and consumer protection laws, the Racketeer Influenced and Corrupt Organizations Act, as well as common law claims. Plaintiffs’ claims include purported challenges to the prices charged for the EpiPen® Auto-Injector and/or the marketing of the product in packages containing two auto-injectors, as well as allegedly anti-competitive conduct. A Mylan officer and other non-Mylan affiliated companies were also named as defendants in some of the class actions. These lawsuits were filed in the various federal and state courts and have either been dismissed or transferred into a multidistrict litigation (“MDL”) in the U.S. District Court for the District of Kansas and have been consolidated. Mylan filed a motion to dismiss the consolidated amended complaint, which was granted in part and denied in part. On December 7, 2018, the Plaintiffs filed a motion for class certification. This motion remains pending. A trial date has been scheduled for July 2020. We believe that the remaining claims in these lawsuits are without merit and intend to defend against them vigorously. On April 24, 2017, Sanofi-Aventis U.S., LLC (“Sanofi”) filed a lawsuit against Mylan Inc. and Mylan Specialty in the U.S. District Court for the District of New Jersey. This lawsuit has been transferred into the aforementioned MDL. In this lawsuit, Sanofi alleges exclusive dealings and anti-competitive marketing practices in violation of the antitrust laws in connection with the sale and marketing of the EpiPen® Auto-Injector. On November 1, 2018, Sanofi filed a Motion for a Suggestion of Remand of the case to the U.S. District Court for the District of New Jersey. On January 23, 2019, the Court denied Sanofi’s motion without prejudice. We believe that Sanofi’s claims in this lawsuit are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector State AG Investigations The Company and certain of its affiliated entities received subpoenas and informal requests from various state attorneys general seeking information and documents relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The Company has cooperated and is fully cooperating with the various state attorneys general. U.S. Congress/State Requests for Information and Documents Mylan received several requests for information and documents from various Committees of the U.S. Congress and federal and state lawmakers concerning the marketing, distribution and sales of Mylan products. Mylan cooperated with federal and state lawmakers as appropriate in response to their requests. The Company has a total accrual of approximately $10.0 million related to this matter at December 31, 2018 , which is included in other current liabilities in the Consolidated Balance Sheets. During the year ended December 31, 2018 , the Company made payments of approximately $472.7 million related to this matter. The Company believes that it has strong defenses to current and future potential civil litigation, as well as governmental investigations and enforcement proceedings, discussed in this “ EpiPen® Auto-Injector and Certain Congressional Matters” section of this Note 19 Litigation . Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. In addition, the Company expects to incur additional legal and other professional service expenses associated with such matters in future periods and will recognize these expenses as services are received. The Company believes that the ultimate amount paid for these services and claims could have a material effect on the Company's business, financial condition, results of operations, cash flows and/or ordinary share price in future periods. Opioids On July 27, 2017, Mylan N.V. received a subpoena from the DOJ seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2013 to December 31, 2016. On August 29, 2017, Mylan N.V. received a civil investigative demand from the Attorney General of the State of Missouri seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2010 to the present and related subject matter. Mylan is fully cooperating with these subpoena requests. Mylan has been named in the U.S. and Canada, along with numerous other manufacturers, distributors, pharmacies, pharmacy benefit managers, and/or individual healthcare professionals, in civil lawsuits, including certain cases in the MDL pending in the United States District Court for the Northern District of Ohio, brought by plaintiffs, including local governmental entities, generally asserting statutory and/or common law claims arising from the manufacture, distribution, marketing, promotion, and sale of purported prescription opioids. The lawsuits seek damages, including punitive and/or exemplary damages, injunctive relief, attorneys’ fees and costs, and other relief. Mylan believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. Drug Pricing Matters Department of Justice On December 3, 2015, a subsidiary of Mylan N.V. received a subpoena from the Antitrust Division of the DOJ seeking information relating to the marketing, pricing, and sale of our generic Doxycycline products and any communications with competitors about such products. On September 8, 2016, a subsidiary of Mylan N.V., as well as certain employees and a member of senior management, received subpoenas from the DOJ seeking additional information relating to the marketing, pricing and sale of our generic Cidofovir, Glipizide-metformin, Propranolol and Verapamil products and any communications with competitors about such products. Related search warrants also were executed. On May 10, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Civil Division of the DOJ seeking information relating to the pricing and sale of its generic drug products. The Company is fully cooperating with the DOJ. Civil Litigation Beginning in 2016, the Company, along with other manufacturers, has been named as a defendant in lawsuits generally alleging anticompetitive conduct with respect to generic drugs. The lawsuits have been filed by putative classes of direct purchasers, indirect purchasers, and indirect resellers, as well as individual direct and indirect purchasers. They allege harm under federal and state antitrust laws, state consumer protection laws and unjust enrichment claims. Some of the lawsuits also name Mylan’s President as a defendant and include allegations against him with respect to doxycycline hyclate delayed release. The lawsuits have been consolidated in an MDL proceeding in the EDPA. The Court has sequenced these lawsuits into separate groups for purposes of briefing motions to dismiss. Defendants filed motions to dismiss complaints in the first group. On October 16, 2018, the Court denied the motions with respect to the federal law claims. On February 15, 2019, the Court granted in part and denied in part the motions with respect to the state law claims. The Company believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. Attorneys General Litigation On December 21, 2015, the Company received a subpoena and interrogatories from the Connecticut Office of the Attorney General seeking information relating to the marketing, pricing and sale of certain of the Company’s generic products (including generic doxycycline) and communications with competitors about such products. On December 14, 2016, attorneys general of twenty states filed a complaint in the United States District Court for the District of Connecticut against several generic pharmaceutical drug manufacturers, including Mylan, alleging anticompetitive conduct with respect to, among other things, doxycycline hyclate delayed release. The complaint was subsequently amended to add certain attorneys general alleging violations of federal and state antitrust laws, as well as violations of various states’ consumer protection laws. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. On October 31, 2017, attorneys general of forty-five states, the District of Columbia and the Commonwealth of Puerto Rico filed a motion for leave to file a consolidated amended complaint (“proposed amended complaint”) against various drug manufacturers, including Mylan. The proposed amended complaint was permitted and was filed on June 18, 2018 and included two additional states. Mylan is alleged to have engaged in anticompetitive conduct with respect to doxycycline hyclate delayed release, doxycycline monohydrate, glipizide-metformin, and verapamil. The amended complaint also includes claims asserted by attorneys general of thirty-seven states and the Commonwealth of Puerto Rico against certain individuals, including Mylan’s President, with respect to doxycycline hyclate delayed release. The allegations in the amended complaint are similar to those in the previously filed complaints. We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. Valsartan Mylan N.V., and three of its subsidiaries (Mylan Inc., Mylan Laboratories Ltd. and Mylan Pharmaceuticals Inc.), along with numerous other manufacturers, retailers and others, have been named as defendants in lawsuits in the United States and Israel stemming from recalls of valsartan-containing medications. The litigation, which will take place in an MDL in the District of New Jersey, includes class action allegations seeking the refund of the purchase price and other economic damages allegedly sustained by consumers who purchased valsartan-containing products as well as claims for personal injuries allegedly caused by ingestion of the medication. Moreover, Mylan has received requests to indemnify purchasers of Mylan’s active pharmaceutical ingredient and/or finished dose forms of the product. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. European Commission Proceedings Perindopril On July 9, 2014 , the Commission issued a decision finding that Mylan Laboratories Limited and Mylan, as well as several other companies, had violated EU competition rules relating to the product Perindopril and fined Mylan Laboratories Limited approximately €17.2 million , including approximately €8.0 million jointly and severally with Mylan Inc. The Company paid approximately $21.7 million related to this matter during the fourth quarter of 2014. In September 2014, the Company filed an appeal of the Commission’s decision to the General Court of the EU. A hearing on the appeal before the General Court of the EU was held in June 2017 and the Commission’s decision was affirmed. Mylan is preparing to appeal this decision to the European Court of Justice (“CJEU”). Citalopram On June 19, 2013, the Commission issued a decision finding that Generics [U.K.] Limited,(“GUK”) as well as several other companies, had violated EU competition rules relating to the product Citalopram and fined GUK approximately €7.8 million , jointly and severally with Merck KGaA. GUK appealed the Commission’s decision to the General Court of the EU. The case is currently on appeal to the CJEU. The U.K. applied and was granted permission to intervene in this proceeding. The Company has accrued approximately €7.4 million as of December 31, 2018 and 2017 , respectively related to this matter. GUK has received notices from European national health services and health insurers stating an intention to commence follow-on litigation and asserting damages. GUK has also sought indemnification from Merck KGaA with respect to the €7.8 million portion of the fine for which Merck KGaA and GUK were held jointly and severally liable. Merck KGaA has counterclaimed against GUK seeking the same indemnification. In June 2018, the Frankfurt Regional Court issued a judgment dismissing GUK claims against Merck KGaA and ordered GUK to indemnify Merck KGaA with respect to the amount for which the parties were held jointly and severally liable. GUK has appealed this decision. A hearing took place on January 24, 2019. It is reasonably possible that we will incur additional losses above the amount accrued but we cannot estimate a range of such reasonably possible losses at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued. U.K. Competition and Markets Authority Paroxetine On August 12, 2011, GUK received notice that the Office of Fair Trading (subsequently changed to the Competition and Markets Authority (the “CMA”)) opened an investigation to explore the possible infringement of the Competition Act 1998 and Articles 101 and 102 of the Treaty on the Functioning of the EU, with respect to alleged agreements related to Paroxetine. The CMA issued a decision on February 12, 2016, finding that, GUK, Merck KGaA and other companies were liable for infringing EU and U.K. competition rules. With respect to Merck KGaA and GUK, the CMA issued a penalty of approximately £5.8 million , for which Merck KGaA is liable for the entire amount; and of that amount GUK is jointly and severally liable for approximately £2.7 million , which has been accrued for as of December 31, 2018 . The matter is currently on appeal to the Competition Appeals Tribunal, which on March 8, 2018, referred certain questions of law to the CJEU. The CJEU sought written observations from GUK, which were filed in September 2018. Nefopam On October 10, 2017, Mylan N.V. and Meda Pharmaceuticals Limited received notice that the CMA was opening an investigation to explore the possible infringement of the Competition Act 1998 and Article 101 of the Treaty on the Functioning of the EU, with respect to alleged agreements related to Nefopam, a product from Meda’s portfolio. On October 16, 2017, the CMA issued a notice under Section 26 of the Competition Act 1998 to Mylan N.V. and Meda Pharmaceuticals Limited to provide specified information and produce specified documents. The CMA has closed its investigation with no action. Italy Investigation On April 18, 2018, certain employees of Mylan S.p.A. were served with search warrants issued by the Public Prosecutor’s Office in Milan, Italy seeking information concerning interactions with an Italian hospital and sales of certain reimbursable Mylan S.p.A. drugs. The Company is assisting its employees in their cooperation with the investigation. Product Liabi

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	MYLAN N.V. AND SUBSIDIARIES SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (In millions) Description Beginning Additions Charged to Costs and Expenses Additions (1) Deductions Ending Allowance for doubtful accounts: Year ended December 31, 2018 $ 75.3 32.3 0.2 (9.6 ) $ 98.2 Year ended December 31, 2017 $ 59.0 16.8 6.0 (6.5 ) $ 75.3 Year ended December 31, 2016 $ 33.6 15.6 13.0 (3.2 ) $ 59.0 Valuation allowance for deferred tax assets: Year ended December 31, 2018 $ 662.8 203.8 — (60.6 ) $ 806.0 Year ended December 31, 2017 $ 460.7 194.1 18.9 (10.9 ) $ 662.8 Year ended December 31, 2016 $ 355.7 108.8 3.4 (7.2 ) $ 460.7 ____________ (1) In 2016, this amount includes opening balances of businesses acquired in the period.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation Policy	Principles of Consolidation. The Consolidated Financial Statements include the accounts of Mylan and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions. Noncontrolling interests in the Company’s subsidiaries are generally recorded net of tax as net earnings attributable to noncontrolling interests.
Use of Estimates in the Preparation of Financial Statements Policy	Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.
Foreign Currencies Policy	Foreign Currencies. The Consolidated Financial Statements are presented in U.S. Dollars, the reporting currency of Mylan . Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the Consolidated Statements of Operations and Cash Flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the Consolidated Balance Sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the Consolidated Statements of Operations .
Cash and Cash Equivalents Policy	Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.
Marketable Securities Policy	Debt and Equity Securities. On January 1, 2018, the Company adopted Accounting Standards Update 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ ASU 2016-01”) which requires all equity securities to be measured at fair value with changes recognized through net income (loss). Debt securities classified as available-for-sale are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net , in the Consolidated Statements of Operations . Debt securities, and marketable equity securities prior to January 1, 2018, classified as trading securities are valued using quoted stock prices from public exchanges, the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date. Realized and unrealized gains and losses are included in other expense, net , in the Consolidated Statements of Operations .
Concentrations of Credit Risk Policy	Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable. Mylan invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.
Inventories Policy	Inventories. Inventories are stated at the lower of cost or market, with cost principally determined by the first-in, first-out method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.
Property, Plant and Equipment Policy	Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives ( 3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years .
Intangible Assets and Goodwill Policy	Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. The cost to acquire a business is allocated to the underlying net assets of the acquired business in proportion to their respective fair values. Amounts allocated to acquired in-process research and development (“IPR&D”) are capitalized at the date of acquisition and are not amortized. As products in development are approved for sale, amounts are allocated to product rights and licenses and amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Purchases of developed products and licenses that are accounted for as an asset acquisition are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value then there is no impairment recognized. If the carrying value recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value is less than the carrying value of the assets being tested in an amount of the difference.
Contingent Consideration Policy	Contingent Consideration. Mylan records contingent consideration resulting from business acquisitions at fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as a charge (credit) to litigation settlements and other contingencies, net within the Consolidated Statements of Operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.
Impairment of Long-Lived Assets Policy	Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on the discounted cash flows. Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.
Research and Development Policy	Research and Development. Research and development (“R&D”) expenses are charged to operations as incurred.
Revenue Recognition Policy	Revenue Recognition. On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”) using the modified retrospective method applied to those contracts which were not completed as of the date of adoption. Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605 Revenue Recognition (“ASC 605”). Under ASC 605, the Company recognized net sales when title and risk of loss passed to its customers and when provisions for estimates, as described below, were reasonably determinable. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). The following briefly describes the nature of our provisions for variable consideration and how such provisions are estimated: • Chargebacks : the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Mylan will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels. • Rebates, promotional programs and other sales allowances : this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. • Returns : consistent with industry practice, Mylan maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. • Governmental rebate programs : government reimbursement programs include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. Also, this provision includes price reductions that are mandated by law outside of the U.S. Wholesaler and distributor inventory levels of our products can fluctuate throughout the year due to the seasonality of certain products, the timing of product demand and other factors. Such fluctuations may impact the comparability of our net sales between periods. Consideration received from licenses of intellectual property is recorded as revenue. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenue in the Consolidated Statements of Operations.
Income Taxes Policy	Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.
Earnings Per Common Share Policy	Earnings per Ordinary Share. Basic earnings per ordinary share is computed by dividing net earnings attributable to Mylan N.V. ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share is computed by dividing net earnings attributable to Mylan N.V. ordinary shareholders by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive. On August 5, 2016 , in conjunction with its acquisition of Meda AB (publ.) (“ Meda ”), the Company issued approximately 26.4 million Mylan N.V. ordinary shares to Meda shareholders. The impact of the issuance of these ordinary shares is included in the calculation of basic earnings per share. The weighted average impact for the year ended December 31, 2016, was approximately 10.8 million ordinary shares. The Company was authorized to repurchase up to $1 billion of the Company’s ordinary shares under its repurchase program that was previously approved by the Company's Board of Directors and announced on November 16, 2015, but was not obligated to acquire any particular amount of ordinary shares. During 2018 , the Company repurchased approximately 9.8 million ordinary shares at a cost of approximately $432.0 million . In 2017 , the Company repurchased approximately 12.4 million ordinary shares at a cost of approximately $500.2 million , and in 2016 , no ordinary shares were repurchased. On September 15, 2008, concurrent with the sale of $575 million aggregate principal amount of Cash Convertible Notes due 2015, Mylan Inc. entered into convertible note hedge and warrant transactions with certain counterparties. On April 15, 2016, in connection with the expiration and settlement of the warrants, the Company issued approximately 17.0 million Mylan N.V. ordinary shares. The impact of the issuance of these ordinary shares is included in the calculation of basic earnings per share from the date of issuance. The dilutive impact of the warrants, prior to settlement, is included in the calculation of diluted earnings per ordinary share based upon the average market value of the Company’s ordinary shares during the period as compared to the exercise price. For the year ended December 31, 2016, warrants included in the calculation of diluted earnings per ordinary share were 4.9 million . Basic and diluted earnings per ordinary share attributable to Mylan N.V. are calculated as follows: Year Ended December 31, (In millions, except per share amounts) 2018 2017 2016 Basic earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Basic earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.69 $ 1.30 $ 0.94 Diluted earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Share-based awards and warrants 2.0 2.2 7.5 Total dilutive shares outstanding 516.5 536.7 520.5 Diluted earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.68 $ 1.30 $ 0.92 Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2018 , 2017 and 2016 but were not included in the computation of diluted earnings per ordinary share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted ordinary shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 8.9 million , 8.5 million and 7.8 million shares for the years ended December 31, 2018 , 2017 and 2016 , respectively
Stock-Based Compensation Policy	Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the Consolidated Statements of Operations over the vesting period.
Derivatives Policy	Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the Consolidated Balance Sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the Consolidated Statements of Operations within other expense, net
Financial Instruments Policy	Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions. The Company uses derivative financial instruments for the purpose of hedging foreign currency and interest rate exposures, which exist as part of ongoing business operations, or to hedge cash, and have been used to hedge share payments required on conversion of issued convertible notes. In addition, the Company has designated certain long-term debt instruments as net investment hedges. The Company carries derivative instruments on the Consolidated Balance Sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value
Recent Accounting Pronouncements	Recent Accounting Pronouncements. Accounting Standards Issued Not Yet Adopted In November 2018, the FASB issued Accounting Standards Update 2018-18 (“ASU 2018-18”), Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606 . The amendments in ASU 2018-18 make targeted improvements to U.S. GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-14 (“ASU 2018-14”), Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 removes certain disclosures that are not considered cost beneficial, clarifies certain required disclosures and added additional disclosures. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2020 with early adoption in any interim period permitted. The amendments in ASU 2018-14 would need to be applied on a retrospective basis. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which modifies the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. The Company does not believe the impact of the adoption of this guidance will have a material impact on its consolidated financial statements and disclosures. In February 2018, the FASB issued Accounting Standards Update 2018-02, Income Statement - Reporting Comprehensive Income , (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the newly enacted federal corporate income tax rate under the comprehensive tax legislation enacted by the U.S. government on December 22, 2017 commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The amount of the reclassification would be the difference between the historical corporate income tax rate and the newly enacted 21% corporate income tax rate. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2018 with early adoption in any interim period permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (Topic 842) which supersedes FASB Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In July 2018, the FASB issued Accounting Standards Update 2018-10, Codification Improvements to Topic 842 (Leases) , and Accounting Standards Update 2018-11, Leases (Topic 842), Targeted Improvements , which provide (i) narrow amendments to clarify how to apply certain aspects of the new lease standard, (ii) entities with an additional transition method to adopt the new standard, and (iii) lessors with a practical expedient for separating components of a contract. In December 2018, the FASB issued Accounting Standards Update 2018-20, Leases (Topic 842): Narrow-Scope Improvements for Lessors, which provides certain narrow-scope improvements to Topic 842 as it relates to lessors. All Accounting Standards Updates related to Topic 842 will be effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is in the process of finalizing the analysis of its lease portfolio, implementing systems and processes and updating its accounting policies to comply with Topic 842. Based on work completed to date, the Company expects to recognize upon adoption an initial right-of-use asset and lease liability on its consolidated balance sheet of approximately $220 million to $260 million. Adoption of New Accounting Standards In October 2018, the FASB issued Accounting Standards Update 2018-16 (“ASU 2018-16”), Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. ASU 2018-16 permits the OIS rate based on SOFR as a U.S. benchmark interest rate for hedge accounting purposes under Topic 815. ASU 2018-16 will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and is required to be adopted in conjunction with ASU 2017-12 (as defined below) on a prospective basis. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures. In August 2017, the FASB issued Accounting Standards Update 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The objective of this update is to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The amendments in this update also make certain targeted improvements to simplify the application of the hedge accounting guidance in current U.S. GAAP based on feedback received from preparers, auditors, users, and other stakeholders. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted, including adoption in any interim period. The Company elected to early adopt this guidance as of January 1, 2018 and applied it on a prospective basis. Upon adoption, the Company recorded a cumulative effect adjustment. In May 2017, the FASB issued Accounting Standards Update 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”), which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions and classification of the awards are the same immediately before and after the modification. As required, the Company applied the provisions of ASU 2017-09 on a prospective basis as of January 1, 2018 and the adoption did not have a material impact on its consolidated financial statements and disclosures. In March 2017, the FASB issued Accounting Standards Update 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (“ASU 2017-07”), which requires companies to disaggregate the service cost component from the other components of net benefit cost and disclose the amount of net benefit cost that is included in the income statement or capitalized in assets, by line item. This guidance requires companies to report the service cost component in the same line item(s) as other compensation costs and to report other pension-related costs (which include interest costs, amortization of pension-related costs from prior periods and gains or losses on plan assets) separately and exclude them from the subtotal of operating income. This guidance also allows only the service cost component to be eligible for capitalization when applicable. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. This guidance should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the income statement and prospectively, on and after the effective date, for the capitalization of the service cost component of net periodic pension cost and net periodic postretirement benefit in assets. The update allows a practical expedient that permits a company to use the amounts disclosed in its pension and other postretirement plan note for the prior comparative periods as the estimation basis for applying the retrospective presentation requirements. As required, the Company applied the provisions of ASU 2017-07 as of January 1, 2018 and the adoption did not have a material impact on its consolidated financial statements and disclosures. In November 2016, the FASB issued Accounting Standards Update 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that the reconciliation of the beginning of period and end of period amounts shown in the statement of cash flows include restricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balance sheet, companies will be required to reconcile the amounts presented on the statement of cash flows to the amounts on the balance sheet. This guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. As required, the Company applied the provisions of ASU 2016-18 as of January 1, 2018. As a result, the change in restricted cash has been excluded from investing activities and included in the change in cash, cash equivalents and restricted cash and the prior year periods have been recast to reflect the new presentation. In January 2016, the FASB issued ASU 2016-01, which supersedes the current guidance to classify equity securities with readily determinable fair values into different categories and requires equity securities to be measured at fair value with changes in the fair value recognized through net income (loss). In February 2018, the FASB issued Accounting Standards Update 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , which clarifies the guidance in ASU 2016-01. The standards are effective for annual and interim periods beginning after December 15, 2017. As required, the Company applied the provisions of ASU 2016-01 as of January 1, 2018. Upon adoption, the Company recorded a cumulative effect adjustment. In May 2014, the FASB issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (updated with Accounting Standards Update 2015-14, 2016-08, 2016-10, 2016-12 and 2016-20), which revises accounting guidance on revenue recognition that will supersede nearly all existing revenue recognition guidance under U.S. GAAP (codified as Topic 606). The core principle of this guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This guidance is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years, and can be applied using a full retrospective or modified retrospective approach. The Company adopted this standard and its updates as of January 1, 2018 and elected to apply the modified retrospective transition approach. As a result, the Company is recognizing revenue on certain arrangements upon the transfer of control of product shipments rather than upon sell-through by the customer, and is recording certain costs historically in cost of sales as contra revenue. The Company elected to apply the following practical expedients and elections in connection with the adoption of ASU 2014-09: i) taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products, primarily in Europe, are excluded from revenues, and ii) shipping and handling activities are accounted for as fulfillment costs and are recorded in cost of sales. Payment terms related to product sales vary by jurisdiction and customer, but revenue for product sales has not been adjusted for the effects of a financing component as we expect that the period between when we transfer control of the product and when we receive payment to be one year or less. The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09, ASU 2016-01 and ASU 2017-12 were as follows: (In millions) Balance as of December 31, 2017 Adjustments Due to ASU 2014-09 Adjustments Due to ASU 2016-01 Adjustments Due to ASU 2017-12 Balance as of January 1, 2018 Consolidated Balance Sheet Assets Prepaid expenses and other current assets $ 766.1 $ 9.2 $ — $ — $ 775.3 Liabilities Deferred income tax liability 2,012.4 3.0 — — 2,015.4 Equity Retained earnings 5,644.5 6.2 10.0 (2.5 ) 5,658.2 Accumulated other comprehensive loss (361.2 ) — (10.0 ) 2.5 (368.7 ) During the fourth quarter of 2018, the Company has revised the cumulative effect of the adoption of ASU 2014-09 which reduced the adjustment to beginning retained earnings by approximately $6.6 million, net of tax. In accordance with ASU 2014-09, the disclosure of the impact of adoption on our consolidated statement of operations and balance sheet was as follows: For the Year Ended December 31, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Consolidated Statement of Operations Revenues $ 11,433.9 $ 11,588.4 $ (154.5 ) Cost of sales 7,432.3 7,593.9 (161.6 ) Income tax benefit (54.1 ) (56.4 ) 2.3 Net earnings 352.5 347.7 4.8 December 31, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Consolidated Balance Sheet Prepaid expenses and other current assets $ 518.4 $ 511.3 $ 7.1 Income taxes payable 121.5 119.2 2.3 Retained earnings 6,010.7 6,005.9 4.8

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Earnings Per Common Share Attributable To Mylan	Basic and diluted earnings per ordinary share attributable to Mylan N.V. are calculated as follows: Year Ended December 31, (In millions, except per share amounts) 2018 2017 2016 Basic earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Basic earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.69 $ 1.30 $ 0.94 Diluted earnings attributable to Mylan N.V. ordinary shareholders (numerator): Net earnings attributable to Mylan N.V. ordinary shareholders $ 352.5 $ 696.0 $ 480.0 Shares (denominator): Weighted average ordinary shares outstanding 514.5 534.5 513.0 Share-based awards and warrants 2.0 2.2 7.5 Total dilutive shares outstanding 516.5 536.7 520.5 Diluted earnings per ordinary share attributable to Mylan N.V. ordinary shareholders $ 0.68 $ 1.30 $ 0.92
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09, ASU 2016-01 and ASU 2017-12 were as follows: (In millions) Balance as of December 31, 2017 Adjustments Due to ASU 2014-09 Adjustments Due to ASU 2016-01 Adjustments Due to ASU 2017-12 Balance as of January 1, 2018 Consolidated Balance Sheet Assets Prepaid expenses and other current assets $ 766.1 $ 9.2 $ — $ — $ 775.3 Liabilities Deferred income tax liability 2,012.4 3.0 — — 2,015.4 Equity Retained earnings 5,644.5 6.2 10.0 (2.5 ) 5,658.2 Accumulated other comprehensive loss (361.2 ) — (10.0 ) 2.5 (368.7 ) During the fourth quarter of 2018, the Company has revised the cumulative effect of the adoption of ASU 2014-09 which reduced the adjustment to beginning retained earnings by approximately $6.6 million, net of tax. In accordance with ASU 2014-09, the disclosure of the impact of adoption on our consolidated statement of operations and balance sheet was as follows: For the Year Ended December 31, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Consolidated Statement of Operations Revenues $ 11,433.9 $ 11,588.4 $ (154.5 ) Cost of sales 7,432.3 7,593.9 (161.6 ) Income tax benefit (54.1 ) (56.4 ) 2.3 Net earnings 352.5 347.7 4.8 December 31, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Consolidated Balance Sheet Prepaid expenses and other current assets $ 518.4 $ 511.3 $ 7.1 Income taxes payable 121.5 119.2 2.3 Retained earnings 6,010.7 6,005.9 4.8

Acquisitions and Other Transa_2

Acquisitions and Other Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Apicore [Member]
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The allocation of the $174.9 million purchase price to the assets acquired and liabilities assumed for this business is as follows: (In millions) Current assets (net of cash acquired) $ 6.5 Identified intangible assets 121.0 Goodwill 92.2 Other assets 1.9 Total assets acquired 221.6 Current liabilities (4.1 ) Deferred tax liabilities (40.9 ) Other non-current liabilities (1.7 ) Net assets acquired $ 174.9
Meda AB
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The allocation of the $6.92 billion purchase price to the assets acquired and liabilities assumed for Meda is as follows: (In millions) Current assets (excluding inventories and net of cash acquired) $ 473.3 Inventories 468.1 Property, plant and equipment 177.5 Identified intangible assets 8,060.7 Goodwill 3,684.6 Other assets 8.8 Total assets acquired 12,873.0 Current liabilities (1,110.8 ) Long-term debt, including current portion (2,864.6 ) Deferred tax liabilities (1,613.2 ) Pension and other postretirement benefits (322.3 ) Other noncurrent liabilities (41.0 ) Net assets acquired $ 6,921.1
Topicals Business
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The allocation of the $972.7 million purchase price to the assets acquired and liabilities assumed for the Topicals Business is as follows: (In millions) Current assets (excluding inventories) $ 57.7 Inventories 74.2 Property, plant and equipment 54.8 Identified intangible assets 467.0 In-process research and development 275.0 Goodwill 318.6 Other assets 0.1 Total assets acquired 1,247.4 Current liabilities (74.2 ) Deferred tax liabilities (194.6 ) Other noncurrent liabilities (5.9 ) Net assets acquired $ 972.7
Meda and EPD Business
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	The following table presents supplemental unaudited pro forma information for the acquisition of Meda as if it had occurred on January 1, 2015. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable subsequent to acquisition of Meda. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred, nor are they indicative of the future operating results of Mylan N.V. (Unaudited, in millions, except per share amounts) Year Ended December 31, 2016 Total revenues $ 12,376.0 Net earnings $ 560.6 Earnings per ordinary share: Basic $ 1.06 Diluted $ 1.05 Weighted average ordinary shares outstanding: Basic 528.7 Diluted 536.2

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following is a rollforward of the categories of variable consideration during 2018 : (In millions) Balance at December 31, 2017 Current Provision Related to Sales Made in the Current Period Checks/ Credits Issued to Third Parties Effects of Foreign Exchange Balance at December 31, 2018 Chargebacks $ 574.3 $ 3,352.2 $ (3,447.1 ) $ (1.2 ) $ 478.2 Rebates, promotional programs and other sales allowances 1,508.1 4,235.6 (4,526.0 ) (15.3 ) 1,202.4 Returns 472.5 261.6 (292.1 ) (2.5 ) 439.5 Governmental rebate programs 240.3 470.0 (486.6 ) (1.5 ) 222.2 Total $ 2,795.2 $ 8,319.4 $ (8,751.8 ) $ (20.5 ) $ 2,342.3 The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the years ended December 31, 2018 , 2017 , and 2016 : (In millions) North America Europe Rest of World Total Year Ended December 31, 2018 Central Nervous System & Anesthesia $ 718.5 $ 877.5 $ 340.7 $ 1,936.7 Infectious Disease 260.8 441.8 826.4 1,529.0 Respiratory & Allergy 643.2 399.9 208.9 1,252.0 Cardiovascular 342.4 567.9 170.6 1,080.9 Gastroenterology 136.4 614.0 364.7 1,115.1 Diabetes & Metabolism 416.5 252.3 121.3 790.1 Dermatology 352.2 330.6 95.8 778.6 Women’s Health 350.7 253.2 104.4 708.3 Oncology 543.4 78.4 137.1 758.9 Immunology 49.5 18.7 38.6 106.8 Other (1) 282.0 323.0 607.3 1,212.3 Total $ 4,095.6 $ 4,157.3 $ 3,015.8 $ 11,268.7 (In millions) North America Europe Rest of World Total Year Ended December 31, 2017 Central Nervous System & Anesthesia $ 1,057.1 $ 862.7 $ 317.0 $ 2,236.8 Infectious Disease 200.0 343.2 921.7 1,464.9 Respiratory & Allergy 709.8 446.3 206.2 1,362.3 Cardiovascular 454.5 579.8 170.3 1,204.6 Gastroenterology 183.5 581.0 357.9 1,122.4 Diabetes & Metabolism 577.7 266.2 103.6 947.5 Dermatology 529.4 295.3 106.0 930.7 Women’s Health 331.2 282.7 94.4 708.3 Oncology 487.4 71.2 148.6 707.2 Immunology 83.5 10.3 37.6 131.4 Other (1) 355.5 219.6 368.8 943.9 Total $ 4,969.6 $ 3,958.3 $ 2,832.1 $ 11,760.0 (In millions) North America Europe Rest of World Total Year Ended December 31, 2016 Central Nervous System & Anesthesia $ 1,105.0 $ 699.5 $ 198.9 $ 2,003.4 Infectious Disease 184.0 270.4 884.0 1,338.4 Respiratory & Allergy 1,348.1 261.4 198.2 1,807.7 Cardiovascular 564.3 473.5 129.6 1,167.4 Gastroenterology 244.5 485.1 293.8 1,023.4 Diabetes & Metabolism 638.3 237.7 95.1 971.1 Dermatology 207.8 134.6 53.8 396.2 Women’s Health 367.9 151.4 70.9 590.2 Oncology 613.6 53.0 120.1 786.7 Immunology 93.6 8.2 32.1 133.9 Other (1) 262.4 179.0 307.3 748.7 Total $ 5,629.5 $ 2,953.8 $ 2,383.8 $ 10,967.1 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales.
Schedule of Accounts Receivable, Net	Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2018 and 2017 , respectively: (In millions) December 31, December 31, Accounts receivable $ 1,715.6 $ 1,977.2 Other current liabilities 626.7 818.0 Total $ 2,342.3 $ 2,795.2

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2018
Balance Sheet Components [Abstract]
Accounts receivable, net	(In millions) December 31, 2018 December 31, 2017 Trade receivables, net $ 2,416.5 $ 3,173.1 Other receivables 464.5 439.3 Accounts receivable, net $ 2,881.0 $ 3,612.4
Inventories	(In millions) December 31, 2018 December 31, 2017 Raw materials $ 955.7 $ 895.5 Work in process 369.9 384.7 Finished goods 1,254.6 1,262.5 Inventories $ 2,580.2 $ 2,542.7
Other current assets	(In millions) December 31, 2018 December 31, 2017 Prepaid expenses $ 130.6 $ 119.8 Restricted cash 1.2 77.8 Available-for-sale fixed income securities 25.0 31.5 Fair value of financial instruments 33.8 88.9 Equity securities 32.5 79.1 Other current assets 295.3 369.0 Prepaid expenses and other current assets $ 518.4 $ 766.1
Property, plant and equipment	Property, plant and equipment, net (In millions) December 31, 2018 December 31, 2017 Machinery and equipment $ 2,421.2 $ 2,414.5 Buildings and improvements 1,182.3 1,191.7 Construction in progress 239.7 252.9 Land and improvements 131.3 143.1 Gross property, plant and equipment 3,974.5 4,002.2 Accumulated depreciation 1,804.3 1,663.1 Property, plant and equipment, net $ 2,170.2 $ 2,339.1
Other assets	Other assets (In millions) December 31, 2018 December 31, 2017 Equity method investments, clean energy investments $ 138.7 $ 226.0 Other long-term assets 73.7 79.6 Other assets $ 212.4 $ 305.6
Trade accounts payable	Accounts payable (In millions) December 31, 2018 December 31, 2017 Trade accounts payable $ 1,123.2 $ 976.0 Other payables 493.8 476.5 Accounts payable $ 1,617.0 $ 1,452.5
Other current liabilities	Other current liabilities (In millions) December 31, 2018 December 31, 2017 Accrued sales allowances $ 626.7 $ 818.0 Payroll and employee benefit liabilities 399.7 404.6 Legal and professional accruals, including litigation accruals 128.1 241.1 Contingent consideration 158.3 167.8 Restructuring 62.3 91.5 Equity method investments, clean energy investments 45.1 56.7 Accrued interest 62.4 42.3 Fair value of financial instruments 29.4 31.1 Other 635.6 1,111.4 Other current liabilities $ 2,147.6 $ 2,964.5
Other noncurrent liabilities	(In millions) December 31, 2018 December 31, 2017 Employee benefit liabilities $ 397.7 $ 408.2 Equity method investments, clean energy investments 100.3 171.8 Contingent consideration 197.0 285.9 Tax contingencies 162.1 237.7 Other 239.7 132.1 Other long-term obligations $ 1,096.8 $ 1,235.7

Equity Method Investments (Tabl

Equity Method Investments (Tables)	12 Months Ended
	Dec. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2018 and 2017 , respectively: (In millions) December 31, 2018 December 31, 2017 Other assets $ 138.7 $ 226.0 Total liabilities 145.4 228.5 Included in other current liabilities 45.1 56.7 Included in other long-term obligations 100.3 171.8 Summarized financial information, in the aggregate, of the Company’s equity method investments on a 100% basis as of December 31, 2018 and 2017 and for the years ended December 31, 2018 , 2017 and 2016 are as follows: (In millions) December 31, 2018 December 31, 2017 Current assets $ 36.6 $ 56.4 Noncurrent assets 2.3 18.2 Total assets 38.9 74.6 Current liabilities 32.8 56.1 Noncurrent liabilities 1.7 3.6 Total liabilities 34.5 59.7 Net assets $ 4.4 $ 14.9 Year Ended December 31, (In millions) 2018 2017 2016 Total revenues $ 483.3 $ 473.0 $ 589.4 Gross (loss) profit (21.1 ) (12.8 ) (13.2 ) Operating and non-operating expense 21.9 22.3 22.2 Net loss $ (43.0 ) $ (35.1 ) $ (35.4 )

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	tangible asset amortization expense for the years ended December 31, 2019 through 2023 is estimated to be as follows: (In millions) 2019 $ 1,703 2020 1,544 2021 1,462 2022 1,392 2023 967
Changes in carrying amount of goodwill	The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2016: Goodwill $ 3,990.4 $ 3,859.1 $ 1,767.4 $ 9,616.9 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,605.4 3,859.1 1,767.4 9,231.9 Acquisitions 92.2 — — 92.2 Reclassifications (1) (200.1 ) 382.2 (182.1 ) — Measurement period adjustments — 7.7 — 7.7 Divestiture — (1.3 ) — (1.3 ) Foreign currency translation 52.1 719.4 103.7 875.2 3,549.6 4,967.1 1,689.0 10,205.7 Balance at December 31, 2017: Goodwill 3,934.6 4,967.1 1,689.0 10,590.7 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,549.6 4,967.1 1,689.0 10,205.7 Foreign currency translation (41.7 ) (309.7 ) (106.5 ) (457.9 ) 3,507.9 4,657.4 1,582.5 9,747.8 Balance at December 31, 2018 Goodwill 3,892.9 4,657.4 1,582.5 10,132.8 Accumulated impairment losses (385.0 ) — — (385.0 ) $ 3,507.9 $ 4,657.4 $ 1,582.5 $ 9,747.8 ____________ (1) The reclassifications relate to the allocation of goodwill for the Meda acquisition.
Components of intangible assets	tangible assets consist of the following components at December 31, 2018 and 2017 : (In millions) Weighted Average Life (Years) Cost Accumulated Amortization Net Book Value December 31, 2018 Product rights, licenses and other (1) 15 $ 20,264.1 $ 7,225.1 $ 13,039.0 In-process research and development 625.6 — 625.6 $ 20,889.7 $ 7,225.1 $ 13,664.6 December 31, 2017 Product rights, licenses and other (1) 15 $ 20,338.7 $ 5,906.1 $ 14,432.6 In-process research and development 813.2 — 813.2 $ 21,151.9 $ 5,906.1 $ 15,245.8 ____________ (1) Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.
Product rights and licenses by therapeutic category	oduct rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic franchise, is as follows: (In millions) December 31, 2018 December 31, 2017 Central Nervous System and Anesthesia $ 2,148.9 $ 2,453.7 Dermatology 2,125.7 2,393.0 Gastroenterology 1,790.9 2,050.0 Diabetes and Metabolism 1,232.4 1,425.6 Cardiovascular 1,541.9 1,779.5 Respiratory and Allergy 2,084.1 1,769.5 Infectious Disease 596.0 494.8 Oncology 206.0 380.1 Women's Healthcare 315.1 371.4 Immunology 258.8 301.5 Other (1) 694.9 970.1 $ 12,994.7 $ 14,389.2 __
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	ortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the Consolidated Statements of Operations, for the years ended December 31, 2018 , 2017 and 2016 was as follows: Year ended December 31, (In millions) 2018 2017 2016 Intangible asset amortization expense $ 1,606.4 $ 1,437.4 $ 1,195.3 IPR&D intangible asset impairment charges 117.7 74.6 49.9 Finite-lived intangible asset impairment charges 106.3 6.2 18.4 Total intangible asset amortization expense (including impairment charges) $ 1,830.4 $ 1,518.2 $ 1,263.6

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative [Line Items]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2016 to December 31, 2018 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2016 $ 256.9 $ 307.7 $ 564.6 Payments (77.3 ) (0.2 ) (77.5 ) Reclassifications 27.0 (27.0 ) — Accretion — 25.9 25.9 Fair value gain (3) (38.8 ) (20.5 ) (59.3 ) Balance at December 31, 2017 $ 167.8 $ 285.9 $ 453.7 Payments (82.9 ) — (82.9 ) Reclassifications 62.1 (62.1 ) — Accretion — 19.8 19.8 Fair value loss (gain) (3) 11.3 (46.6 ) (35.3 ) Balance at December 31, 2018 $ 158.3 $ 197.0 $ 355.3 ____________ (1) Included in other current liabilities on the Consolidated Balance Sheets. (2) Included in other long-term obligations on the Consolidated Balance Sheets. (3) Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.
Financial Assets and Liabilities Carried at Fair Value	Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: December 31, 2018 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 71.0 $ — $ — $ 71.0 Total cash equivalents 71.0 — — 71.0 Equity securities: Exchange traded funds 31.7 — — 31.7 Marketable securities 0.8 — — 0.8 Total equity securities 32.5 — — 32.5 Available-for-sale fixed income investments: Corporate bonds — 9.9 — 9.9 U.S. Treasuries — 9.4 — 9.4 Agency mortgage-backed securities — 1.6 — 1.6 Asset backed securities — 3.2 — 3.2 Other — 0.9 — 0.9 Total available-for-sale fixed income investments — 25.0 — 25.0 Foreign exchange derivative assets — 30.2 — 30.2 Interest rate swap derivative assets — 3.6 — 3.6 Total assets at recurring fair value measurement $ 103.5 $ 58.8 $ — $ 162.3 Financial Liabilities Foreign exchange derivative liabilities $ — $ 29.4 $ — $ 29.4 Contingent consideration — — 355.3 355.3 Total liabilities at recurring fair value measurement $ — $ 29.4 $ 355.3 $ 384.7 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 8.4 $ — $ — $ 8.4 Total cash equivalents 8.4 — — 8.4 Equity securities: Exchange traded funds 33.9 — — 33.9 Marketable securities 45.2 — — 45.2 Total equity securities 79.1 — — 79.1 Available-for-sale fixed income investments: Corporate bonds — 16.5 — 16.5 U.S. Treasuries — 7.4 — 7.4 Agency mortgage-backed securities — 4.1 — 4.1 Asset backed securities — 2.1 — 2.1 Other — 1.4 — 1.4 Total available-for-sale fixed income investments — 31.5 — 31.5 Foreign exchange derivative assets — 72.7 — 72.7 Interest rate swap derivative assets — 16.2 — 16.2 Total assets at recurring fair value measurement $ 87.5 $ 120.4 $ — $ 207.9 Financial Liabilities Foreign exchange derivative liabilities $ — $ 31.1 $ — $ 31.1 Contingent consideration — — 453.7 453.7 Total liabilities at recurring fair value measurement $ — $ 31.1 $ 453.7 $ 484.8
Schedule of Available-for-Sale Securities Reconciliation	The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows: (In millions) Cost Gross Gross Fair December 31, 2018 (1) Debt securities $ 24.8 $ 0.2 $ — $ 25.0 $ 24.8 $ 0.2 $ — $ 25.0 December 31, 2017 Debt securities $ 31.5 $ — $ — $ 31.5 Equity securities 29.5 16.9 (1.2 ) 45.2 $ 61.0 $ 16.9 $ (1.2 ) $ 76.7
Maturities Of Available-for-Sale Debt Securities At Fair Value	Maturities of available-for-sale debt securities at fair value as of December 31, 2018 , were as follows: (In millions) Mature within one year $ 3.1 Mature in one to five years 13.4 Mature in five years and later 8.5 $ 25.0
Fair value hedging relationships
Derivative [Line Items]
Effect of Derivative Instruments on the Consolidated Statements of Operations	Location of Loss Recognized in Earnings on Derivatives Amount of Loss Recognized in Earnings on Derivatives Year Ended December 31, (In millions) 2018 2017 2016 Interest rate swaps Interest expense $ (12.6 ) $ (10.0 ) $ (10.0 ) Total $ (12.6 ) $ (10.0 ) $ (10.0 ) Location of Gain Recognized in Earnings on Hedged Items Amount of Gain Recognized in Earnings on Hedging Items Year Ended December 31, (In millions) 2018 2017 2016 2023 Senior Notes (3.125% coupon) Interest expense $ 12.6 $ 10.0 $ 10.0 Total $ 12.6 $ 10.0 $ 10.0
Net Investment Hedging
Derivative [Line Items]
Effect of Derivative Instruments on the Consolidated Statements of Operations	Derivatives in Net Investment Hedging Relationships Amount of Gain or (Loss) Recognized in AOCE (Net of Tax) on Derivatives (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency borrowings and forward contracts $ 108.9 $ (238.4 ) $ (1.4 ) Total $ 108.9 $ (238.4 ) $ (1.4 )
Cash flow hedging relationships
Derivative [Line Items]
Effect of Derivative Instruments on the Consolidated Statements of Operations	Derivatives in Cash Flow Hedging Relationships Amount of (Loss) or Gain Recognized in AOCE (Net of Tax) on Derivatives (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts $ (46.6 ) $ 28.1 $ (27.5 ) Interest rate swaps — — (38.7 ) Total $ (46.6 ) $ 28.1 $ (66.2 ) The Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion) Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion) Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts Net sales $ 6.2 $ 1.1 $ (44.3 ) Interest rate swaps Interest expense (7.7 ) (7.3 ) (8.7 ) Total $ (1.5 ) $ (6.2 ) $ (53.0 ) Location of Loss Excluded from the Assessment of Hedge Effectiveness Amount of Loss Excluded from the Assessment of Hedge Effectiveness Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency forward contracts Other expense, net $ — $ (3.3 ) $ 33.5 Total $ — $ (3.3 ) $ 33.5
Designated as hedging instrument
Derivative [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ 3.6 Prepaid expenses and other current assets $ 16.2 Foreign currency forward contracts Prepaid expenses and other current assets — Prepaid expenses and other current assets 63.4 Total $ 3.6 $ 79.6 Liability Derivatives December 31, 2018 December 31, 2017 Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 12.1 Other current liabilities $ — $ 12.1 $ —
Not designated as hedging instrument
Derivative [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 30.2 Prepaid expenses and other current assets $ 9.3 Total $ 30.2 $ 9.3 Liability Derivatives December 31, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 17.3 Other current liabilities $ 31.1 Total $ 17.3 $ 31.1
Effect of Derivative Instruments on the Consolidated Statements of Operations	Location of Gain or (Loss) Recognized in Earnings on Derivatives Amount of Gain or (Loss) Recognized in Earnings on Derivatives Year Ended December 31, (In millions) 2018 2017 2016 Foreign currency option and forward contracts Other expense, net $ 34.8 $ 47.7 $ (104.5 ) Total $ 34.8 $ 47.7 $ (104.5 )

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Short-term Debt	Short-Term Borrowings (In millions) December 31, December 31, Receivables Facility $ — $ 45.0 Other 1.9 1.5 Short-term borrowings $ 1.9 $ 46.5
Summary of Long-Term Debt	A summary of long-term debt is as follows: (In millions) Coupon December 31, December 31, Current portion of long-term debt: 2016 Term Facility (a) ** 3.897 % $ 100.0 $ — 2018 Senior Notes * 2.600 % — 649.9 2018 Floating Rate Euro Notes (b) ** — 600.2 2018 Senior Notes ** 3.000 % — 499.8 2019 Senior Notes ** 2.500 % 549.9 — Other 6.2 2.4 Deferred financing fees (0.9 ) (3.1 ) Current portion of long-term debt $ 655.2 $ 1,749.2 Non-current portion of long-term debt: 2016 Term Facility (a) ** 3.897 % $ — $ 100.0 2019 Senior Notes ** 2.500 % — 999.5 2019 Senior Notes * 2.550 % — 499.7 2020 Floating Rate Euro Notes (c) ** 573.3 600.2 2020 Euro Senior Notes ** 1.250 % 858.1 897.6 2020 Senior Notes ** 3.750 % 499.9 499.9 2021 Senior Notes ** 3.150 % 2,248.7 2,248.2 2023 Senior Notes * 3.125 % 752.9 765.4 2023 Senior Notes * 4.200 % 498.9 498.8 2024 Euro Senior Notes ** 2.250 % 1,144.2 1,197.7 2025 Euro Senior Notes * 2.125 % 572.0 — 2026 Senior Notes ** 3.950 % 2,236.5 2,235.0 2028 Euro Senior Notes ** 3.125 % 852.5 892.0 2028 Senior Notes * 4.550 % 748.2 — 2043 Senior Notes * 5.400 % 497.2 497.1 2046 Senior Notes ** 5.250 % 999.8 999.8 2048 Senior Notes * 5.200 % 747.6 — Other 5.1 6.3 Deferred financing fees (73.7 ) (71.9 ) Long-term debt $ 13,161.2 $ 12,865.3 ____________ (a) The 2016 Term Facility bears interest at LIBOR plus a base rate, which margins can fluctuate based on the Company’s credit ratings. (b) Interest rate of the instrument was three-month EURIBOR plus 0.870% per annum, reset quarterly. (c) Instrument bears interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V. (In millions) Interest Rate Principal Amount 2028 Senior Notes (1) 4.550 % $ 750.0 2048 Senior Notes (1) 5.200 % 750.0 Total April 2018 Senior Notes $ 1,500.0 ____________ (1) Redeemable, in whole or in part, at our option at any time prior to three months (in the case of the 2028 Senior Notes) or six months (in the case of the 2048 Senior Notes) of the maturity date at the greater of 100% of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread of 0.30% (in the case of the 2028 Senior Notes) or 0.35% (in the case of the 2048 Senior Notes), plus, in each case, accrued and unpaid interest.
Minimum Repayments on Outstanding Borrowings	Mandatory minimum repayments remaining on the outstanding long-term debt at December 31, 2018 , excluding the discounts and premiums, are as follows for each of the periods ending December 31: (In millions) Total 2019 $ 650 2020 1,933 2021 2,250 2022 — 2023 1,250 Thereafter 7,830 Total $ 13,913

Comprehensive Earnings (Tables)

Comprehensive Earnings (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss , as reflected on the Consolidated Balance Sheets , is comprised of the following: (In millions) December 31, 2018 December 31, 2017 Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ — $ 10.1 Net unrecognized gains and prior service cost related to defined benefit plans, net of tax 1.7 6.0 Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax (53.1 ) (3.7 ) Net unrecognized losses on derivatives in net investment hedging relationships, net of tax (130.9 ) (239.8 ) Foreign currency translation adjustment (1,259.0 ) (133.8 ) $ (1,441.3 ) $ (361.2 )
Components of Other Comprehensive Loss	Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following: Year Ended December 31, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Other comprehensive (loss) earnings before reclassifications, before tax (80.7 ) 111.6 (0.1 ) (3.0 ) (1,125.2 ) (1,097.4 ) Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (6.2 ) (6.2 ) (6.2 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 7.7 7.7 7.7 Amortization of prior service costs included in SG&A (0.4 ) (0.4 ) Amortization of actuarial loss included in SG&A (0.4 ) (0.4 ) Net other comprehensive (loss) earnings, before tax (79.2 ) 111.6 (0.1 ) (3.8 ) (1,125.2 ) (1,096.7 ) Income tax (benefit) provision (27.3 ) 2.7 — 0.5 — (24.1 ) Cumulative effect of the adoption of new accounting standards $ 2.5 $ — $ (10.0 ) $ — $ — $ (7.5 ) Balance at December 31, 2018, net of tax $ (53.1 ) $ (130.9 ) $ — $ 1.7 $ (1,259.0 ) $ (1,441.3 ) Year Ended December 31, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 ) Other comprehensive (loss) earnings before reclassifications, before tax 46.5 (238.4 ) (6.7 ) 2.9 2,103.9 1,908.2 Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (1.1 ) (1.1 ) (1.1 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 7.3 7.3 7.3 Amortization of prior service costs included in SG&A 0.2 0.2 Amortization of actuarial gain included in SG&A 0.7 0.7 Net other comprehensive (loss) earnings, before tax 52.7 (238.4 ) (6.7 ) 3.8 2,103.9 1,915.3 Income tax (benefit) provision 17.8 — (2.3 ) (2.7 ) — 12.8 Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Year Ended December 31, 2016 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2015, net of tax $ (18.1 ) $ — $ (1.0 ) $ (14.9 ) $ (1,730.3 ) $ (1,764.3 ) Other comprehensive earnings (loss) before reclassifications, before tax (84.2 ) (1.8 ) 24.6 20.0 (507.4 ) (548.8 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales (44.3 ) 44.3 44.3 Loss on interest rate swaps classified as cash flow hedges, included in interest expense (8.7 ) 8.7 8.7 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial gain included in SG&A 1.1 1.1 Net other comprehensive loss, before tax (31.2 ) (1.8 ) 24.6 21.4 (507.4 ) (494.4 ) Income tax provision (benefit) (10.7 ) (0.4 ) 9.1 7.0 — 5.0 Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Provision	ncome tax provision (benefit) consisted of the following components: Year Ended December 31, (In millions) 2018 2017 2016 U.S. Federal: Current $ (68.2 ) $ 39.5 $ 86.8 Deferred (112.9 ) 28.2 (303.8 ) (181.1 ) 67.7 (217.0 ) U.S. State: Current 6.8 3.9 13.8 Deferred (12.3 ) (0.6 ) (14.8 ) (5.5 ) 3.3 (1.0 ) Non-U.S.: Current 271.6 275.0 150.6 Deferred (139.1 ) (139.0 ) (290.9 ) 132.5 136.0 (140.3 ) Income tax (benefit) provision $ (54.1 ) $ 207.0 $ (358.3 ) Earnings before income taxes: United Kingdom $ 1,259.8 $ 89.7 $ (129.4 ) United States (1,000.5 ) (414.5 ) (187.4 ) Foreign - Other 39.1 1,227.8 438.5 Total earnings before income taxes $ 298.4 $ 903.0 $ 121.7
Schedule of Deferred Tax Assets and Liabilities	Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows: (In millions) December 31, 2018 December 31, 2017 Deferred tax assets: Employee benefits $ 184.8 $ 215.0 Litigation reserves 15.7 45.3 Accounts receivable allowances 217.7 251.7 Tax credit and loss carry-forwards 891.4 849.9 Interest expense 373.5 151.7 Intangible assets 104.1 114.9 Other 182.4 212.4 1,969.6 1,840.9 Less: Valuation allowance (806.0 ) (662.8 ) Total deferred tax assets 1,163.6 1,178.1 Deferred tax liabilities: Plant and equipment 105.6 120.7 Intangible assets and goodwill 2,189.2 2,538.2 Other 18.7 34.8 Total deferred tax liabilities 2,313.5 2,693.7 Deferred tax liabilities, net $ (1,149.9 ) $ (1,515.6 )
Statutory Tax Rate to Effective Tax Rate Reconciliation	reconciliation of the UK statutory tax rate of 19% to the effective tax rate is as follows: Year Ended December 31, 2018 2017 2016 Statutory tax rate 19.0 % 19.0 % 20.0 % United States Operations Clean energy and research credits (33.1 )% (10.1 )% (85.9 )% U.S. rate differential (5.4 )% 7.4 % (36.9 )% Tax Act - transition tax & deferred tax rate change (4.9 )% 8.4 % — % Uncertain tax positions (22.5 )% 1.0 % 2.2 % State income taxes and credits (3.2 )% (0.6 )% (8.1 )% Valuation allowance 54.2 % 10.3 % 4.4 % Global intangible low-taxed income 8.6 % — % — % Other U.S. items 7.5 % 0.2 % 1.3 % Other Foreign Operations Luxembourg (28.3 )% (10.1 )% (52.6 )% Luxembourg — U.S. Branch — % — % (28.8 )% Gibraltar (19.2 )% (6.5 )% (49.2 )% India (0.6 )% (0.5 )% (13.0 )% Ireland (3.5 )% (1.4 )% (7.2 )% Other 9.0 % 2.7 % 2.0 % Deferred tax rate change (5.2 )% (2.6 )% (5.2 )% Valuation allowance (4.3 )% 3.9 % 79.9 % Withholding taxes 4.1 % 1.3 % 14.3 % Merger of foreign subsidiaries — % — % (123.5 )% Other foreign items 9.7 % 0.5 % (8.1 )% Effective tax rate (18.1 )% 22.9 % (294.4 )%
Schedule of Unrecognized Tax Benefits	A reconciliation of the unrecognized tax benefits is as follows: Year Ended December 31, (In millions) 2018 2017 2016 Unrecognized tax benefit — beginning of year $ 185.7 $ 190.9 $ 174.1 Additions for current year tax positions — 4.4 2.1 Additions for prior year tax positions 20.0 5.5 — Reductions for prior year tax positions (5.8 ) (0.8 ) (1.8 ) Settlements (32.9 ) (0.4 ) — Reductions due to expirations of statute of limitations (70.7 ) (13.9 ) (7.7 ) Addition due to acquisition — — 24.2 Unrecognized tax benefit — end of year $ 96.3 $ 185.7 $ 190.9

Share-Based Incentive Plan (Tab

Share-Based Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Awards Activity	The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2015 7,732,499 $ 31.85 Granted 876,397 45.51 Exercised (612,477 ) 23.13 Forfeited (296,978 ) 50.70 Outstanding at December 31, 2016 7,699,441 $ 33.38 Granted 964,475 42.48 Exercised (902,041 ) 20.06 Forfeited (563,191 ) 47.36 Outstanding at December 31, 2017 7,198,684 $ 35.17 Granted 905,265 40.38 Exercised (820,603 ) 21.75 Forfeited (468,068 ) 47.86 Outstanding at December 31, 2018 6,815,278 $ 36.61 Vested and expected to vest at December 31, 2018 6,603,247 $ 36.41 Exercisable at December 31, 2018 5,134,445 $ 34.76
Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity	A summary of the status of the Company’s nonvested restricted ordinary shares and restricted stock unit awards, including PSUs (collectively, “restricted stock awards”) as of December 31, 2017 and the changes during the year ended December 31, 2018 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value Per Share Nonvested at December 31, 2017 5,964,207 $ 41.92 Granted 1,542,727 41.00 Released (762,561 ) 49.11 Forfeited (351,292 ) 43.70 Nonvested at December 31, 2018 6,393,081 $ 40.75
Long Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation Plans, Valuation Assumptions	The assumptions used for options granted under the 2003 Plan are as follows: Year Ended December 31, 2018 2017 2016 Volatility 35.8% 33.2% 38.1% Risk-free interest rate 2.8% 2.2% 1.4% Expected term (years) 6.5 6.4 6.3 Forfeiture rate 5.5% 5.5% 5.5% Weighted average grant date fair value per option $16.51 $15.88 $17.90

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost	Included in accumulated other comprehensive loss as of December 31, 2018 and 2017 are: Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2018 2017 Unrecognized actuarial (gains) losses $ (10.3 ) $ (8.6 ) $ 1.1 $ 2.0 Unrecognized prior service costs 12.1 2.0 0.7 0.7 Total $ 1.8 $ (6.6 ) $ 1.8 $ 2.7
Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits	The increase in accumulated other comprehensive income in 2018 relating to pension benefits and other postretirement benefits consists of: (In millions) Pension Benefits Other Postretirement Benefits Unrecognized actuarial (gain)/loss $ (2.1 ) $ (0.6 ) Amortization of actuarial (gain)/loss (0.1 ) (0.3 ) Unrecognized prior service costs 6.6 — Amortization of prior service costs (0.4 ) — Impact of foreign currency translation 0.7 — Net change $ 4.7 $ (0.9 )
Net Periodic Benefit Cost	Components of net periodic benefit cost for the years ended December 31, 2018 , 2017 and 2016 were as follows: Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2016 2018 2017 2016 Service cost $ 19.2 $ 20.1 $ 17.4 $ 0.6 $ 0.7 $ 0.6 Interest cost 13.0 13.6 8.2 1.5 1.6 1.3 Expected return on plan assets (14.4 ) (14.3 ) (10.9 ) — — — Plan curtailment, settlement and termination (0.1 ) (1.7 ) (2.4 ) — — — Amortization of prior service costs 0.3 0.2 0.3 — — — Recognized net actuarial (gains) losses (0.1 ) 0.3 0.8 0.2 0.4 0.3 Net periodic benefit cost $ 17.9 $ 18.2 $ 13.4 $ 2.3 $ 2.7 $ 2.2
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan	The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2018 and 2017 . Pension Benefits Other Postretirement Benefits (In millions) 2018 2017 2018 2017 Change in Projected Benefit Obligation Projected benefit obligation, beginning of year $ 665.2 $ 632.9 $ 35.1 $ 38.0 Service cost 19.2 20.1 0.7 0.7 Interest cost 13.0 13.6 1.3 1.6 Participant contributions 1.0 1.0 0.2 0.2 Transferred liabilities 16.1 0.5 — — Plan settlements and terminations (7.6 ) (28.4 ) — — Actuarial losses (gains) (27.4 ) 9.3 (0.6 ) (2.7 ) Benefits paid (24.9 ) (24.5 ) (2.7 ) (2.5 ) Impact of foreign currency translation (19.2 ) 40.7 — (0.2 ) Projected benefit obligation, end of year $ 635.4 $ 665.2 $ 34.0 $ 35.1 Change in Plan Assets Fair value of plan assets, beginning of year $ 296.1 $ 291.7 $ — $ — Actual return on plan assets (11.0 ) 21.7 — — Company contributions 28.9 31.5 2.5 2.3 Participant contributions 1.0 1.0 0.2 0.2 Transferred assets 16.1 0.5 — — Plan settlements (16.5 ) (28.0 ) — — Benefits paid (24.9 ) (24.5 ) (2.7 ) (2.5 ) Other (1.6 ) (0.4 ) — — Impact of foreign currency translation (4.6 ) 2.6 — — Fair value of plan assets, end of year 283.5 296.1 — — Funded status of plans $ (351.9 ) $ (369.1 ) $ (34.0 ) $ (35.1 )
Net Accrued Benefit Costs Classification on Balance Sheet	Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s Consolidated Balance Sheets at December 31, 2018 and 2017 : Pension Benefits Other Postretirement Benefits December 31, December 31, (In millions) 2018 2017 2018 2017 Noncurrent assets $ 5.9 $ 6.0 $ — $ — Current liabilities (11.9 ) (11.7 ) (1.7 ) (1.6 ) Noncurrent liabilities (345.9 ) (363.4 ) (32.3 ) (33.5 ) Net accrued benefit costs $ (351.9 ) $ (369.1 ) $ (34.0 ) $ (35.1 )
Plans with Accumulated Benefit Obligation in Excess of Plan Assets	The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2018 and 2017 were as follows: December 31, (In millions) 2018 2017 Plans with accumulated benefit obligation in excess of plan assets: Projected benefit obligation $ 502.9 $ 530.1 Accumulated benefit obligation 483.1 506.0 Fair value of plan assets 154.8 164.8
Schedule of Allocation of Plan Assets	The table below presents total plan assets by investment category as of December 31, 2018 and 2017 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value: December 31, 2018 (In millions) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 3.5 $ 0.4 $ — $ 3.9 Equity securities 58.5 66.0 — 124.5 Fixed income securities 65.4 58.4 — 123.8 Assets held by insurance companies and other 0.1 7.2 24.0 31.3 Total $ 127.5 $ 132.0 $ 24.0 $ 283.5 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 2.5 $ 0.3 $ — $ 2.8 Equity securities 65.2 71.8 — 137.0 Fixed income securities 45.2 57.6 — 102.8 Assets held by insurance companies and other 10.4 23.9 19.2 53.5 Total $ 123.3 $ 153.6 $ 19.2 $ 296.1
Schedule of Assumptions Used	The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2018 and 2017 : Pension Benefits Other Postretirement Benefits 2018 2017 2018 2017 Discount rate 2.3 % 2.0 % 4.3 % 3.7 % Expected return on plan assets 4.9 % 4.9 % — % — % Rate of compensation increase 2.9 % 2.8 % — % — % The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2018 : Pension Benefits Other Postretirement Benefits 2018 2017 2016 2018 2017 2016 Discount rate 2.0 % 2.2 % 2.1 % 3.7 % 4.2 % 4.2 % Expected return on plan assets 4.9 % 5.0 % 4.9 % — % — % — % Rate of compensation increase 2.9 % 2.8 % 3.2 % — % — % — %
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates	If these 2019 healthcare cost trend rates were increased or decreased by one percentage point per year, such increase or decrease would have the following effects: (In millions) Increase Decrease Increase (decrease) in the aggregate of service and interest cost components of annual expense $ 0.1 $ (0.1 ) Increase (decrease) in the projected benefit obligation 1.2 (1.0 )
Schedule of Expected Benefit Payments	Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows: (In millions) Pension Benefits Other Postretirement Benefits 2019 $ 32.0 $ 1.7 2020 34.2 1.7 2021 35.7 2.0 2022 34.0 2.3 2023 36.4 2.2 Thereafter 192.1 11.6 Total $ 364.4 $ 21.5

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Reconciliation of Segment Information to Total Consolidated Information	Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2018 Net sales $ 4,095.6 $ 4,157.3 $ 3,015.8 $ — $ 11,268.7 Other revenue 112.4 27.1 25.7 — 165.2 Intersegment revenue 85.2 107.8 343.9 (536.9 ) — Total $ 4,293.2 $ 4,292.2 $ 3,385.4 $ (536.9 ) $ 11,433.9 Segment profitability $ 1,838.4 $ 1,089.5 $ 692.0 $ — $ 3,619.9 Intangible asset amortization expense (1,606.4 ) Intangible asset impairment charges (224.0 ) Globally managed research and development costs (250.3 ) Corporate costs and special items (683.1 ) Litigation settlements & other contingencies 49.5 Earnings from operations $ 905.6 North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2017 Net sales $ 4,969.6 $ 3,958.3 $ 2,832.1 $ — $ 11,760.0 Other revenue 86.5 36.5 24.7 — 147.7 Intersegment revenue 74.6 112.4 379.2 (566.2 ) — Total $ 5,130.7 $ 4,107.2 $ 3,236.0 $ (566.2 ) $ 11,907.7 Segment profitability $ 2,497.1 $ 1,082.8 $ 572.7 $ — $ 4,152.6 Intangible asset amortization expense (1,437.4 ) Intangible asset impairment charges (80.8 ) Globally managed research and development costs (356.4 ) Corporate costs and special items (853.9 ) Litigation settlements & other contingencies 13.1 Earnings from operations $ 1,437.2 North America Europe Rest of World Corporate / Other Consolidated Year Ended December 31, 2016 Net sales $ 5,629.5 $ 2,953.8 $ 2,383.8 $ — $ 10,967.1 Other revenue 88.4 12.6 8.8 — 109.8 Intersegment revenue 45.4 106.3 407.6 (559.3 ) — Total $ 5,763.3 $ 3,072.7 $ 2,800.2 $ (559.3 ) $ 11,076.9 Segment profitability $ 2,921.2 $ 669.4 $ 423.5 $ — $ 4,014.1 Intangible asset amortization expense (1,195.3 ) Intangible asset impairment charges (68.3 ) Globally managed research and development costs (423.7 ) Corporate costs and special items (955.1 ) Litigation settlements & other contingencies (672.5 ) Earnings from operations $ 699.2
Schedule of Revenue by Major Customers by Reporting Segments	The following table represents the percentage of consolidated net sales to Mylan’s major customers during the years ended December 31, 2018 , 2017 , and 2016 : Percentage of Consolidated Net Sales 2018 2017 2016 McKesson Corporation 12 % 13 % 16 % AmerisourceBergen Corporation 8 % 8 % 14 % Cardinal Health, Inc. 8 % 10 % 11 %
Net Third Party Sales Classified Based on Geographic Location of Subsidiaries	Net sales by country are presented on the basis of geographic location of our subsidiaries: Year Ended December 31, (In millions) 2018 2017 2016 United States $ 3,865.2 $ 4,683.7 $ 5,385.6 India 1,164.8 1,082.6 985.8 The Netherlands (1) 132.2 117.5 88.3 Other countries (2) 6,106.5 5,876.2 4,507.4 $ 11,268.7 $ 11,760.0 $ 10,967.1 ____________ (1) Mylan N.V. has its corporate seat in the Netherlands. (2) No other country’s net sales represents more than 10% of consolidated net sales for the years ended December 31, 2018 , 2017 and 2016 , respectively.

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments [Abstract]
Schedule Of Operating Leases	Future minimum lease payments under operating lease commitments are as follows: (In millions) December 31, 2019 $ 73.7 2020 54.7 2021 40.2 2022 28.5 2023 18.3 Thereafter 54.2 $ 269.6

Subsidiary Guarantors (Tables)

Subsidiary Guarantors (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Balance Sheet	CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 18.2 $ — $ 369.9 $ — $ 388.1 Accounts receivable, net — 24.3 — 2,856.7 — 2,881.0 Inventories — — — 2,580.2 — 2,580.2 Intercompany receivables 342.9 518.7 — 13,107.1 (13,968.7 ) — Prepaid expenses and other current assets 5.6 71.3 — 441.5 — 518.4 Total current assets 348.5 632.5 — 19,355.4 (13,968.7 ) 6,367.7 Property, plant and equipment, net — 259.7 — 1,910.5 — 2,170.2 Investments in subsidiaries 18,995.9 13,129.5 — — (32,125.4 ) — Intercompany notes and interest receivable 6,287.4 10,732.6 — 2,519.8 (19,539.8 ) — Intangible assets, net — — — 13,664.6 — 13,664.6 Goodwill — 17.1 — 9,730.7 — 9,747.8 Other assets 0.3 68.9 — 715.4 — 784.6 Total assets $ 25,632.1 $ 24,840.3 $ — $ 47,896.4 $ (65,633.9 ) $ 32,734.9 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 70.6 $ — $ 1,546.4 $ — $ 1,617.0 Short-term borrowings — — — 1.9 — 1.9 Income taxes payable — — — 121.5 — 121.5 Current portion of long-term debt and other long-term obligations 649.0 0.2 — 50.6 — 699.8 Intercompany payables 1,618.8 12,326.4 — 23.5 (13,968.7 ) — Other current liabilities 21.0 216.0 — 1,910.6 — 2,147.6 Total current liabilities 2,288.8 12,613.2 — 3,654.5 (13,968.7 ) 4,587.8 Long-term debt 9,370.1 3,786.2 — 4.9 — 13,161.2 Intercompany notes payable 1,806.1 3,094.2 — 14,639.5 (19,539.8 ) — Other long-term obligations — 48.6 — 2,770.2 — 2,818.8 Total liabilities 13,465.0 19,542.2 — 21,069.1 (33,508.5 ) 20,567.8 Total equity 12,167.1 5,298.1 — 26,827.3 (32,125.4 ) 12,167.1 Total liabilities and equity $ 25,632.1 $ 24,840.3 $ — $ 47,896.4 $ (65,633.9 ) $ 32,734.9 CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Accounts receivable, net — 1.0 — 3,611.4 — 3,612.4 Inventories — — — 2,542.7 — 2,542.7 Intercompany receivables 317.2 462.1 — 11,828.5 (12,607.8 ) — Prepaid expenses and other current assets 5.6 171.1 — 589.4 — 766.1 Total current assets 322.8 634.4 — 18,863.9 (12,607.8 ) 7,213.3 Property, plant and equipment, net — 294.1 — 2,045.0 — 2,339.1 Investments in subsidiaries 19,736.5 13,683.3 — — (33,419.8 ) — Intercompany notes and interest receivable 7,822.6 10,271.2 — 2,186.3 (20,280.1 ) — Intangible assets, net — — — 15,245.8 — 15,245.8 Goodwill — 17.1 — 10,188.6 — 10,205.7 Other assets 4.9 56.5 — 741.0 — 802.4 Total assets $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 45.3 $ — $ 1,407.2 $ — $ 1,452.5 Short-term borrowings — — — 46.5 — 46.5 Income taxes payable — — — 112.9 — 112.9 Current portion of long-term debt and other long-term obligations 1,097.8 649.1 — 62.0 — 1,808.9 Intercompany payables 664.7 11,911.5 — 31.6 (12,607.8 ) — Other current liabilities 35.5 397.0 — 2,532.0 — 2,964.5 Total current liabilities 1,798.0 13,002.9 — 4,192.2 (12,607.8 ) 6,385.3 Long-term debt 10,614.3 2,244.5 — 6.5 — 12,865.3 Intercompany notes payable 2,166.9 3,312.7 — 14,800.5 (20,280.1 ) — Other long-term obligations — 57.3 — 3,190.8 — 3,248.1 Total liabilities 14,579.2 18,617.4 — 22,190.0 (32,887.9 ) 22,498.7 Total equity 13,307.6 6,339.2 — 27,080.6 (33,419.8 ) 13,307.6 Total liabilities and equity $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3
Condensed Consolidating Statement of Operations	ENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 11,268.7 $ — $ 11,268.7 Other revenues — — — 165.2 — 165.2 Total revenues — — — 11,433.9 — 11,433.9 Cost of sales — — — 7,432.3 — 7,432.3 Gross profit — — — 4,001.6 — 4,001.6 Operating expenses: Research and development — — — 704.5 — 704.5 Selling, general and administrative 40.7 517.3 — 1,883.0 — 2,441.0 Litigation settlements and other contingencies, net — 7.1 — (56.6 ) — (49.5 ) Total operating expenses 40.7 524.4 — 2,530.9 — 3,096.0 (Losses) earnings from operations (40.7 ) (524.4 ) — 1,470.7 — 905.6 Interest expense 349.0 154.6 — 38.7 — 542.3 Other (income) expense, net (316.4 ) (273.3 ) — 654.6 — 64.9 (Losses) earnings before income taxes (73.3 ) (405.7 ) — 777.4 — 298.4 Income tax (benefit) provision (28.7 ) (27.4 ) — 2.0 — (54.1 ) Earnings of equity interest subsidiaries 397.1 328.8 — — (725.9 ) — Net earnings (loss) $ 352.5 $ (49.5 ) $ — $ 775.4 $ (725.9 ) $ 352.5 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 11,760.0 $ — $ 11,760.0 Other revenues — — — 147.7 — 147.7 Total revenues — — — 11,907.7 — 11,907.7 Cost of sales — — — 7,124.6 — 7,124.6 Gross profit — — — 4,783.1 — 4,783.1 Operating expenses: Research and development — — — 783.3 — 783.3 Selling, general and administrative 45.5 650.9 — 1,879.3 — 2,575.7 Litigation settlements and other contingencies, net — 17.0 — (30.1 ) — (13.1 ) Total operating expenses 45.5 667.9 — 2,632.5 — 3,345.9 (Losses) earnings from operations (45.5 ) (667.9 ) — 2,150.6 — 1,437.2 Interest expense 378.0 104.1 — 52.5 — 534.6 Other (income) expense, net (484.9 ) (264.6 ) — 749.1 — (0.4 ) Earnings (losses) before income taxes and noncontrolling interest 61.4 (507.4 ) — 1,349.0 — 903.0 Income tax (benefit) provision (21.1 ) (14.0 ) — 242.1 — 207.0 Earnings of equity interest subsidiaries 613.5 886.4 — — (1,499.9 ) — Net earnings $ 696.0 $ 393.0 $ — $ 1,106.9 $ (1,499.9 ) $ 696.0 CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 10,967.1 $ — $ 10,967.1 Other revenues — — — 109.8 — 109.8 Total revenues — — — 11,076.9 — 11,076.9 Cost of sales — — — 6,379.9 — 6,379.9 Gross profit — — — 4,697.0 — 4,697.0 Operating expenses: Research and development — — — 826.8 — 826.8 Selling, general and administrative 71.6 664.1 — 1,762.8 — 2,498.5 Litigation settlements and other contingencies, net — — — 672.5 — 672.5 Total operating expenses 71.6 664.1 — 3,262.1 — 3,997.8 (Losses) earnings from operations (71.6 ) (664.1 ) — 1,434.9 — 699.2 Interest expense 198.4 161.3 — 95.1 — 454.8 Other (income) expense, net (55.6 ) (193.2 ) — 371.5 — 122.7 (Losses) earnings before income taxes and noncontrolling interest (214.4 ) (632.2 ) — 968.3 — 121.7 Income tax benefit (19.5 ) (18.2 ) — (320.6 ) — (358.3 ) Earnings of equity interest subsidiaries 674.9 1,360.2 — — (2,035.1 ) — Net earnings $ 480.0 $ 746.2 $ — $ 1,288.9 $ (2,035.1 ) $ 480.0
Condensed Consolidating Statement of Comprehensive Earnings	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 352.5 $ (49.5 ) $ — $ 775.4 $ (725.9 ) $ 352.5 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (1,125.2 ) — — (1,125.2 ) 1,125.2 (1,125.2 ) Change in unrecognized gain and prior service cost related to defined benefit plans (3.8 ) 0.6 — (4.4 ) 3.8 (3.8 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (79.2 ) 7.7 — (86.9 ) 79.2 (79.2 ) Net unrecognized gain on derivatives in net investment hedging relationships 111.6 11.6 — (11.6 ) 111.6 Net unrealized loss on marketable securities (0.1 ) — — (0.1 ) 0.1 (0.1 ) Other comprehensive (loss) earnings, before tax (1,096.7 ) 19.9 — (1,216.6 ) 1,196.7 (1,096.7 ) Income tax benefit (24.1 ) (4.7 ) — (19.4 ) 24.1 (24.1 ) Other comprehensive (loss) earnings, net of tax (1,072.6 ) 24.6 — (1,197.2 ) 1,172.6 (1,072.6 ) Comprehensive loss $ (720.1 ) $ (24.9 ) $ — $ (421.8 ) $ 446.7 $ (720.1 ) CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 696.0 $ 393.0 $ — $ 1,106.9 $ (1,499.9 ) $ 696.0 Other comprehensive earnings, before tax: Foreign currency translation adjustment 2,103.9 — — 2,103.9 (2,103.9 ) 2,103.9 Change in unrecognized gain and prior service cost related to defined benefit plans 3.8 3.0 — 0.8 (3.8 ) 3.8 Net unrecognized gain on derivatives 52.7 7.3 — 45.4 (52.7 ) 52.7 Net unrecognized loss on derivatives in net investment hedging relationships (238.4 ) — — — — (238.4 ) Net unrealized loss on marketable securities (6.7 ) (6.4 ) — (0.3 ) 6.7 (6.7 ) Other comprehensive earnings, before tax 1,915.3 3.9 — 2,149.8 (2,153.7 ) 1,915.3 Income tax provision (benefit) 12.8 (1.6 ) — 14.4 (12.8 ) 12.8 Other comprehensive earnings, net of tax 1,902.5 5.5 — 2,135.4 (2,140.9 ) 1,902.5 Comprehensive earnings $ 2,598.5 $ 398.5 $ — $ 3,242.3 $ (3,640.8 ) $ 2,598.5 CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 480.0 $ 746.2 $ — $ 1,288.9 $ (2,035.1 ) $ 480.0 Other comprehensive loss, before tax: Foreign currency translation adjustment (507.4 ) — — (507.4 ) 507.4 (507.4 ) Change in unrecognized gain (loss) and prior service cost related to defined benefit plans 21.4 (1.1 ) — 22.5 (21.4 ) 21.4 Net unrecognized (loss) gain on derivatives (31.2 ) (47.7 ) — 16.5 31.2 (31.2 ) Net unrecognized loss on derivatives in net investment hedging relationships (1.8 ) — — (1.8 ) 1.8 (1.8 ) Net unrealized gain on marketable securities 24.6 24.6 — — (24.6 ) 24.6 Other comprehensive loss, before tax (494.4 ) (24.2 ) — (470.2 ) 494.4 (494.4 ) Income tax provision (benefit) 5.0 (9.1 ) — 4.1 5.0 5.0 Other comprehensive loss, net of tax (499.4 ) (15.1 ) — (474.3 ) 489.4 (499.4 ) Comprehensive (loss) earnings $ (19.4 ) $ 731.1 $ — $ 814.6 $ (1,545.7 ) $ (19.4 )
Condensed Consolidating Statement of Cash Flows	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (230.4 ) $ (1,551.7 ) $ — $ 4,123.8 $ — $ 2,341.7 Cash flows from investing activities: Capital expenditures — (28.6 ) — (223.5 ) — (252.1 ) Cash paid for acquisitions, net of cash acquired — — — (65.9 ) — (65.9 ) Proceeds from sale of assets and subsidiaries — — — 29.3 — 29.3 Purchase of marketable securities — — — (63.4 ) — (63.4 ) Proceeds from the sale of marketable securities — 36.3 — 48.9 — 85.2 Investments in affiliates — (28.8 ) — — 28.8 — Dividends from affiliates 118.6 — — — (118.6 ) — Loans to affiliates (492.2 ) — — (5,687.8 ) 6,180.0 — Repayments of loans from affiliates 2,615.4 — — 4,066.8 (6,682.2 ) — Payments for product rights and other, net — (0.5 ) — (943.0 ) — (943.5 ) Net cash provided by (used in) investing activities 2,241.8 (21.6 ) — (2,838.6 ) (592.0 ) (1,210.4 ) Cash flows from financing activities: Payments of financing fees (0.6 ) (20.8 ) — — — (21.4 ) Purchase of ordinary shares (432.0 ) — — — — (432.0 ) Change in short-term borrowings, net — — — (44.4 ) — (44.4 ) Proceeds from issuance of long-term debt 496.5 2,079.2 — 2.2 — 2,577.9 Payments of long-term debt (2,012.5 ) (1,150.0 ) — (2.7 ) — (3,165.2 ) Proceeds from exercise of stock options 17.8 — — — — 17.8 Taxes paid related to net share settlement of equity awards (10.1 ) — — — — (10.1 ) Contingent consideration payments — — — (11.9 ) — (11.9 ) Capital contribution from affiliates — — — 28.8 (28.8 ) — Capital payments to affiliates — — — (118.6 ) 118.6 — Payments on borrowings from affiliates (1,454.2 ) (3,691.6 ) — (1,536.4 ) 6,682.2 — Proceeds from borrowings from affiliates 1,383.7 4,350.9 — 445.4 (6,180.0 ) — Acquisition of noncontrolling interest — — — (0.6 ) — (0.6 ) Other items, net — — — (1.0 ) — (1.0 ) Net cash (used in) provided by financing activities (2,011.4 ) 1,567.7 — (1,239.2 ) 592.0 (1,090.9 ) Effect on cash of changes in exchange rates — — — (21.0 ) — (21.0 ) Net (decrease) increase in cash, cash equivalents and restricted cash — (5.6 ) — 25.0 — 19.4 Cash, cash equivalents and restricted cash — beginning of period — 23.8 — 346.1 — 369.9 Cash, cash equivalents and restricted cash — end of period $ — $ 18.2 $ — $ 371.1 $ — $ 389.3 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (326.6 ) $ (381.1 ) $ — $ 2,772.5 $ — $ 2,064.8 Cash flows from investing activities: Capital expenditures — (54.8 ) — (221.1 ) — (275.9 ) Cash paid for acquisitions, net of cash acquired (71.6 ) — — (95.4 ) — (167.0 ) Proceeds from sale of assets and subsidiaries — — — 86.7 — 86.7 Purchase of marketable securities — — — (96.5 ) — (96.5 ) Proceeds from the sale of marketable securities — — — 96.6 — 96.6 Investments in affiliates — (30.2 ) — — 30.2 — Dividends from affiliates 261.3 — — — (261.3 ) — Loans to affiliates (322.7 ) (98.0 ) — (3,493.7 ) 3,914.4 — Repayments of loans from affiliates 1,258.8 0.3 — 1,630.9 (2,890.0 ) — Payments for product rights and other, net — (0.9 ) — (619.4 ) — (620.3 ) Net cash provided by (used in) investing activities 1,125.8 (183.6 ) — (2,711.9 ) 793.3 (976.4 ) Cash flows from financing activities: Payments of financing fees (9.7 ) (0.4 ) — — — (10.1 ) Purchase of ordinary shares (500.2 ) — — — — (500.2 ) Change in short-term borrowings, net — — — (2.9 ) — (2.9 ) Proceeds from issuance of long-term debt 874.5 — — 1.6 — 876.1 Payments of long-term debt (1,820.0 ) — — (412.7 ) — (2,232.7 ) Proceeds from exercise of stock options 17.8 — — — — 17.8 Taxes paid related to net share settlement of equity awards (7.4 ) — — — — (7.4 ) Contingent consideration payments — — — (26.1 ) — (26.1 ) Capital contribution from affiliates — — — 30.2 (30.2 ) — Capital payments to affiliates — — — (261.3 ) 261.3 — Payments on borrowings from affiliates — (2,447.2 ) — (442.8 ) 2,890.0 — Proceeds from borrowings from affiliates 645.5 2,966.7 — 302.2 (3,914.4 ) — Acquisition of noncontrolling interest — — — (7.5 ) — (7.5 ) Other items, net — (16.0 ) — 15.9 — (0.1 ) Net cash (used in) provided by financing activities (799.5 ) 503.1 — (803.4 ) (793.3 ) (1,893.1 ) Effect on cash of changes in exchange rates — — — 27.6 — 27.6 Net decrease in cash, cash equivalents and restricted cash (0.3 ) (61.6 ) — (715.2 ) — (777.1 ) Cash, cash equivalents and restricted cash — beginning of period 0.3 85.4 — 1,061.3 — 1,147.0 Cash, cash equivalents and restricted cash — end of period $ — $ 23.8 $ — $ 346.1 $ — $ 369.9 Supplemental disclosures of cash flow information — Non-cash transactions: Contingent consideration $ — $ — $ — $ 4.0 $ — $ 4.0 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Year Ended December 31, 2016 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (0.3 ) $ (518.3 ) $ — $ 2,565.8 $ — $ 2,047.2 Cash flows from investing activities: Capital expenditures — (94.4 ) — (296.0 ) — (390.4 ) Cash paid for acquisitions, net of cash acquired (5,608.8 ) (931.3 ) — 58.2 — (6,481.9 ) Cash paid for Meda's unconditional deferred payment — — — (308.0 ) — (308.0 ) Settlement of acquisition-related foreign currency derivatives (128.6 ) — — — — (128.6 ) Purchase of marketable securities — (4.3 ) — (25.9 ) — (30.2 ) Proceeds from the sale of marketable securities — — — 21.5 — 21.5 Investments in affiliates — (49.6 ) — — 49.6 — Dividends from affiliates 135.6 — — — (135.6 ) — Loans to affiliates (14,073.5 ) (530.2 ) — (3,185.0 ) 17,788.7 — Repayments of loans from affiliates 8,539.6 793.0 — 1,914.1 (11,246.7 ) — Payments for product rights and other, net — 3.3 — (363.5 ) — (360.2 ) Net cash used in investing activities (11,135.7 ) (813.5 ) — (2,184.6 ) 6,456.0 (7,677.8 ) Cash flows from financing activities: Payments of financing fees (112.6 ) — — — — (112.6 ) Change in short-term borrowings, net — — — 40.8 — 40.8 Contingent consideration payments — — — (35.5 ) — (35.5 ) Proceeds from issuance of long-term debt 11,652.6 — — 99.6 — 11,752.2 Payments of long-term debt (400.0 ) (3,400.0 ) — (2,496.3 ) — (6,296.3 ) Proceeds from exercise of stock options 13.8 — — — — 13.8 Taxes paid related to net share settlement of equity awards (17.5 ) — — — — (17.5 ) Capital payments to affiliates — — — (135.6 ) 135.6 — Capital contribution from affiliates — — — 49.6 (49.6 ) — Proceeds from borrowings from affiliates — 6,961.2 — 10,827.6 (17,788.8 ) — Payments on borrowings from affiliates — (3,021.9 ) — (8,224.9 ) 11,246.8 — Acquisition of noncontrolling interest — — (1.1 ) — (1.1 ) Other items, net — (16.2 ) — 17.0 — 0.8 Net cash provided by financing activities 11,136.3 523.1 — 141.2 (6,456.0 ) 5,344.6 Effect on cash of changes in exchange rates — — — (9.6 ) — (9.6 ) Net increase (decrease) in cash, cash equivalents and restricted cash 0.3 (808.7 ) — 512.8 — (295.6 ) Cash, cash equivalents and restricted cash — beginning of period — 894.1 — 548.5 — 1,442.6 Cash, cash equivalents and restricted cash — end of period $ 0.3 $ 85.4 $ — $ 1,061.3 $ — $ 1,147.0 Supplemental disclosures of cash flow information — Non-cash transactions: Contingent consideration $ — $ — $ — $ 16.0 $ — $ 16.0 Ordinary shares issued for acquisition $ 1,281.7 $ — $ — $ — $ — $ 1,281.7
Schedule of Cash, Cash Equivalents, and Restricted Cash	The following tables provide a reconciliation of cash and cash equivalents, as reported on our Condensed Consolidating Balance Sheets, to cash, cash equivalents and restricted cash, as reported on our Condensed Consolidating Statements of Cash Flows (in millions): December 31, 2018 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 18.2 $ — $ 369.9 $ — $ 388.1 Restricted cash, included in prepaid expenses and other current assets — — — 1.2 — 1.2 Cash, cash equivalents and restricted cash $ — $ 18.2 $ — $ 371.1 $ — $ 389.3 December 31, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Restricted cash, included in prepaid expenses and other current assets — 23.6 — 54.2 — 77.8 Cash, cash equivalents and restricted cash $ — $ 23.8 $ — $ 346.1 $ — $ 369.9

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	(In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2016: $ 138.6 $ 1.6 $ 140.2 Charges 107.4 80.6 188.0 Cash payment (150.0 ) (2.4 ) (152.4 ) Reclassifications (8.3 ) 8.3 — Utilization — (74.4 ) (74.4 ) Foreign currency translation $ 5.2 $ 0.4 $ 5.6 Balance at December 31, 2017: $ 92.9 $ 14.1 $ 107.0 Charges (1) 71.6 168.6 240.2 Cash payment (100.8 ) (26.1 ) (126.9 ) Utilization — (144.5 ) (144.5 ) Foreign currency translation (2.9 ) (0.3 ) (3.2 ) Balance at December 31, 2018 $ 60.8 $ 11.8 $ 72.6 ____________ (1) For the year ended December 31, 2018 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $129.1 million , $73.4 million , $16.2 million and $21.5 million , respectively. For the year ended December 31, 2017 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $48.0 million , $70.1 million , $36.5 million and $33.4 million respectively.

Nature of Operations (Narrative

Nature of Operations (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018segmentsUSD ($)
Number of reportable segments | segments	3
Operating Segments | Europe Segment
Number of Countries in which Entity Operates	0
Operating Segments | Rest of World Segment
Number of Countries in which Entity Operates	0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) shares in Millions	Jan. 01, 2019	Aug. 05, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 15, 2008
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years			15 years	15 years
Weighted average ordinary shares issued to settle warrants				17
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants						4.9
Share repurchased during period, shares				12.4
Share repurchased during period, value			$ 432,000,000	$ 500,200,000
Anti-dilutive securities excluded from computation of earnings per share			8.9	8.5	7.8
Convertible Debt | Cash Convertible Notes
Accounting Policies [Line Items]
Aggregate principal amount							$ 575,000,000
Minimum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years			3 years
Maximum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years			20 years
Repurchase authorization, value			up to $1 billion
Machinery and equipment | Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			3 years
Machinery and equipment | Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			18 years
Buildings and improvements | Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			15 years
Buildings and improvements | Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			39 years
Capitalized software | Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			3 years
Capitalized software | Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)			7 years
Meda AB
Accounting Policies [Line Items]
Consideration transferred, shares		26.4
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants			10.8
Scenario, Forecast | Accounting Standards Update 2018-20 [Member] | Initial Right-of-use Asset [Member] | Minimum
Accounting Policies [Line Items]
Effect of new accounting pronouncement	$ 220
Scenario, Forecast | Accounting Standards Update 2018-20 [Member] | Initial Right-of-use Asset [Member] | Maximum
Accounting Policies [Line Items]
Effect of new accounting pronouncement	260
Scenario, Forecast | Accounting Standards Update 2018-20 [Member] | Lease Liability [Member] | Minimum
Accounting Policies [Line Items]
Effect of new accounting pronouncement	220
Scenario, Forecast | Accounting Standards Update 2018-20 [Member] | Lease Liability [Member] | Maximum
Accounting Policies [Line Items]
Effect of new accounting pronouncement	260
Receivables Facility [Member]
Accounting Policies [Line Items]
Accounts receivable securitization facility maximum borrowing capacity			$ 400,000,000
Retained Earnings [Member] | Scenario, Forecast | Accounting Standards Update 2018-20 [Member]
Accounting Policies [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 6,600,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net earnings	$ 352.5	$ 696	$ 480
Weighted average common shares outstanding	514.5	534.5	513
Basic earnings per ordinary share attributable to Mylan N.V. ordinary shareholders	$ 0.69	$ 1.30	$ 0.94
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	2	2.2	7.5
Total dilutive shares outstanding	516.5	536.7	520.5
Diluted earnings per ordinary share attributable to Mylan N.V. ordinary shareholders	$ 0.68	$ 1.30	$ 0.92

Summary of Significant Accoun_6

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Adoption of ASU 2014-09) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018	Dec. 31, 2015
Revenues	$ 11,433.9	$ 11,907.7	$ 11,076.9
Prepaid Expense and Other Assets, Current	518.4	766.1		$ 775.3
Income taxes payable	121.5	112.9
Deferred Tax Liabilities, Net, Noncurrent	1,722	2,012.4		2,015.4
Total equity	12,167.1	13,307.6	11,117.6		$ 9,765.8
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,441.3)	(361.2)
Retained earnings	6,010.7	5,644.5
Cost of sales	7,432.3	7,124.6	6,379.9
Income tax (benefit) provision	(54.1)	207	(358.3)
Net earnings	352.5	696	480
Retained Earnings [Member]
Total equity	6,010.7	5,644.5	4,942.1	5,658.2	4,462.1
Net earnings	352.5	696	480
AOCI Attributable to Parent [Member]
Total equity	(1,441.3)	(361.2)	(2,263.7)	$ (368.7)	(1,764.3)
Accumulated Other Comprehensive Income (Loss), Net of Tax			$ (2,263.7)		$ (1,764.3)
Accounting Standards Update 2014-09 [Member]
Prepaid Expense and Other Assets, Current		9.2
Deferred Tax Liabilities, Net, Noncurrent		3
Retained earnings		6.2
Accounting Standards Update 2016-01 [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(10)
Retained earnings		10
Accounting Standards Update 2017-12 [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		2.5
Retained earnings		$ (2.5)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenues	11,588.4
Prepaid Expense and Other Assets, Current	511.3
Income taxes payable	119.2
Total equity	6,005.9
Cost of sales	7,593.9
Income tax (benefit) provision	(56.4)
Net earnings attributable to Mylan N.V. ordinary shareholders	347.7
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenues	(154.5)
Prepaid Expense and Other Assets, Current	7.1
Income taxes payable	2.3
Total equity	4.8
Cost of sales	(161.6)
Income tax (benefit) provision	2.3
Net earnings attributable to Mylan N.V. ordinary shareholders	$ 4.8

Acquisitions and Other Transa_3

Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore) (Narrative) (Details) - USD ($) $ in Millions	Dec. 25, 2017	Oct. 03, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2016
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			$ 453.7	$ 355.3	$ 564.6
Acquired intangible assets, weighted average useful life, in years	5 years		4 years
Goodwill			$ 10,205.7	9,747.8	$ 9,231.9
Apicore [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		$ 174.9
Business Combination, Contingent Consideration, Liability		4		$ 0
Current assets (excluding inventories)		$ 121
Acquired intangible assets, weighted average useful life, in years		7 years
In-process research and development		$ 9
Goodwill		92.2
Amount of goodwill expected to be tax deductible		0
Maximum | Apicore [Member]
Business Acquisition [Line Items]
Change in contingent consideration, increase		$ 15

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Net sales	$ 11,268.7	$ 11,760	$ 10,967.1
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	1,936.7	2,236.8	2,003.4
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	1,529	1,464.9	1,338.4
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	1,252	1,362.3	1,807.7
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	1,080.9	1,204.6	1,167.4
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	1,115.1	1,122.4	1,023.4
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	790.1	947.5	971.1
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	778.6	930.7	396.2
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	708.3	708.3	590.2
Oncology
Disaggregation of Revenue [Line Items]
Net sales	758.9	707.2	786.7
Immunology
Disaggregation of Revenue [Line Items]
Net sales	106.8	131.4	133.9
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	1,212.3	943.9	748.7
North America Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	718.5	1,057.1	1,105
North America Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	260.8	200	184
North America Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	643.2	709.8	1,348.1
North America Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	342.4	454.5	564.3
North America Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	136.4	183.5	244.5
North America Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	416.5	577.7	638.3
North America Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	352.2	529.4	207.8
North America Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	350.7	331.2	367.9
North America Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	543.4	487.4	613.6
North America Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	49.5	83.5	93.6
North America Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	282	355.5	262.4
Europe Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	877.5	862.7	699.5
Europe Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	441.8	343.2	270.4
Europe Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	399.9	446.3	261.4
Europe Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	567.9	579.8	473.5
Europe Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	614	581	485.1
Europe Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	252.3	266.2	237.7
Europe Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	330.6	295.3	134.6
Europe Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	253.2	282.7	151.4
Europe Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	78.4	71.2	53
Europe Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	18.7	10.3	8.2
Europe Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	323	219.6	179
Rest of World Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	340.7	317	198.9
Rest of World Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	826.4	921.7	884
Rest of World Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	208.9	206.2	198.2
Rest of World Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	170.6	170.3	129.6
Rest of World Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	364.7	357.9	293.8
Rest of World Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	121.3	103.6	95.1
Rest of World Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	95.8	106	53.8
Rest of World Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	104.4	94.4	70.9
Rest of World Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	137.1	148.6	120.1
Rest of World Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	38.6	37.6	32.1
Rest of World Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	607.3	368.8	307.3
Operating Segments | North America Segment
Disaggregation of Revenue [Line Items]
Net sales	4,095.6	4,969.6	5,629.5
Operating Segments | Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	4,157.3	3,958.3	2,953.8
Operating Segments | Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 3,015.8	$ 2,832.1	$ 2,383.8
Net sales
Disaggregation of Revenue [Line Items]
Therapeutic class disclosure threshold	5.00%

Acquisitions and Other Transa_4

Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Oct. 03, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 9,747.8	$ 10,205.7		$ 9,231.9
Apicore [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			$ 6.5
Current assets (excluding inventories)			121
Goodwill			92.2
Other assets (including equity method investment)			1.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			221.6
Current liabilities			(4.1)
Deferred tax liabilities			(40.9)
Other noncurrent liabilities			(1.7)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 174.9

Revenue Recognition and Accou_4

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Revenue Recognition And Accounts Receivable [Line Items]
Securitized accounts receivable	$ 320	$ 1,040
Receivables Facility [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 400

Acquisitions and Other Transa_5

Acquisitions and Other Transactions (Meda) (Narrative) (Details) kr / shares in Units, € in Millions, shares in Millions, $ in Millions, kr in Billions	Dec. 25, 2017	Aug. 05, 2016EUR (€)shares	Aug. 05, 2016USD ($)shares	Nov. 30, 2016USD ($)shares	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Nov. 15, 2017USD ($)	Dec. 31, 2018kr / shares	Dec. 31, 2018USD ($)	Nov. 01, 2016kr / shares	Aug. 05, 2016kr / shares	Aug. 05, 2016USD ($)	Jul. 29, 2016shares	Feb. 10, 2016USD ($)	Feb. 10, 2016SEK (kr)
Business Acquisition [Line Items]
Acquisition purchase price					$ 463
Ordinary shares issued for acquisition								$ 0	$ 0	$ 1,281.7
Compulsory acquisition proceeding liability																$ 431
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net								34.8	$ 47.7	(104.5)
Acquired intangible assets, weighted average useful life, in years	5 years								4 years
Goodwill						$ 10,205.7	$ 9,231.9		$ 10,205.7	9,231.9			$ 9,747.8
Other Payments to Acquire Businesses			$ 308					0	0	308
Net sales								11,268.7	11,760	10,967.1
Net earnings								352.5	696	480
Meda AB
Business Acquisition [Line Items]
Net assets acquired						6,921.1			6,921.1							6,920		$ 9,900	kr 83.6
Foreign Currency Exchange Rate, Translation																		8.4158	8.4158
Business acquisition, number of shares tendered | shares				19													343
Cash paid for shares tendered				$ 330.3				71.6
Compulsory acquisition proceeding award per share | kr / shares												kr 163.07
Compulsory acquisition award statutory interest rate											2.00%
Compulsory acquisition proceeding payment											$ 0.9
Business Acquisition, Percentage of Voting Interests Acquired																	94.00%
Business Acquisition, Share Price | kr / shares														kr 161.31
Acquisition purchase price			$ 5,300
Consideration transferred, shares | shares		26.4	26.4
Business Combination, Acquisition Related Costs								182
Business combination, fair value inventory step-up																$ 107
Identified intangible assets						8,060.7			8,060.7
Goodwill						3,684.6			3,684.6
Amount of goodwill expected to be tax deductible													0
Other Payments to Acquire Businesses | €		€ 275
Net sales							833.9
Net earnings							208.7
Twenty percent of number of shares tendered | Meda AB
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired																20.00%
Business combination, share conversion ratio																0.386
Eighty percent of number of shares tendered | Meda AB
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired																80.00%
Maximum | Eighty percent of number of shares tendered | Meda AB
Business Acquisition [Line Items]
Business Acquisition, Share Price | kr / shares															kr 165
Swedish krona denominated contracts | Other expense
Business Acquisition [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net									128.6
Bridge Loan
Business Acquisition [Line Items]
Debt Related Commitment Fees and Debt Issuance Costs								$ 45.2
Product rights and licenses | Meda AB
Business Acquisition [Line Items]
Acquisition purchase price						300
Identified intangible assets																$ 8,060
Acquired intangible assets, weighted average useful life, in years		20 years	20 years
Rest of World Segment
Business Acquisition [Line Items]
Goodwill						1,689	1,767.4		1,689	1,767.4			1,582.5
Rest of World Segment | Meda AB
Business Acquisition [Line Items]
Goodwill													6
Europe Segment
Business Acquisition [Line Items]
Goodwill						4,967.1	3,859.1		4,967.1	3,859.1			4,657.4
Europe Segment | Meda AB
Business Acquisition [Line Items]
Goodwill													3,400
North America Segment
Business Acquisition [Line Items]
Goodwill						$ 3,549.6	$ 3,605.4		$ 3,549.6	$ 3,605.4			3,507.9
North America Segment | Meda AB
Business Acquisition [Line Items]
Goodwill													$ 290

Revenue Recognition and Accou_5

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Gross sales	$ 19,588.1	$ 22,206.1	$ 21,058.9
Chargebacks	(3,352.2)	(4,239.5)	(4,277.9)
Rebates, promotional programs and other sales allowances	(4,235.6)	(5,281.1)	(5,147.9)
Returns	(261.6)	(390.7)	(301.7)
Medicaid and other governmental rebates	(470)	(534.8)	(364.3)
Sales Revenue, Gross to net adjustments	8,319.4	10,446.1	10,091.8
Net sales	$ 11,268.7	$ 11,760	$ 10,967.1

Acquisitions and Other Transa_6

Acquisitions and Other Transactions (Meda Schedule of Purchase Price Allocation) (Details) $ in Millions, kr in Billions	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Aug. 05, 2016USD ($)	Feb. 10, 2016USD ($)	Feb. 10, 2016SEK (kr)
Business Acquisition [Line Items]
Goodwill	$ 9,747.8	$ 10,205.7	$ 9,231.9
Meda AB
Business Acquisition [Line Items]
Other current assets	$ 473.3
Inventories		468.1
Property, plant and equipment		177.5
Identified intangible assets		8,060.7
Goodwill		3,684.6
Other assets (including equity method investment)		8.8
Total assets acquired		12,873
Current liabilities		(1,110.8)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(2,864.6)
Deferred tax liabilities		(1,613.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities		(322.3)
Other noncurrent liabilities		(41)
Net assets acquired		$ 6,921.1		$ 6,920	$ 9,900	kr 83.6

Revenue Recognition and Accou_6

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 2,416.5	$ 3,173.1
Other receivables	464.5	439.3
Accounts receivable, net	2,881	3,612.4
Variable Consideration [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	1,715.6	1,977.2
Other receivables	626.7	818
Accounts receivable, net	$ 2,342.3	$ 2,795.2

Acquisitions and Other Transa_7

Acquisitions and Other Transactions (Topicals Business) (Narrative) (Details)	Dec. 25, 2017	Jun. 15, 2016USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)		Dec. 31, 2016USD ($)
Business Acquisition [Line Items]
Ordinary shares issued for acquisition					$ 0	$ 0		$ 1,281,700,000
Acquisition purchase price			$ 463,000,000
Business Combination, Contingent Consideration, Liability				$ 453,700,000	355,300,000	$ 453,700,000		564,600,000
Acquired intangible assets, weighted average useful life, in years	5 years					4 years
Goodwill				10,205,700,000	9,747,800,000	$ 10,205,700,000		$ 9,231,900,000
Contingent consideration payments					(82,900,000)	(77,500,000)	[1]
Topicals Business
Business Acquisition [Line Items]
Acquisitions						$ 23,500,000
Acquisition purchase price		$ 1,000,000,000
Net assets acquired		972,700,000
Business Combination, Contingent Consideration, Liability		16,000,000
In-process research and development		275,000,000
Expected cost to complete					15,000,000
Identified intangible assets		467,000,000
Goodwill		318,600,000
Amount of goodwill expected to be tax deductible					0
Business Combination, Acquisition Related Costs					3,600,000
Contingent consideration payments				$ 40,000,000
Maximum | Topicals Business
Business Acquisition [Line Items]
Change in contingent consideration, increase		50,000,000
Product rights and licenses | Topicals Business
Business Acquisition [Line Items]
Identified intangible assets		$ 454,000,000
Acquired intangible assets, weighted average useful life, in years		14 years
Contractual Rights | Topicals Business
Business Acquisition [Line Items]
Identified intangible assets		$ 13,000,000
Acquired intangible assets, weighted average useful life, in years		5 years
Measurement Input, Discount Rate [Member] | Topicals Business
Business Acquisition [Line Items]
Rate used to discount net cash inflows to present values		0.125
Measurement Input, Discount Rate [Member] | Product rights and licenses | Maximum
Business Acquisition [Line Items]
Identified intangible assets					$ 0.100
[1]	Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.

Revenue Recognition and Accou_7

Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	$ 3,612.4
End of period	2,881
Variable Consideration [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	2,795.2
Current Provision Related to Sales Made in the Current Period	8,319.4
Checks/ Credits Issued to Third Parties	(8,751.8)
Effects of Foreign Exchange	(20.5)
End of period	2,342.3
Variable Consideration [Member] | Chargebacks [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	574.3
Current Provision Related to Sales Made in the Current Period	3,352.2
Checks/ Credits Issued to Third Parties	(3,447.1)
Effects of Foreign Exchange	(1.2)
End of period	478.2
Variable Consideration [Member] | Rebates, Promotional Programs and Other Sales Allowances [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	1,508.1
Current Provision Related to Sales Made in the Current Period	4,235.6
Checks/ Credits Issued to Third Parties	(4,526)
Effects of Foreign Exchange	(15.3)
End of period	1,202.4
Variable Consideration [Member] | Variable Consideration Returns [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	472.5
Current Provision Related to Sales Made in the Current Period	261.6
Checks/ Credits Issued to Third Parties	(292.1)
Effects of Foreign Exchange	(2.5)
End of period	439.5
Variable Consideration [Member] | Governmental Rebate Programs [Member]
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	240.3
Current Provision Related to Sales Made in the Current Period	470
Checks/ Credits Issued to Third Parties	(486.6)
Effects of Foreign Exchange	(1.5)
End of period	$ 222.2

Acquisitions and Other Transa_8

Acquisitions and Other Transactions (Topicals Business Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 15, 2016
Business Acquisition [Line Items]
Goodwill	$ 9,747.8	$ 10,205.7	$ 9,231.9
Topicals Business
Business Acquisition [Line Items]
Other current assets				$ 57.7
Inventories				74.2
Property, plant and equipment				54.8
Identified intangible assets				467
In-process research and development				275
Goodwill				318.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets				0.1
Total assets acquired				1,247.4
Current liabilities				(74.2)
Deferred tax liabilities				(194.6)
Other noncurrent liabilities				(5.9)
Net assets acquired				$ 972.7

Acquisitions and Other Transa_9

Acquisitions and Other Transactions (Jai Pharma Limited) (Narrative) (Details) - USD ($)	Dec. 25, 2017	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2016
Business Acquisition [Line Items]
Acquisition purchase price		$ 463,000,000
Acquired intangible assets, weighted average useful life, in years	5 years		4 years
Goodwill			$ 10,205,700,000	$ 9,747,800,000	$ 9,231,900,000
Measurement Input, Discount Rate [Member] | Maximum | Product rights and licenses
Business Acquisition [Line Items]
Identified intangible assets				$ 0.100

Acquisitions and Other Trans_10

Acquisitions and Other Transactions (Jai Pharma Limited Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 9,747.8	$ 10,205.7	$ 9,231.9

Acquisitions and Other Trans_11

Acquisitions and Other Transactions (Meda and EPD Business Pro Forma Financial Information) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Basic	514.5	534.5	513
Diluted	516.5	536.7	520.5
Meda and EPD Business
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Total revenues				$ 12,376
Net earnings				$ 560.6
Basic (in USD per share)				$ 1.06
Diluted (in USD per share)				$ 1.05
Basic				528.7
Diluted				536.2

Acquisitions and Other Trans_12

Acquisitions and Other Transactions (EPD Business) (Narrative) (Details) - USD ($) $ in Millions	Dec. 25, 2017	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Acquisition purchase price		$ 463
Acquired intangible assets, weighted average useful life, in years	5 years			4 years
Goodwill			$ 9,747.8	$ 10,205.7	$ 9,231.9
Net sales			$ 11,268.7	$ 11,760	$ 10,967.1

Acquisitions and Other Trans_13

Acquisitions and Other Transactions (EPD Business Schedule of Purchase Price Allocation) (Details) shares in Millions, $ in Millions, kr in Billions	12 Months Ended
	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Aug. 05, 2016USD ($)	Feb. 10, 2016USD ($)	Feb. 10, 2016SEK (kr)
Business Acquisition [Line Items]
Weighted average common shares outstanding | shares	514.5	534.5	513
Goodwill	$ 9,747.8	$ 10,205.7	$ 9,231.9
Meda AB
Business Acquisition [Line Items]
Inventories		468.1
Other current assets	$ 473.3
Property, plant and equipment		177.5
Identified intangible assets		8,060.7
Goodwill		3,684.6
Other assets (including equity method investment)		8.8
Total assets acquired		12,873
Current liabilities		(1,110.8)
Deferred tax liabilities		(1,613.2)
Other noncurrent liabilities		(41)
Net assets acquired		$ 6,921.1		$ 6,920	$ 9,900	kr 83.6

Acquisitions and Other Trans_14

Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) - USD ($) $ in Millions

Dec. 01, 2018

Feb. 28, 2018

Dec. 25, 2017

Sep. 29, 2017

Jun. 19, 2017

Jun. 02, 2017

Mar. 29, 2017

Jan. 09, 2017

Aug. 05, 2016

Dec. 31, 2018

Sep. 30, 2018

Dec. 31, 2017

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Aug. 31, 2018

Feb. 14, 2017

Business Acquisition [Line Items]

Ordinary shares issued for acquisition

$ 0

$ 0

$ 1,281.7

Acquisition purchase price

$ 463

Acquired intangible assets, weighted average useful life, in years

5 years

4 years

Meda AB

Business Acquisition [Line Items]

Acquisition purchase price

$ 5,300

Identified intangible assets

$ 8,060.7

$ 8,060.7

Meda AB | Product rights and licenses

Business Acquisition [Line Items]

Acquisition purchase price

$ 300

Identified intangible assets

$ 8,060

Acquired intangible assets, weighted average useful life, in years

20 years

Series of Individually Immaterial Business Acquisitions [Member]

Business Acquisition [Line Items]

Acquisition purchase price

$ 135

$ 256.7

Identified intangible assets

$ 252.5

ColdEeze

Business Acquisition [Line Items]

Acquisition purchase price

$ 50

Other companies

Business Acquisition [Line Items]

Acquired intangible assets, weighted average useful life, in years

5 years

Other companies | Product rights and licenses

Business Acquisition [Line Items]

Acquisition purchase price

$ 90

$ 40

$ 128

$ 220

$ 57.9

52

Cash paid to acquire asset

22.5

Expected future payments in 2017

$ 29.5

Acquired intangible assets, weighted average useful life, in years

5 years

5 years

15 years

5 years

15 months

Payments To Acquire Collaborative Agreement

$ 20

160

TOBI [Member]

Business Acquisition [Line Items]

Cash paid to acquire asset

240

Payments made in current year

130

Expected future payments in 2017

$ 93

Acquired intangible assets, weighted average useful life, in years

10 years

Payment for Contingent Consideration Liability, Financing Activities

$ 20

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

$ 91

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets

$ 574.8

Research and Development Expense | Other companies

Business Acquisition [Line Items]

Joint development and marketing agreement

$ 50

Revance [Member]

Business Acquisition [Line Items]

Payments To Acquire Collaborative Agreement

$ 25

Revance [Member] | Maximum

Business Acquisition [Line Items]

Development Milestone Payments

100

$ 100

Sales Milestone Payments

$ 225

$ 225

Other companies

Business Acquisition [Line Items]

Payments To Acquire Collaborative Agreement

$ 53.7

Balance Sheet Components (Narra

Balance Sheet Components (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Schedule of Equity Method Investments [Line Items]
Concentration risk, percentage	10.00%
Capitalized Computer Software, Net	$ 112	$ 143
Net realizable value of inventory recognized as expense	300.5	229.3	$ 195.7
Depreciation	279.5	287.6	259.4
Other Liabilities, Current	2,147.6	2,964.5
Restricted Cash	1.2	$ 77.8
India | Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member]
Schedule of Equity Method Investments [Line Items]
Other Liabilities, Current	$ 22.6
Accounts Receivable
Schedule of Equity Method Investments [Line Items]
Concentration risk, percentage	21.00%	35.00%
Concentration risk, number of major customers	3
Allowance for doubtful accounts
Schedule of Equity Method Investments [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount	$ 98.2	$ 75.3	$ 59	$ 33.6
Contingent consideration
Schedule of Equity Method Investments [Line Items]
Restricted Cash	51
Merck KGaA income tax refund [Member]
Schedule of Equity Method Investments [Line Items]
Restricted Cash	$ 23.5

Balance Sheet Components Balanc

Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 388.1	$ 292.1
Restricted cash, included in prepaid expenses and other current assets	1.2	77.8
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 389.3	$ 369.9	$ 1,147	$ 1,442.6

Balance Sheet Components (Accou

Balance Sheet Components (Accounts receivable, net) (Details) $ in Millions	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Receivables, Net, Current [Abstract]
Trade receivables, net	$ 2,416.5	$ 3,173.1
Other receivables	464.5	439.3
Accounts receivable, net	$ 2,881	$ 3,612.4
Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, number of major customers	3

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Raw materials	$ 955.7	$ 895.5
Work in process	369.9	384.7
Finished goods	1,254.6	1,262.5
Inventories	2,580.2	2,542.7
Inventory reserves	228.2	171
Net realizable value of inventory recognized as expense	$ 300.5	$ 229.3	$ 195.7

Balance Sheet Components (Prepa

Balance Sheet Components (Prepaids and other current assets) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 130.6		$ 119.8
Restricted cash	1.2		77.8
Available-for-sale fixed income securities	25		31.5
Fair value of financial instruments	33.8		88.9
Equity securities	32.5		79.1
Other current assets	295.3		369
Prepaid expenses and other current assets	$ 518.4	$ 775.3	$ 766.1

Balance Sheet Components (Prope

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,974.5	$ 4,002.2
Accumulated depreciation	1,804.3	1,663.1
Property, plant and equipment, net	2,170.2	2,339.1
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	131.3	143.1
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,182.3	1,191.7
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,421.2	2,414.5
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 239.7	$ 252.9

Balance Sheet Components (Other

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Schedule of Other Assets [Line Items]
Investments in subsidiaries	$ 0	$ 0
Other long-term assets	73.7	79.6
Other assets	212.4	305.6
Clean energy investments | Other assets
Schedule of Other Assets [Line Items]
Investments in subsidiaries	$ 138.7	$ 226

Balance Sheet Components (Trade

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 1,123.2	$ 976
Other payables	493.8	476.5
Accounts payable	$ 1,617	$ 1,452.5

Balance Sheet Components (Oth_2

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of other current liabilities [Line Items]
Other receivables	$ 464.5	$ 439.3
Employee-related Liabilities, Current	399.7	404.6
Estimated Litigation Liability, Current	128.1	241.1
Business Combination, Contingent Consideration, Liability	355.3	453.7	$ 564.6
Restructuring Reserve, Current	62.3	91.5
Accrued interest	62.4	42.3
Liability derivatives, fair value	29.4
Other Accrued Liabilities, Current	635.6	1,111.4
Other current liabilities	2,147.6	2,964.5
Clean energy investments
Schedule of other current liabilities [Line Items]
Other current liabilities	45.1	56.7
Other current liabilities
Schedule of other current liabilities [Line Items]
Business Combination, Contingent Consideration, Liability	$ 158.3	$ 167.8	$ 256.9	[1]
[1]	Included in other current liabilities on the Consolidated Balance Sheets.

Balance Sheet Components (Oth_3

Balance Sheet Components (Other noncurrent liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Other Noncurrent Liabilities [Line Items]
Liability, Defined Benefit Pension Plan, Noncurrent	$ 397.7	$ 408.2
Other long-term obligations	1,096.8	1,235.7
Business Combination, Contingent Consideration, Liability	355.3	453.7	$ 564.6
Liability for Uncertainty in Income Taxes, Noncurrent	162.1	237.7
Liabilities, Other than Long-term Debt, Noncurrent	239.7	132.1
Other Noncurrent Liabilities
Schedule of Other Noncurrent Liabilities [Line Items]
Business Combination, Contingent Consideration, Liability	197	285.9	$ 307.7	[1]
Clean energy investments
Schedule of Other Noncurrent Liabilities [Line Items]
Other long-term obligations	$ 100.3	$ 171.8
[1]	Included in other long-term obligations on the Consolidated Balance Sheets.

Equity Method Investments (Narr

Equity Method Investments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 78.7	$ 58	$ 112.8
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3
Impairment of Equity Method Investments		47
Reduction in Equity Method Investment Long-Term Obligation		89
Loss from equity method investments		$ 42

Equity Method Investments (Bala

Equity Method Investments (Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]
Investments in subsidiaries	$ 0	$ 0
Other current liabilities	2,147.6	2,964.5
Other Liabilities, Noncurrent	1,096.8	1,235.7
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Other liabilities	145.4	228.5
Other current liabilities	45.1	56.7
Other Liabilities, Noncurrent	100.3	171.8
Other assets | Clean energy investments
Schedule of Equity Method Investments [Line Items]
Investments in subsidiaries	$ 138.7	$ 226

Equity Method Investments (Net

Equity Method Investments (Net Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Equity Method Investments and Joint Ventures [Abstract]
Current assets	$ 36.6	$ 56.4
Noncurrent assets	2.3	18.2
Total assets	38.9	74.6
Current liabilities	32.8	56.1
Noncurrent liabilities	1.7	3.6
Total liabilities	34.5	59.7
Net assets	$ 4.4	$ 14.9

Equity Method Investments (Inco

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Total revenues	$ 483.3	$ 473	$ 589.4
Gross (loss) profit	(21.1)	(12.8)	(13.2)
Operating and non-operating expense	21.9	22.3	22.2
Net loss	$ (43)	$ (35.1)	$ (35.4)

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Narrative) (Details)		6 Months Ended	12 Months Ended
		Jun. 30, 2018	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2018	Apr. 01, 2018USD ($)	Jun. 30, 2017USD ($)
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net			$ 13,039,000,000	$ 14,432,600,000
Fair value loss (gain)	[1]		(35,300,000)	(59,300,000)
Business Combination, Contingent Consideration, Liability			355,300,000	453,700,000	$ 564,600,000
In-process research and development			625,600,000	813,200,000
Goodwill, Impaired, Accumulated Impairment Loss			$ 385,000,000	385,000,000	385,000,000
Goodwill, Impaired, Change in Estimate, Period			5 years
Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year		2.00%
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges			$ 117,700,000	74,600,000	49,900,000
Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net			12,994,700,000	14,389,200,000
Impairment of products rights and licenses intangible assets			106,300,000	6,200,000	18,400,000
North America Generics [Member]
Intangible Assets Excluding Goodwill [Line Items]
Goodwill, Impaired, Accumulated Impairment Loss							$ 2,890,000,000
North America Specialty [Member]
Intangible Assets Excluding Goodwill [Line Items]
Goodwill, Impaired, Accumulated Impairment Loss							660,000,000
Europe Segment
Intangible Assets Excluding Goodwill [Line Items]
Goodwill, Impaired, Accumulated Impairment Loss			0	0	0		4,970,000,000
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount							$ 800,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount							6.00%
Rest of World Segment
Intangible Assets Excluding Goodwill [Line Items]
Goodwill, Impaired, Accumulated Impairment Loss			$ 0	$ 0	$ 0		$ 1,800,000,000
Measurement Input, Discount Rate [Member] | In-process research and development | Minimum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values			0.095	0.084	0.085
Measurement Input, Discount Rate [Member] | In-process research and development | Maximum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values			0.130	0.105	0.119
Measurement Input, Discount Rate [Member] | Goodwill [Member]
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values			0.090
Measurement Input, Discount Rate [Member] | Product rights and licenses | Minimum
Intangible Assets Excluding Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 0.090
Measurement Input, Discount Rate [Member] | Product rights and licenses | Maximum
Intangible Assets Excluding Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 0.100
Measurement Input, Long-term Revenue Growth Rate [Member]
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values						0.04
Measurement Input, Estimated Tax Rate [Member]
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values			0.24
Measurement Input, EBITDA Multiple [Member] | Minimum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		9
Measurement Input, EBITDA Multiple [Member] | Maximum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		10.5
Measurement Input, Control Premium [Member]
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		0.15
Increased Discount Rate [Domain] | Measurement Input, Discount Rate [Member]
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment Test, Measurement Input, Increase		0.015
Reduction in Terminal Value Growth Rate [Domain] | Measurement Input, Long-term Revenue Growth Rate [Member]
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment Test, Measurement Input, Reduction		0.02
Respiratory delivery platform [Member]
Intangible Assets Excluding Goodwill [Line Items]
Fair value loss (gain)			$ 44,000,000	$ 93,500,000
Business Combination, Contingent Consideration, Liability			$ 336,500,000
In-process research and development								$ 347,200,000
[1]	Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill, gross, beginning balance	$ 10,590.7	$ 9,616.9
Accumulated impairment losses, beginning balance	(385)	(385)
Goodwill	9,747.8	10,205.7	$ 9,231.9
Acquisitions		92.2
Reclassifications			0
Measurement period adjustments		7.7
Divestiture		(1.3)
Foreign currency translation	(457.9)	875.2
Goodwill, gross, ending balance	10,132.8	10,590.7	9,616.9
Accumulated impairment losses, ending balance	(385)	(385)	(385)
Goodwill, net, ending balance	9,747.8	10,205.7	9,231.9
Rest of World Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	1,689	1,767.4
Accumulated impairment losses, beginning balance	0	0
Goodwill	1,582.5	1,689	1,767.4
Acquisitions		0
Reclassifications			(182.1)
Measurement period adjustments		0
Divestiture		0
Foreign currency translation	(106.5)	103.7
Goodwill, gross, ending balance	1,582.5	1,689	1,767.4
Accumulated impairment losses, ending balance	0	0	0
Goodwill, net, ending balance	1,582.5	1,689	1,767.4
Europe Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	4,967.1	3,859.1
Accumulated impairment losses, beginning balance	0	0
Goodwill	4,657.4	4,967.1	3,859.1
Acquisitions		0
Reclassifications			382.2
Measurement period adjustments		7.7
Divestiture		(1.3)
Foreign currency translation	(309.7)	719.4
Goodwill, gross, ending balance	4,657.4	4,967.1	3,859.1
Accumulated impairment losses, ending balance	0	0	0
Goodwill, net, ending balance	4,657.4	4,967.1	3,859.1
North America Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	3,934.6	3,990.4
Accumulated impairment losses, beginning balance	(385)	(385)
Goodwill	3,507.9	3,549.6	3,605.4
Acquisitions		92.2
Reclassifications			(200.1)
Measurement period adjustments		0
Divestiture		0
Foreign currency translation	(41.7)	52.1
Goodwill, gross, ending balance	3,892.9	3,934.6	3,990.4
Accumulated impairment losses, ending balance	(385)	(385)	(385)
Goodwill, net, ending balance	$ 3,507.9	$ 3,549.6	$ 3,605.4

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived intangible asset, estimated useful life, in years	15 years	15 years
Finite-lived intangible assets, original cost	$ 20,264.1	$ 20,338.7
Finite-lived intangible assets, accumulated amortization	7,225.1	5,906.1
Finite-lived intangible assets, net book value	13,039	14,432.6
In-process research and development	625.6	813.2
Intangible assets, gross, excluding goodwill	20,889.7	21,151.9
Intangible assets, net book value, excluding goodwill	$ 13,664.6	$ 15,245.8

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2017
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		$ 13,039		$ 14,432.6
Product rights and licenses
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		$ 12,994.7		14,389.2
Therapeutic class disclosure threshold		5.00%	5.00%
Product rights and licenses | Central Nervous System and Anesthesia
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		$ 2,148.9		2,453.7
Product rights and licenses | Dermatological
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		2,125.7		2,393
Product rights and licenses | Gastrointestinal
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		1,790.9		2,050
Product rights and licenses | Diabetes and Metabolism
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		1,232.4		1,425.6
Product rights and licenses | Cardiovascular
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		1,541.9		1,779.5
Product rights and licenses | Respiratory and Allergy
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		2,084.1		1,769.5
Product rights and licenses | Infectious Disease
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		596		494.8
Product rights and licenses | Oncology
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		206		380.1
Product rights and licenses | Women's Healthcare
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		315.1		371.4
Product rights and licenses | Immunology
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net		258.8		301.5
Product rights and licenses | Other
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	[1]	$ 694.9		$ 970.1
[1]	her consists of numerous therapeutic classes, none of which individually exceeds 5% of total product rights and licenses.A

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets Excluding Goodwill [Line Items]
Intangible asset amortization expense	$ 1,606.4	$ 1,437.4	$ 1,195.3
Total intangible asset amortization expense (including impairment charges)	1,830.4	1,518.2	1,263.6
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges	$ 117.7	$ 74.6	$ 49.9

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) $ in Millions	Dec. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future Amortization 2019	$ 1,703
Future Amortization 2020	1,544
Future Amortization 2021	1,462
Future Amortization 2022	1,392
Future Amortization 2023	$ 967

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)		Dec. 31, 2016USD ($)		May 23, 2018	Apr. 09, 2018	Nov. 22, 2016	Aug. 05, 2016EUR (€)	Jun. 15, 2016USD ($)	Jun. 09, 2016USD ($)	Sep. 17, 2015USD ($)	Dec. 24, 2013USD ($)
Derivative [Line Items]
Notional amount of derivative		$ 750		$ 750
Maximum length of time hedged in cash flow hedge, in years			10 years
Debt instrument, interest rate at period end			2.86%
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months			$ (58)
Purchase consideration, contingent consideration		453.7	355.3	453.7		$ 564.6
Reclassifications			0	0
Accretion			19.8	25.9
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net			34.8	47.7		(104.5)
Contingent consideration payments			(82.9)	(77.5)	[1]
Fair value loss (gain)	[1]		(35.3)	(59.3)
Minimum
Derivative [Line Items]
Accretion			15
Maximum
Derivative [Line Items]
Accretion			20
Jai Pharma Limited
Derivative [Line Items]
Fair value loss (gain)			(8.6)	(9.9)
Respiratory delivery platform [Member]
Derivative [Line Items]
Purchase consideration, contingent consideration			336.5
Fair value loss (gain)			44	93.5
Topicals Business
Derivative [Line Items]
Purchase consideration, contingent consideration												$ 16
Acquisitions				23.5
Contingent consideration payments		40
Senior Notes | 2020 Floating Rate Euro Notes [Domain]
Derivative [Line Items]
Long-term debt		600.2	573.3	600.2
Senior Notes | 2026 Senior Notes (3.950%)
Derivative [Line Items]
Long-term debt		2,235	2,236.5	2,235									$ 2,250
Debt instrument, interest rate, stated percentage													3.95%
Senior Notes | 2020 Euro Senior Notes
Derivative [Line Items]
Long-term debt		897.6	858.1	897.6
Debt instrument, interest rate, stated percentage										1.25%
Senior Notes | 2024 Euro Senior Notes
Derivative [Line Items]
Long-term debt		1,197.7	1,144.2	1,197.7
Debt instrument, interest rate, stated percentage										2.25%
Senior Notes | 2023 Senior Notes (3.125% coupon)
Derivative [Line Items]
Notional amount of derivative			750
Long-term debt		765.4	752.9	765.4
Debt instrument, interest rate, stated percentage															3.125%
Aggregate principal amount															$ 750
Senior Notes | 2028 Senior Notes [Member]
Derivative [Line Items]
Long-term debt		0	748.2	0
Debt instrument, interest rate, stated percentage									4.55%
Senior Notes | 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Long-term debt		0	572	0
Debt instrument, interest rate, stated percentage								2.125%
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative		1,854	2,354	1,854
Long-term debt			3,500
Net Investment Hedging | 2020 Floating Rate Euro Notes [Domain]
Derivative [Line Items]
Notional amount of derivative		0	0	0
Long-term debt			500
Net Investment Hedging | 2020 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		104	104	104
Long-term debt			750
Net Investment Hedging | 2024 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative		1,000	1,000	1,000
Long-term debt			1,000
Net Investment Hedging | 2028 Senior Notes [Member]
Derivative [Line Items]
Notional amount of derivative		750	750	750
Long-term debt			750
Net Investment Hedging | 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Notional amount of derivative		0	500	0
Long-term debt			500
Interest rate swaps
Derivative [Line Items]
Notional amount of derivative | €											€ 750
September 2015 Swaps Effective Date June 2016
Derivative [Line Items]
Notional amount of derivative														$ 500
September 2015 Swaps Effective Date November 2016
Derivative [Line Items]
Notional amount of derivative														$ 500
Other Comprehensive Income (Loss) | September 2015 Swaps Effective Date June 2016
Derivative [Line Items]
Derivative, Loss on Derivative			64.9
Other Noncurrent Liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration		285.9	197	285.9		307.7	[2]
Reclassifications	[2]		(62.1)	(27)
Accretion	[2]		19.8	25.9
Contingent consideration payments	[2]		0	(0.2)	[1]
Fair value loss (gain)	[1],[2]		(46.6)	(20.5)
Other current liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration		$ 167.8	158.3	167.8		$ 256.9	[3]
Reclassifications	[3]		62.1	27
Accretion	[3]		0	0
Contingent consideration payments	[3]		(82.9)	(77.3)	[1]
Fair value loss (gain)	[1],[3]		11.3	(38.8)
Other current liabilities | Agila Specialties
Derivative [Line Items]
Contingent consideration payments			51	13.7
Other current liabilities | Jai Pharma Limited
Derivative [Line Items]
Contingent consideration payments			$ 30	20
Other current liabilities | Topicals Business
Derivative [Line Items]
Contingent consideration payments				$ 40
Measurement Input, Discount Rate [Member] | Minimum
Derivative [Line Items]
Derivative Asset (Liability) Net, Measurement Input		0.005		0.005
Measurement Input, Discount Rate [Member] | Maximum
Derivative [Line Items]
Derivative Asset (Liability) Net, Measurement Input		0.100		0.100
Measurement Input, Discount Rate [Member] | Contingent consideration | Minimum
Derivative [Line Items]
Rate used to discount net cash inflows to present values			0.021
Measurement Input, Discount Rate [Member] | Contingent consideration | Maximum
Derivative [Line Items]
Rate used to discount net cash inflows to present values			0.110
[1]	Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.
[2]	Included in other long-term obligations on the Consolidated Balance Sheets.
[3]	Included in other current liabilities on the Consolidated Balance Sheets.

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 33.8	$ 88.9
Liability derivatives, fair value	29.4
Designated as hedging instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	3.6	79.6
Liability derivatives, fair value	12.1	0
Designated as hedging instrument | Prepaid expenses and other current assets | Interest rate swaps
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	3.6	16.2
Designated as hedging instrument | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	0	63.4
Designated as hedging instrument | Other current liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability derivatives, fair value	$ 12.1	$ 0

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 33.8	$ 88.9
Liability derivatives, fair value	29.4
Not designated as hedging instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	30.2	9.3
Liability derivatives, fair value	17.3	31.1
Not designated as hedging instrument | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	30.2	9.3
Not designated as hedging instrument | Other current liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Liability derivatives, fair value	$ 17.3	$ 31.1

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - Fair value hedging relationships - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in Earnings on Derivatives	$ (12.6)	$ (10)	$ (10)
Amount of Gain Recognized in Earnings on Hedging Items	12.6	10	10
Interest expense | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in Earnings on Derivatives	(12.6)	(10)	(10)
Interest expense | 2023 Senior Notes (3.125% coupon)
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Earnings on Hedging Items	$ 12.6	$ 10	$ 10

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign currency borrowings and forward contracts | Net Investment Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 108.9	$ (238.4)	$ (1.4)

Financial Instruments and Ris_8

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) - Cash flow hedging relationships - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ (46.6)	$ 28.1	$ (66.2)
Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	(46.6)	28.1	(27.5)
Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 0	$ 0	$ (38.7)

Financial Instruments and Ris_9

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - Cash flow hedging relationships - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)	$ (1.5)	$ (6.2)	$ (53)
Amount of Loss Excluded from the Assessment of Hedge Effectiveness	0	(3.3)		$ 33.5
Foreign currency forward contracts | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)	6.2	1.1	(44.3)
Foreign currency forward contracts | Other income
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Excluded from the Assessment of Hedge Effectiveness	0	(3.3)		$ 33.5
Interest rate swaps | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from AOCE into Earnings (Effective Portion)	$ (7.7)	$ (7.3)	$ (8.7)

Financial Instruments and Ri_10

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in Earnings on Derivatives	$ 34.8	$ 47.7	$ (104.5)
Foreign currency forward contracts | Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in Earnings on Derivatives	$ 34.8	$ 47.7	$ (104.5)

Financial Instruments and Ri_11

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 71	$ 8.4
Equity securities	32.5	79.1
Available-for-sale securities	25	76.7
Total assets at recurring fair value measurement	162.3	207.9
Total liabilities at recurring fair value measurement	384.7	484.8
Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	30.2	72.7
Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	29.4	31.1
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	355.3	453.7
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	71	8.4
Equity securities — exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	31.7	33.9
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	25	31.5
U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9.4	7.4
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9.9	16.5
Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.6	4.1
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	3.2	2.1
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0.9	1.4
Total equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		79.1
Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.8	45.2
Interest rate swap derivatives
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets	3.6	16.2
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	71	8.4
Equity securities	32.5
Total assets at recurring fair value measurement	103.5	87.5
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	71	8.4
Level 1 | Equity securities — exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	31.7	33.9
Level 1 | Total equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		79.1
Level 1 | Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.8
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	58.8	120.4
Total liabilities at recurring fair value measurement	29.4	31.1
Level 2 | Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	30.2	72.7
Level 2 | Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	29.4	31.1
Level 2 | Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	25	31.5
Level 2 | U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9.4	7.4
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	9.9	16.5
Level 2 | Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.6	4.1
Level 2 | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	3.2	2.1
Level 2 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0.9	1.4
Level 2 | Interest rate swap derivatives
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets	3.6	16.2
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at recurring fair value measurement	355.3	453.7
Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 355.3	$ 453.7

Financial Instruments and Ri_12

Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period		$ 453.7	$ 564.6
Payments		82.9	77.5	[1]
Accretion		19.8	25.9
Reclassifications		0	0
Fair value loss (gain)	[1]	(35.3)	(59.3)
Balance at end of period		355.3	453.7
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period		167.8	256.9	[2]
Payments	[2]	82.9	77.3	[1]
Accretion	[2]	0	0
Reclassifications	[2]	62.1	27
Fair value loss (gain)	[1],[2]	11.3	(38.8)
Balance at end of period		158.3	167.8
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period		285.9	307.7	[3]
Payments	[3]	0	0.2	[1]
Accretion	[3]	19.8	25.9
Reclassifications	[3]	(62.1)	(27)
Fair value loss (gain)	[1],[3]	(46.6)	(20.5)
Balance at end of period		$ 197	$ 285.9
[1]	Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.
[2]	Included in other current liabilities on the Consolidated Balance Sheets.
[3]	Included in other long-term obligations on the Consolidated Balance Sheets.

Financial Instruments and Ri_13

Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 24.8	$ 61
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.2	16.9
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	(1.2)
Fair Value	25	76.7
Debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	24.8	31.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.2	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Fair Value	$ 25	31.5
Equity securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		29.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		16.9
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.2)
Fair Value		$ 45.2

Financial Instruments and Ri_14

Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) $ in Millions	Dec. 31, 2018USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Mature within one year	$ 3.1
Mature in one to five years	13.4
Mature in five years and later	8.5
Available-for-sale securities, debt securities	$ 25

Debt (Short-term borrowings) (D

Debt (Short-term borrowings) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Short-term borrowings	$ 1.9	$ 46.5
Receivables Facility [Member]
Short-term Debt [Line Items]
Short-term borrowings	0	45
Other Current Portion of Long-term Debt
Short-term Debt [Line Items]
Debt, Current	$ 1.9	$ 1.5

Debt Debt (Receivables Facility

Debt Debt (Receivables Facility and Commercial Paper Program) (Details) - USD ($) $ in Millions	Jun. 06, 2017	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Securitized accounts receivable		$ 320	$ 1,040
Commercial Paper Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,650
Debt Instrument, Term	364 days
Receivables Facility [Member]
Debt Instrument [Line Items]
Accounts receivable securitization facility maximum borrowing capacity		$ 400

Debt (Summary of Long-term Debt

Debt (Summary of Long-term Debt) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	May 23, 2018	Apr. 09, 2018	Dec. 31, 2017	Nov. 22, 2016	Jun. 09, 2016	Dec. 09, 2015	Dec. 24, 2013	Nov. 13, 2013	Jun. 18, 2013
Debt Instrument [Line Items]
Debt, Current	$ 655.2			$ 1,749.2
Unamortized Debt Issuance Expense	(73.7)			(71.9)
Long-term debt	$ 13,161.2			12,865.3
2016 Term Loans
Debt Instrument [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	3.897%
Debt, Current	$ 100			0
Long-term debt	0			100
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Debt, Current	6.2			2.4
2018 Floating Rate Euro Notes
Debt Instrument [Line Items]
Debt, Current	0			600.2
2018 Senior Notes (2.600%)
Debt Instrument [Line Items]
Debt, Current	0			649.9
Debt instrument, interest rate, stated percentage										2.60%
2018 Senior Notes (3.000% coupon)
Debt Instrument [Line Items]
Debt, Current	0			499.8
Debt instrument, interest rate, stated percentage							3.00%
2019 Senior Notes (2.500%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						2.50%
2019 Senior Notes (2.550%)
Debt Instrument [Line Items]
Debt, Current	549.9			0
Other Long Term Debt
Debt Instrument [Line Items]
Long-term debt	5.1			6.3
Senior Notes | 2019 Senior Notes (2.500%)
Debt Instrument [Line Items]
Long-term debt	0			999.5
Senior Notes | 2019 Senior Notes (2.550%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									2.55%
Long-term debt	0			499.7
Senior Notes | 2020 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					1.25%
Long-term debt	858.1			897.6
Senior Notes | 2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage							3.75%
Long-term debt	499.9			499.9
Senior Notes | 2021 Senior Notes (3.150%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						3.15%
Long-term debt	2,248.7			2,248.2
Senior Notes | 2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage								3.125%
Long-term debt	752.9			765.4
Senior Notes | 2023 Senior Notes (4.200%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									4.20%
Long-term debt	498.9			498.8
Senior Notes | 2024 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					2.25%
Long-term debt	1,144.2			1,197.7
Senior Notes | 2025 Euro Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.125%
Long-term debt	$ 572			0
Long-term debt		$ 500
Debt Instrument, Basis Spread on Variable Rate	0.30%
Senior Notes | 2026 Senior Notes (3.950%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						3.95%
Long-term debt	$ 2,236.5			2,235		$ 2,250
Senior Notes | 2028 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					3.125%
Long-term debt	852.5			892
Senior Notes | 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			4.55%
Long-term debt	$ 748.2			0
Long-term debt			$ 750
Debt Instrument, Basis Spread on Variable Rate	0.30%
Senior Notes | 2043 Senior Notes (5.400%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						5.40%
Long-term debt	$ 497.2			497.1
Senior Notes | 2046 Senior Notes (5.250%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						5.25%
Long-term debt	999.8			999.8
Senior Notes | 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			5.20%
Long-term debt	$ 747.6			0
Long-term debt			$ 750
Debt Instrument, Basis Spread on Variable Rate	0.35%
Senior Notes | 2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 573.3			600.2
Debt Instrument, Basis Spread on Variable Rate	0.17%
Current portion of long-term debt
Debt Instrument [Line Items]
Unamortized Debt Issuance Expense	$ (0.9)			$ (3.1)

Debt (Revolving Facilities and

Debt (Revolving Facilities and Term Facilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Jul. 27, 2018	Dec. 31, 2017	Nov. 22, 2016
Line of Credit Facility [Line Items]
Debt, Current	$ 655.2		$ 1,749.2
2016 Senior Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 2,000
2016 Term Loans
Line of Credit Facility [Line Items]
Debt, Current	$ 100		$ 0
Debt Instrument, Covenant Description	3.75 to 1.00
Revolving Credit Facility [Member] | Line of Credit
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,000
Trailing Four Quarters | 2016 Senior Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Debt Instrument, Covenant Description	3.75 to 1.00
Three Full Fiscal Quarters Following Qualifying Acquisition | 2016 Term Loans
Line of Credit Facility [Line Items]
Debt Instrument, Covenant Description	4.25 to 1.00

Debt (Issuance of 2018 Senior N

Debt (Issuance of 2018 Senior Notes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Apr. 09, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Long-term debt	$ 13,161.2		$ 12,865.3
Senior Notes [Member] | 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.55%
Long-term debt		$ 750
Debt Instrument, Basis Spread on Variable Rate	0.30%
Senior Notes [Member] | 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.20%
Long-term debt		$ 750
Debt Instrument, Basis Spread on Variable Rate	0.35%
Senior Notes [Member] | April 2018 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,500

Debt (Senior Notes) (Details)

Debt (Senior Notes) (Details) € in Millions, $ in Millions

Jun. 15, 2018USD ($)

Apr. 28, 2018USD ($)

Dec. 31, 2018USD ($)

May 23, 2018USD ($)

Apr. 09, 2018USD ($)

Dec. 31, 2017USD ($)

May 24, 2017EUR (€)

Nov. 22, 2016

Jun. 09, 2016

Dec. 09, 2015

Nov. 13, 2013

Jun. 18, 2013

Debt Instrument [Line Items]

Long-term debt

$ 13,161.2

$ 12,865.3

Long-term Debt, Gross

$ 13,913

2018 Senior Notes (2.600%)

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

2.60%

2018 Senior Notes (3.000% coupon)

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

3.00%

2019 Senior Notes (2.500%)

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

2.50%

Senior Notes | 2018 Senior Notes (2.600%)

Debt Instrument [Line Items]

Repayments of Debt

$ 650

Senior Notes | 2020 Floating Rate Euro Notes [Domain]

Debt Instrument [Line Items]

Long-term Debt, Gross | €

€ 500

Debt Instrument, Basis Spread on Variable Rate

0.17%

Long-term debt

$ 573.3

600.2

Senior Notes | 2020 Floating Rate Euro Notes [Domain] | Minimum

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate

0.00%

Senior Notes | 2020 Euro Senior Notes

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

1.25%

Long-term debt

$ 858.1

897.6

Senior Notes | 2024 Euro Senior Notes

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

2.25%

Long-term debt

1,144.2

1,197.7

Senior Notes | 2028 Euro Senior Notes

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

3.125%

Long-term debt

852.5

892

Senior Notes | 2018 Senior Notes (3.000% coupon)

Debt Instrument [Line Items]

Repayments of Debt

500

Senior Notes | 2019 Senior Notes (2.550%)

Debt Instrument [Line Items]

Repayments of Debt

$ 150

350

Debt Instrument, Face Amount

$ 500

Debt instrument, interest rate, stated percentage

2.55%

Long-term debt

0

499.7

Senior Notes | 2019 Senior Notes (2.500%)

Debt Instrument [Line Items]

Repayments of Debt

450

Debt Instrument, Face Amount

$ 1,000

Long-term debt

$ 0

999.5

Senior Notes | 2028 Senior Notes [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

4.55%

Long-term debt

$ 750

Debt Instrument, Basis Spread on Variable Rate

0.30%

Long-term debt

$ 748.2

0

Senior Notes | 2048 Senior Notes [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

5.20%

Long-term debt

$ 750

Debt Instrument, Basis Spread on Variable Rate

0.35%

Long-term debt

$ 747.6

0

Senior Notes | 2025 Euro Senior Notes [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage

2.125%

Long-term debt

$ 500

Debt Instrument, Basis Spread on Variable Rate

0.30%

Long-term debt

$ 572

$ 0

EURIBOR [Member] | Senior Notes | 2020 Floating Rate Euro Notes [Domain]

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate

0.50%

EURIBOR [Member] | Senior Notes | 2018 Floating Rate Euro Notes

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate

0.87%

Debt (Fair Value) (Narrative) (

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Billions	Dec. 31, 2018	Dec. 31, 2017
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt	$ 13.1	$ 14.9

Debt (Minimum Repayments on Out

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Dec. 31, 2018USD ($)
Debt Disclosure [Abstract]
2,019	$ 650
2,020	1,933
2,021	2,250
2,022	0
2,023	1,250
Thereafter	7,830
Total	$ 13,913

Comprehensive Earnings (Accumul

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total equity	$ 12,167.1		$ 13,307.6	$ 11,117.6	$ 9,765.8
Net unrealized gain on marketable securities, net of tax	0		10.1
Net unrecognized gains and prior service cost related to defined benefit plans, net of tax	1.7		6
Foreign currency translation adjustment	(1,259)		(133.8)
Accumulated other comprehensive loss	(1,441.3)		(361.2)
AOCI Attributable to Parent [Member]
Total equity	(1,441.3)	$ (368.7)	(361.2)	(2,263.7)	(1,764.3)
Accumulated other comprehensive loss				(2,263.7)	(1,764.3)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax				(38.6)	(18.1)
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax	(53.1)		(3.7)
Net Investment Hedging
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	$ (130.9)		$ (239.8)	$ (1.4)	$ 0

Comprehensive Earnings (Compone

Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	$ 12,167.1	$ 13,307.6	$ 11,117.6		$ 9,765.8
Net unrealized gains on marketable securities, net of tax, beginning of period	10.1
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period	6
Foreign currency translation adjustment, beginning of period	(133.8)
Accumulated other comprehensive loss, net of tax, beginning of period	(361.2)
Other comprehensive (loss) earnings before reclassifications, before tax	(0.1)
Net sales	11,268.7	11,760	10,967.1
Interest expense	(542.3)	(534.6)	(454.8)
Amortization of prior service costs included in SG&A			0
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax related to items of other comprehensive (loss) earnings, derivatives	54.1	(207)	358.3
Net unrealized gains on marketable securities, net of tax, end of period	0	10.1
Net unrealized gains on marketable securities, net of tax, end of period	1.7	6
Foreign currency translation adjustment, end of period	(1,259)	(133.8)
Accumulated other comprehensive loss, net of tax, end of period	(1,441.3)	(361.2)
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	3.8	(3.8)	(21.4)
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Income tax (benefit) provision	(24.1)	12.8	5
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	0
Cumulative Effect of New Accounting Principle in Period of Adoption	(10)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(38.6)	(18.1)
Other comprehensive (loss) earnings before reclassifications, before tax			(84.2)
Income tax related to items of other comprehensive (loss) earnings, derivatives		(17.8)
Net unrecognized gains (losses) on derivatives, net of tax, end of period			(38.6)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales			44.3
Interest expense			8.7
Income tax related to items of other comprehensive (loss) earnings, derivatives			(10.7)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.2)	(1.1)	(44.3)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(7.7)	(7.3)	(8.7)
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gains on marketable securities, net of tax, beginning of period		14.5	(1)
Other comprehensive (loss) earnings before reclassifications, before tax		(6.7)	24.6
Net unrealized gains on marketable securities, net of tax, end of period			14.5
Net unrealized (loss) gain on marketable securities			24.6
Gains and Losses on Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives		2.3	9.1
Defined Pension Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period		(0.5)	(14.9)
Other comprehensive (loss) earnings before reclassifications, before tax	(3)	2.9	20
Net unrealized gains on marketable securities, net of tax, end of period			(0.5)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax			21.4
Defined Pension Plan Items | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.4)	0.2	0.3
Amortization of actuarial loss included in SG&A	(0.4)	0.7	1.1
Income tax related to items of other comprehensive (loss) earnings, derivatives	(0.5)	(2.7)	7
Cumulative Effect of New Accounting Principle in Period of Adoption	0
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period		(2,237.7)	(1,730.3)
Other comprehensive (loss) earnings before reclassifications, before tax	(1,125.2)	2,103.9	(507.4)
Income tax related to items of other comprehensive (loss) earnings, derivatives		0
Foreign currency translation adjustment, end of period			(2,237.7)
Foreign currency translation adjustment	(1,125.2)		(507.4)
Foreign Currency Translation Adjustment | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	0		0
Cumulative Effect of New Accounting Principle in Period of Adoption	0
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	(1,441.3)	(361.2)	(2,263.7)	$ (368.7)	(1,764.3)
Accumulated other comprehensive loss, net of tax, beginning of period		(2,263.7)	(1,764.3)
Other comprehensive (loss) earnings before reclassifications, before tax	(1,097.4)	1,908.2	(548.8)
Other comprehensive (loss) earnings, before tax		1,915.3	(494.4)
Accumulated other comprehensive loss, net of tax, end of period			(2,263.7)
Accumulated Other Comprehensive Loss | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.4)	0.2	0.3
Amortization of actuarial loss included in SG&A	(0.4)	0.7	1.1
Income tax (benefit) provision	(24.1)	12.8	5
Cumulative Effect of New Accounting Principle in Period of Adoption	(7.5)
Accumulated Other Comprehensive Loss | Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.2)	(1.1)	44.3
Accumulated Other Comprehensive Loss | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(7.7)	(7.3)	8.7
Cash Flow Hedging [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	(79.2)	52.7	(31.2)
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period	(3.7)
Other comprehensive (loss) earnings before reclassifications, before tax	(80.7)	46.5
Income tax related to items of other comprehensive (loss) earnings, derivatives	27.3
Net unrecognized gains (losses) on derivatives, net of tax, end of period	(53.1)	(3.7)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	(79.2)		(31.2)
Cumulative Effect of New Accounting Principle in Period of Adoption	2.5
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(6.2)
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales		(1.1)
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(7.7)
Cash Flow Hedging [Member] | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense		(7.3)
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	(130.9)	(239.8)	(1.4)		$ 0
Other comprehensive (loss) earnings before reclassifications, before tax	111.6	(238.4)	(1.8)
Income tax related to items of other comprehensive (loss) earnings, derivatives	(2.7)	0	0.4
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	111.6	(238.4)	(1.8)
Cumulative Effect of New Accounting Principle in Period of Adoption	0
Mylan N.V.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	12,167.1	13,307.6
Net sales	0	0	0
Interest expense	(349)	(378)	(198.4)
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax related to items of other comprehensive (loss) earnings, derivatives	28.7	21.1	19.5
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	3.8	(3.8)	(21.4)
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Income tax (benefit) provision	(24.1)	12.8	5
Mylan N.V. | Cash Flow Hedging [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	(79.2)	52.7	(31.2)
Mylan N.V. | Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	$ 111.6	$ (238.4)	$ (1.8)

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries		$ 1,800
Statutory tax rate		19.00%	19.00%	20.00%
Valuation allowance, amount		$ 806	$ 662.8
Unrecognized tax benefit		96.3	185.7	$ 190.9		$ 174.1
Unrecognized tax benefits that impact effective tax rate		96.3	138.4
Accrued interest and penalties		72.6	$ 90.9
Interest expense (income) related to uncertain tax positions		(18.3)		$ 11.1	$ 6.9
Amount of unrecognized deferred tax liability		$ 40
Deduction limit of GILTI tax		50.00%
Net tax provision due to enactment of the Tax Cuts and Jobs Act		$ 128.6
Expense on remeasurement of deferred taxes under Tax Act 2017		15
Transition tax expense recognized on enactment of U.S. Tax Act 2017		99.1
Amount of transition tax adjustment during period		14.5
U.S. Federal Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards		0
U.S. State Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards		2,800
Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		1,700
Capital loss carryforward		73.4
Credit carryforward		211
Indefinite | Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		1,390
2016 through 2035 | Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards		300
foreign deductible attributes - carried-forward indefinitely		71
Jai Pharma Limited
Income Tax Contingency [Line Items]
Amount of goodwill expected to be tax deductible		150
Scenario, Forecast
Income Tax Contingency [Line Items]
Deduction limit of GILTI tax	37.50%
Previously Reported
Income Tax Contingency [Line Items]
Transition tax expense recognized on enactment of U.S. Tax Act 2017		$ 113.6

Income Taxes (Schedule of Compo

Income Taxes (Schedule of Components of Income Tax Provision) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Contingency [Line Items]
Income tax provision	$ (54.1)	$ 207	$ (358.3)
Earnings (loss) before income taxes and noncontrolling interest:
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	298.4	903	121.7
Foreign Tax Authority
Income Tax Contingency [Line Items]
U.S. Federal Current	(68.2)	39.5	86.8
U.S. Federal Deferred	(112.9)	28.2	(303.8)
Income tax provision (benefit), U.S. Federal	(181.1)	67.7	(217)
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, United States	(1,000.5)	(414.5)	(187.4)
U.S. State Tax Authority
Income Tax Contingency [Line Items]
U.S. State Current	6.8	3.9	13.8
U.S. State Deferred	(12.3)	(0.6)	(14.8)
Income tax provision (benefit), U.S. State	(5.5)	3.3	(1)
Non-U.S. state tax authority
Income Tax Contingency [Line Items]
Non-U.S. Current	271.6	275	150.6
Non-U.S. Deferred	(139.1)	(139)	(290.9)
Income tax provision (benefit), Non-U.S.	132.5	136	(140.3)
Domestic Tax Authority
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, foreign	1,259.8	89.7	(129.4)
Other Foreign Operations
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, foreign	$ 39.1	$ 1,227.8	$ 438.5

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Deferred tax assets, employee benefits	$ 184.8	$ 215
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies	15.7	45.3
Deferred tax assets, accounts receivable allowances	217.7	251.7
Deferred tax assets, tax credits and loss carryforwards	891.4	849.9
Deferred Tax Assets, Deferred tax expense, interest expense	373.5	151.7
Deferred tax assets, intangible assets and goodwill	104.1	114.9
Deferred tax assets, other	182.4	212.4
Total deferred tax assets, gross	1,969.6	1,840.9
Valuation allowance	(806)	(662.8)
Total deferred tax assets	1,163.6	1,178.1
Deferred tax liabilities:
Deferred tax liabilities, plant and equipment	105.6	120.7
Deferred tax liabilities, intangible assets	2,189.2	2,538.2
Deferred tax liabilities, other	18.7	34.8
Total deferred tax liabilities	2,313.5	2,693.7
Deferred tax assets (liabilities), net	$ (1,149.9)	$ (1,515.6)

Income Taxes (Statutory Tax Rat

Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Contingency [Line Items]
Statutory tax rate	19.00%	19.00%	20.00%
Effective tax rate	(18.10%)	22.90%	(294.40%)
United States
Income Tax Contingency [Line Items]
Clean energy and research credits	(33.10%)	(10.10%)	(85.90%)
Rate differential	(5.40%)	7.40%	(36.90%)
Other	7.50%	0.20%	1.30%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent	(4.90%)	8.40%	0.00%
Uncertain tax positions	(22.50%)	1.00%	2.20%
State income taxes and credits	(3.20%)	(0.60%)	(8.10%)
Valuation allowance	54.20%	10.30%	4.40%
LUXEMBOURG
Income Tax Contingency [Line Items]
Other Foreign Operations	(28.30%)	(10.10%)	(52.60%)
Luxembourg U.S. Branch
Income Tax Contingency [Line Items]
Other Foreign Operations	0.00%	0.00%	(28.80%)
GIBRALTAR
Income Tax Contingency [Line Items]
Other Foreign Operations	(19.20%)	(6.50%)	(49.20%)
India
Income Tax Contingency [Line Items]
Other Foreign Operations	(0.60%)	(0.50%)	(13.00%)
IRELAND
Income Tax Contingency [Line Items]
Other Foreign Operations	(3.50%)	(1.40%)	(7.20%)
Other foreign
Income Tax Contingency [Line Items]
Other Foreign Operations	9.00%	2.70%	2.00%
Other Foreign Operations
Income Tax Contingency [Line Items]
Other	9.70%	0.50%	(8.10%)
Uncertain tax positions	(5.20%)	(2.60%)	(5.20%)
Valuation allowance	(4.30%)	3.90%	79.90%
Merger of foreign subsidiaries	0.00%	0.00%	(123.50%)

Income Taxes (Schedule of Unrec

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Unrecognized tax benefit — beginning of year	$ 96.3	$ 190.9		$ 185.7	$ 174.1
Additions for current year tax positions	0	4.4	$ 2.1
Additions for prior year tax positions	20	5.5	0
Reductions for prior year tax positions	(5.8)	(0.8)	(1.8)
Settlements	(32.9)	(0.4)	0
Reductions due to expirations of statute of limitations	(70.7)	(13.9)	(7.7)
Addition due to acquisition	0	0	$ 24.2
Unrecognized tax benefit — end of year	$ 96.3	$ 190.9

Share-Based Incentive Plan (Nar

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reduction in Share-based Compensation Expense	$ 70.6
Accrued Bonuses	$ 20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,815,278	7,198,684	2,600,000	7,699,441	7,732,499
Restricted stock | Vest ratably in five years or less [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	3 years
Number of restricted stock awards, granted	757,433
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards, granted	1,542,727
Performance Shares | Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	3 years
Number of restricted stock awards, granted	668,878
Long Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares reserved for issuance to employees	55,300,000
Total unrecognized compensation expense, net of estimated forfeitures	$ 80.6
Weighted-average period over which total unrecognized compensation expense expected to be recognized (years)	1 year 6 months 13 days
Intrinsic value of stock-based awards exercised and restricted stock units converted	$ 46.3	$ 39.1
Long Term Incentive Plan 2003 | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years	10 years
Average remaining contractual term for options outstanding, in years	5 years 3 months 12 days
Average remaining contractual term for options vested and expected to vest, in years	5 years 2 months 5 days
Average remaining contractual term for options exercisable, in years	4 years 2 months 12 days
Aggregate intrinsic value for options outstanding	$ 15.9
Long Term Incentive Plan 2003 | Minimum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	3 years
Long Term Incentive Plan 2003 | Maximum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	4 years
2014 Program | Stock appreciation rights and performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	5 years
Not Subject to Market Conditions [Member] | Performance Shares | Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years	1 year
Number of restricted stock awards, granted	116,416

Share-Based Incentive Plan (Sto

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares under stock awards, outstanding at beginning of period	7,198,684	7,699,441	7,732,499
Weightedaverage exercise price per share, outstanding at beginning of period	$ 35.17	$ 33.38	$ 31.85
Number of shares under stock awards, granted	905,265	964,475	876,397
Weighted average exercise price per share, granted	$ 40.38	$ 42.48	$ 45.51
Number of shares under stock awards, exercised	(820,603)	(902,041)	(612,477)
Weighted average exercise price per share, exercised	$ 21.75	$ 20.06	$ 23.13
Number of shares under stock awards, forfeited	(468,068)	(563,191)	(296,978)
Weighted average exercise price per share, forfeited	$ 47.86	$ 47.36	$ 50.70
Number of shares under stock awards, outstanding at end of period	6,815,278	7,198,684	7,699,441
Weighted average exercise price per share, outstanding at end of period	$ 36.61	$ 35.17	$ 33.38
Number of shares under stock awards, vested and expected to vest at period end	6,603,247
Weighted average exercise price per share, vested and expected to vest at period end	$ 36.41
Number of shares under stock awards, exercisable at period end	5,134,445
Weighted average exercise price per share, exercisable at period end	$ 34.76

Share-Based Incentive Plan (Non

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted Stock Awards	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning balance | shares	5,964,207
Weighted average grant-date fair value per share, nonvested beginning balance | $ / shares	$ 41.92
Number of restricted stock awards, granted | shares	1,542,727
Weighted average grant-date fair value per share, granted | $ / shares	$ 41
Number of restricted stock awards, released | shares	(762,561)
Weighted average grant-date fair value per share, released | $ / shares	$ 49.11
Number of restricted stock awards, forfeited | shares	(351,292)
Weighted average grant-date fair value per share, forfeited | $ / shares	$ 43.70
Number of restricted stock awards, nonvested ending balance | shares	6,393,081
Weighted average grant-date fair value per share, nonvested ending balance | $ / shares	$ 40.75

Share-Based Incentive Plan (Val

Share-Based Incentive Plan (Valuation Assumptions) (Details) - Long Term Incentive Plan 2003 - Stock options - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	35.80%	33.20%	38.10%
Risk-free interest rate	2.80%	2.20%	1.40%
Expected term (years)	6 years 6 months	6 years 4 months 24 days	6 years 3 months 18 days
Forfeiture rate	5.50%	5.50%	5.50%
Weighted average grant date fair value per option	$ 16.51	$ 15.88	$ 17.90

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated other comprehensive income expected to be recognized as net periodic benefit costs	$ 0.9
Future unrecognized actuarial losses	$ 1
Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year	10.00%
Accumulated benefit obligation	$ 592.5	$ 598.5
Defined benefit plan, ultimate health care cost trend rate	7.50%
Defined benefit plan, ultimate health care cost trend rate, projected	5.00%
Total employer contributions	$ 85.2	95.9	$ 95.6
Multiemployer plans, withdrawal obligation	$ 15.1	$ 18.1		$ 27
Fiscal Year 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, ultimate health care cost trend rate	5.60%
Defined benefit plan, ultimate health care cost trend rate, projected	4.50%
Deferred Base Salary
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	50.00%
Deferred Bonus
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	100.00%

Employee Benefit Plans (Accumul

Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gains) losses	$ (10.3)	$ (8.6)
Unrecognized prior service costs	12.1	2
Total	1.8	(6.6)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gains) losses	1.1	2
Unrecognized prior service costs	0.7	0.7
Total	$ 1.8	$ 2.7

Employee Benefit Plans (Change

Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net change	$ (3.8)	$ 3.8	$ 21.4
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain)/loss	(2.1)
Amortization of actuarial (gain)/loss	(0.1)
Unrecognized prior service costs	(6.6)
Amortization of prior service costs	(0.4)
Impact of foreign currency translation	0.7
Net change	4.7
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain)/loss	(0.6)
Amortization of actuarial (gain)/loss	(0.3)
Unrecognized prior service costs	0
Amortization of prior service costs	0
Impact of foreign currency translation	0
Net change	$ (0.9)

Employee Benefit Plans (Net Per

Employee Benefit Plans (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost			$ 0.6
Interest cost			1.3
Expected return on plan assets			0
Plan curtailment, settlement and termination			0
Amortization of prior service costs included in SG&A			0
Recognized net actuarial losses			0.3
Net periodic benefit cost			2.2
Other Pension, Postretirement and Supplemental Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0.6	$ 0.7
Interest cost	1.5	1.6
Expected return on plan assets	0	0
Plan curtailment, settlement and termination	0	0
Amortization of prior service costs included in SG&A	0	0
Recognized net actuarial losses	0.2	0.4
Net periodic benefit cost	2.3	2.7
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	19.2	20.1	17.4
Interest cost	13	13.6	8.2
Expected return on plan assets	(14.4)	(14.3)	(10.9)
Plan curtailment, settlement and termination	(0.1)	(1.7)	(2.4)
Amortization of prior service costs included in SG&A	0.3	0.2	0.3
Recognized net actuarial losses	(0.1)	0.3	0.8
Net periodic benefit cost	17.9	18.2	$ 13.4
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0.7	0.7
Interest cost	$ 1.3	$ 1.6

Employee Benefit Plans (Changes

Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Projected benefit obligation, beginning of year
Service cost			$ 0.6
Interest cost			1.3
Change in Plan Assets
Fair value of plan assets, beginning of year	$ 296.1
Fair value of plan assets, end of year	283.5	$ 296.1
Pension Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	665.2	632.9
Service cost	19.2	20.1	17.4
Interest cost	13	13.6	8.2
Participant contributions	1	1
Transferred liabilities	16.1	0.5
Plan settlements and terminations	(7.6)	(28.4)
Actuarial losses (gains)	(27.4)	9.3
Benefits paid	(24.9)	(24.5)
Impact of foreign currency translation	(19.2)	40.7
Projected benefit obligation, end of year	635.4	665.2	632.9
Change in Plan Assets
Fair value of plan assets, beginning of year	296.1	291.7
Actual return on plan assets	(11)	21.7
Company contributions	28.9	31.5
Participant contributions	1	1
Plan settlements	(16.5)	(28)
Other	(1.6)	(0.4)
Impact of foreign currency translation	(4.6)	2.6
Fair value of plan assets, end of year	283.5	296.1	291.7
Funded status of plans	(351.9)	(369.1)
Other Postretirement Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	35.1	38
Service cost	0.7	0.7
Interest cost	1.3	1.6
Participant contributions	0.2	0.2
Transferred liabilities	0	0
Plan settlements and terminations	0	0
Actuarial losses (gains)	(0.6)	(2.7)
Benefits paid	(2.7)	(2.5)
Impact of foreign currency translation	0	(0.2)
Projected benefit obligation, end of year	34	35.1	38
Change in Plan Assets
Fair value of plan assets, beginning of year	0	0
Actual return on plan assets	0	0
Company contributions	2.5	2.3
Participant contributions	0.2	0.2
Plan settlements	0	0
Other	0	0
Impact of foreign currency translation	0	0
Fair value of plan assets, end of year	0	0	$ 0
Funded status of plans	$ (34)	$ (35.1)

Employee Benefit Plans (Net Acc

Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	$ 5.9	$ 6
Current liabilities	(11.9)	(11.7)
Noncurrent liabilities	(345.9)	(363.4)
Net accrued benefit costs	(351.9)	(369.1)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	0	0
Current liabilities	(1.7)	(1.6)
Noncurrent liabilities	(32.3)	(33.5)
Net accrued benefit costs	$ (34)	$ (35.1)

Employee Benefit Plans (Plans w

Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) - Pension Benefits - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 502.9	$ 530.1
Accumulated benefit obligation	483.1	506
Fair value of plan assets	$ 154.8	$ 164.8

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Values of Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 283.5	$ 296.1
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3.9	2.8
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	124.5	137
Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	123.8	102.8
Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31.3	53.5
Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	127.5	123.3
Level 1 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3.5	2.5
Level 1 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	58.5	65.2
Level 1 | Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	65.4	45.2
Level 1 | Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.1	10.4
Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	132	153.6
Level 2 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.4	0.3
Level 2 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	66	71.8
Level 2 | Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	58.4	57.6
Level 2 | Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7.2	23.9
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24	19.2
Level 3 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 24	$ 19.2

Employee Benefit Plans (Weighte

Employee Benefit Plans (Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	2.30%			2.00%
Expected return on plan assets	4.90%			4.90%
Rate of compensation increase	2.90%			2.80%
Discount rate	2.00%	2.20%	2.10%
Expected return on plan assets	4.90%	5.00%	4.90%
Rate of compensation increase	2.90%	2.80%	3.20%
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.30%			3.70%
Expected return on plan assets	0.00%			0.00%
Rate of compensation increase	0.00%			0.00%
Discount rate	3.70%	4.20%	4.20%
Expected return on plan assets	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%

Employee Benefit Plans (Effect

Employee Benefit Plans (Effect of One Percentage Point Increase or Decrease in Health Care Cost Trend Rates) (Details) - Pension Benefits $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Increase in the benefit obligation	$ 1.2
Decrease in the benefit obligation	(1)
Increase in the aggregate of service and interest cost components of annual expense	0.1
Decrease in the aggregate of service and interest cost components of annual expense	$ (0.1)

Employee Benefit Plans (Estimat

Employee Benefit Plans (Estimated Future Benefit Payments) (Details) $ in Millions	Dec. 31, 2018USD ($)
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2,019	$ 32
2,020	34.2
2,021	35.7
2,022	34
2,023	36.4
Thereafter	192.1
Total	364.4
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2,019	1.7
2,020	1.7
2,021	2
2,022	2.3
2,023	2.2
Thereafter	11.6
Total	$ 21.5

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions		3 Months Ended	12 Months Ended
		Sep. 30, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Fair value loss (gain)	[1]		$ (35.3)	$ (59.3)
Operating Segments | Europe Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates			0
Operating Segments | Rest of World Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates			0
Contingent consideration
Segment Reporting Information [Line Items]
Fair value loss (gain)		$ 78.2
[1]	Included in litigation settlements and other contingencies, net in the Consolidated Statements of Operations.

Segment Information (Reconcilia

Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Revenues		$ 11,433.9	$ 11,907.7	$ 11,076.9
Net sales		11,268.7	11,760	10,967.1
Segment profitability		905.6	1,437.2	699.2
Gross Profit Less Selling General and Administrative Expense and Research and Development		3,619.9	4,152.6	4,014.1
Intangible asset amortization expense		1,606.4	1,437.4	1,195.3
Research and Development Expense		704.5	783.3	826.8
Gain (Loss) Related to Litigation Settlement		49.5	13.1	(672.5)
Corporate (Other)
Segment Reporting Information [Line Items]
Revenues		(536.9)	(566.2)	(559.3)
Segment profitability		0	0	0
Other revenue
Segment Reporting Information [Line Items]
Intangible asset amortization expense		(1,606.4)	(1,437.4)	(1,195.3)
IPR&D intangible asset impairment charges		(224)	(80.8)	(68.3)
Research and Development Expense		(250.3)	(356.4)	(423.7)
Corporate costs		(683.1)	(853.9)	(955.1)
Gain (Loss) Related to Litigation Settlement		49.5	13.1	(672.5)
Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	$ (536.9)		(566.2)	(559.3)
Net sales	0
North America Segment
Segment Reporting Information [Line Items]
Revenues	4,293.2		5,130.7	5,763.3
North America Segment | Operating Segments
Segment Reporting Information [Line Items]
Net sales		4,095.6	4,969.6	5,629.5
Segment profitability		1,838.4	2,497.1	2,921.2
North America Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues		112.4
North America Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues		85.2	74.6	45.4
Europe Segment
Segment Reporting Information [Line Items]
Revenues	4,292.2		4,107.2	3,072.7
Europe Segment | Operating Segments
Segment Reporting Information [Line Items]
Net sales		4,157.3	3,958.3	2,953.8
Segment profitability		1,089.5	1,082.8	669.4
Europe Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues		27.1
Europe Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues		107.8	112.4	106.3
Rest of World Segment
Segment Reporting Information [Line Items]
Revenues	$ 3,385.4		3,236	2,800.2
Rest of World Segment | Operating Segments
Segment Reporting Information [Line Items]
Net sales		3,015.8	2,832.1	2,383.8
Segment profitability		692	572.7	423.5
Rest of World Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues		25.7
Rest of World Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues		343.9	379.2	407.6
Other
Segment Reporting Information [Line Items]
Revenues		$ 165.2	147.7	109.8
Other | North America Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues			86.5	88.4
Other | Europe Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues			36.5	12.6
Other | Rest of World Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues			$ 24.7	$ 8.8

Segment Information (Third Part

Segment Information (Third Party Net Sales by Major Customers) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue, Major Customer [Line Items]
Concentration risk, percentage	10.00%
Third party net sales | McKesson Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	12.00%	13.00%	16.00%
Third party net sales | AmeriSourceBergen Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	8.00%	8.00%	14.00%
Third party net sales | Cardinal Health Inc
Revenue, Major Customer [Line Items]
Concentration risk, percentage	8.00%	10.00%	11.00%

Segment Information (Net Third

Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 11,268.7	$ 11,760	$ 10,967.1
Concentration risk, percentage	10.00%
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 3,865.2	4,683.7	5,385.6
India
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,164.8	1,082.6	985.8
The Netherlands
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	132.2	117.5	88.3
Other foreign
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 6,106.5	$ 5,876.2	$ 4,507.4

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015
Commitments [Abstract]
Operating Leases, Rent Expense, Net	$ 78.9	$ 83.8	$ 70.8

Commitments (Schedule of Operat

Commitments (Schedule of Operating Leases) (Details) $ in Millions	Dec. 31, 2018USD ($)
Commitments [Abstract]
2,019	$ 73.7
2,020	54.7
2,021	40.2
2,022	28.5
2,023	18.3
Thereafter	54.2
Total operating lease minimum commitments	$ 269.6

Subsidiary Guarantors (Narrativ

Subsidiary Guarantors (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Apr. 09, 2018	Dec. 31, 2017	Jun. 09, 2016	Dec. 09, 2015	Dec. 24, 2013	Nov. 13, 2013
Investments in subsidiaries	$ 0		$ 0
2023 Senior Notes (3.125% coupon) | Senior Notes
Debt instrument, interest rate, stated percentage						3.125%
2023 Senior Notes (4.200%) | Senior Notes
Debt instrument, interest rate, stated percentage							4.20%
2028 Senior Notes [Member] | Senior Notes
Debt instrument, interest rate, stated percentage		4.55%
2043 Senior Notes (5.400%) | Senior Notes
Debt instrument, interest rate, stated percentage				5.40%
2019 Senior Notes (2.500%)
Debt instrument, interest rate, stated percentage				2.50%
Senior Notes Two Thousand Twenty - 3.75 Percent [Member] | Senior Notes
Debt instrument, interest rate, stated percentage					3.75%
2021 Senior Notes (3.150%) | Senior Notes
Debt instrument, interest rate, stated percentage				3.15%
2026 Senior Notes (3.950%) | Senior Notes
Debt instrument, interest rate, stated percentage				3.95%
2046 Senior Notes (5.250%) | Senior Notes
Debt instrument, interest rate, stated percentage				5.25%
2048 Senior Notes [Member] | Senior Notes
Debt instrument, interest rate, stated percentage		5.20%
Mylan Inc.
Investments in subsidiaries	$ 13,129.5		13,683.3
Mylan Inc. | Previously Reported
Investments in subsidiaries			15,300
Mylan Inc. | Restatement Adjustment [Member]
Investments in subsidiaries			$ 13,680

Subsidiary Guarantors Condensed

Subsidiary Guarantors Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 388.1	$ 292.1
Accounts receivable, net	2,881	3,612.4
Inventories	2,580.2	2,542.7
Intercompany receivables	0	0
Prepaid expenses and other current assets	518.4	766.1
Total current assets	6,367.7	7,213.3
Property, plant and equipment, net	2,170.2	2,339.1
Investments in subsidiaries	0	0
Intercompany notes and interest receivable	0	0
Intangible assets, net	13,664.6	15,245.8
Goodwill	9,747.8	10,205.7	$ 9,231.9
Other assets	784.6	802.4
Total assets	32,734.9	35,806.3
Current and liabilities
Accounts payable	1,617	1,452.5
Short-term borrowings	1.9	46.5
Income taxes payable	121.5	112.9
Current portion of long-term debt and other long-term obligations	699.8	1,808.9
Intercompany payables	0	0
Other current liabilities	2,147.6	2,964.5
Total current liabilities	4,587.8	6,385.3
Long-term debt	13,161.2	12,865.3
Intercompany notes payable	0	0
Other long-term obligations	2,818.8	3,248.1
Total liabilities	20,567.8	22,498.7
Equity
Total equity	12,167.1	13,307.6	$ 11,117.6	$ 9,765.8
Total liabilities and equity	32,734.9	35,806.3
Eliminations
Current assets:
Cash and cash equivalents	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivables	(13,968.7)	(12,607.8)
Prepaid expenses and other current assets	0	0
Total current assets	(13,968.7)	(12,607.8)
Property, plant and equipment, net	0	0
Investments in subsidiaries	(32,125.4)	(33,419.8)
Intercompany notes and interest receivable	(19,539.8)	(20,280.1)
Intangible assets, net	0	0
Goodwill	0	0
Other assets	0	0
Total assets	(65,633.9)	(66,307.7)
Current and liabilities
Accounts payable	0	0
Short-term borrowings	0	0
Income taxes payable	0	0
Current portion of long-term debt and other long-term obligations	0	0
Intercompany payables	(13,968.7)	(12,607.8)
Other current liabilities	0	0
Total current liabilities	(13,968.7)	(12,607.8)
Long-term debt	0	0
Intercompany notes payable	(19,539.8)	(20,280.1)
Other long-term obligations	0	0
Total liabilities	(33,508.5)	(32,887.9)
Equity
Total equity	(32,125.4)	(33,419.8)
Total liabilities and equity	(65,633.9)	(66,307.7)
Mylan N.V.
Current assets:
Cash and cash equivalents	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivables	342.9	317.2
Prepaid expenses and other current assets	5.6	5.6
Total current assets	348.5	322.8
Property, plant and equipment, net	0	0
Investments in subsidiaries	18,995.9	19,736.5
Intercompany notes and interest receivable	6,287.4	7,822.6
Intangible assets, net	0	0
Goodwill	0	0
Other assets	0.3	4.9
Total assets	25,632.1	27,886.8
Current and liabilities
Accounts payable	0	0
Short-term borrowings	0	0
Income taxes payable	0	0
Current portion of long-term debt and other long-term obligations	649	1,097.8
Intercompany payables	1,618.8	664.7
Other current liabilities	21	35.5
Total current liabilities	2,288.8	1,798
Long-term debt	9,370.1	10,614.3
Intercompany notes payable	1,806.1	2,166.9
Other long-term obligations	0	0
Total liabilities	13,465	14,579.2
Equity
Total equity	12,167.1	13,307.6
Total liabilities and equity	25,632.1	27,886.8
Mylan Inc.
Current assets:
Cash and cash equivalents	18.2	0.2
Accounts receivable, net	24.3	1
Inventories	0	0
Intercompany receivables	518.7	462.1
Prepaid expenses and other current assets	71.3	171.1
Total current assets	632.5	634.4
Property, plant and equipment, net	259.7	294.1
Investments in subsidiaries	13,129.5	13,683.3
Intercompany notes and interest receivable	10,732.6	10,271.2
Intangible assets, net	0	0
Goodwill	17.1	17.1
Other assets	68.9	56.5
Total assets	24,840.3	24,956.6
Current and liabilities
Accounts payable	70.6	45.3
Short-term borrowings	0	0
Income taxes payable	0	0
Current portion of long-term debt and other long-term obligations	0.2	649.1
Intercompany payables	12,326.4	11,911.5
Other current liabilities	216	397
Total current liabilities	12,613.2	13,002.9
Long-term debt	3,786.2	2,244.5
Intercompany notes payable	3,094.2	3,312.7
Other long-term obligations	48.6	57.3
Total liabilities	19,542.2	18,617.4
Equity
Total equity	5,298.1	6,339.2
Total liabilities and equity	24,840.3	24,956.6
Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivables	0	0
Prepaid expenses and other current assets	0	0
Total current assets	0	0
Property, plant and equipment, net	0	0
Investments in subsidiaries	0	0
Intercompany notes and interest receivable	0	0
Intangible assets, net	0	0
Goodwill	0	0
Other assets	0	0
Total assets	0	0
Current and liabilities
Accounts payable	0	0
Short-term borrowings	0	0
Income taxes payable	0	0
Current portion of long-term debt and other long-term obligations	0	0
Intercompany payables	0	0
Other current liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Intercompany notes payable	0	0
Other long-term obligations	0	0
Total liabilities	0	0
Equity
Total equity	0	0
Total liabilities and equity	0	0
Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	369.9	291.9
Accounts receivable, net	2,856.7	3,611.4
Inventories	2,580.2	2,542.7
Intercompany receivables	13,107.1	11,828.5
Prepaid expenses and other current assets	441.5	589.4
Total current assets	19,355.4	18,863.9
Property, plant and equipment, net	1,910.5	2,045
Investments in subsidiaries	0	0
Intercompany notes and interest receivable	2,519.8	2,186.3
Intangible assets, net	13,664.6	15,245.8
Goodwill	9,730.7	10,188.6
Other assets	715.4	741
Total assets	47,896.4	49,270.6
Current and liabilities
Accounts payable	1,546.4	1,407.2
Short-term borrowings	1.9	46.5
Income taxes payable	121.5	112.9
Current portion of long-term debt and other long-term obligations	50.6	62
Intercompany payables	23.5	31.6
Other current liabilities	1,910.6	2,532
Total current liabilities	3,654.5	4,192.2
Long-term debt	4.9	6.5
Intercompany notes payable	14,639.5	14,800.5
Other long-term obligations	2,770.2	3,190.8
Total liabilities	21,069.1	22,190
Equity
Total equity	26,827.3	27,080.6
Total liabilities and equity	$ 47,896.4	$ 49,270.6

Subsidiary Guarantors Condens_2

Subsidiary Guarantors Condensed Consolidating Statement of Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Condensed Income Statements, Captions [Line Items]
Net sales	$ 11,268.7	$ 11,760	$ 10,967.1
Total revenues	11,433.9	11,907.7	11,076.9
Cost of sales	7,432.3	7,124.6	6,379.9
Gross profit	4,001.6	4,783.1	4,697
Research and development	704.5	783.3	826.8
Selling, general and administrative	2,441	2,575.7	2,498.5
Litigation settlements and other contingencies, net	(49.5)	(13.1)	672.5
Total operating expenses	3,096	3,345.9	3,997.8
Earnings from operations	905.6	1,437.2	699.2
Interest expense	542.3	534.6	454.8
Other expense (income), net	64.9	(0.4)	122.7
Earnings before income taxes and noncontrolling interest	298.4	903	121.7
Income tax (benefit) provision	(54.1)	207	(358.3)
Earnings of equity interest subsidiaries	0	0	0
Net earnings	352.5	696	480
Other
Condensed Income Statements, Captions [Line Items]
Total revenues	165.2	147.7	109.8
Eliminations
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0
Total revenues	0	0	0
Cost of sales	0	0	0
Gross profit	0	0	0
Research and development	0	0	0
Selling, general and administrative	0	0	0
Litigation settlements and other contingencies, net	0	0	0
Total operating expenses	0	0	0
Earnings from operations	0	0	0
Interest expense	0	0	0
Other expense (income), net	0	0	0
Earnings before income taxes and noncontrolling interest	0	0	0
Income tax (benefit) provision	0	0	0
Earnings of equity interest subsidiaries	(725.9)	(1,499.9)	(2,035.1)
Net earnings	(725.9)	(1,499.9)	(2,035.1)
Eliminations | Other
Condensed Income Statements, Captions [Line Items]
Total revenues	0	0	0
Mylan N.V.
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0
Total revenues	0	0	0
Cost of sales	0	0	0
Gross profit	0	0	0
Research and development	0	0	0
Selling, general and administrative	40.7	45.5	71.6
Litigation settlements and other contingencies, net	0	0	0
Total operating expenses	40.7	45.5	71.6
Earnings from operations	(40.7)	(45.5)	(71.6)
Interest expense	349	378	198.4
Other expense (income), net	(316.4)	(484.9)	(55.6)
Earnings before income taxes and noncontrolling interest	(73.3)	61.4	(214.4)
Income tax (benefit) provision	(28.7)	(21.1)	(19.5)
Earnings of equity interest subsidiaries	397.1	613.5	674.9
Net earnings	352.5	696	480
Mylan N.V. | Other
Condensed Income Statements, Captions [Line Items]
Total revenues	0	0	0
Mylan Inc.
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0
Total revenues	0	0	0
Cost of sales	0	0	0
Gross profit	0	0	0
Research and development	0	0	0
Selling, general and administrative	517.3	650.9	664.1
Litigation settlements and other contingencies, net	7.1	17	0
Total operating expenses	524.4	667.9	664.1
Earnings from operations	(524.4)	(667.9)	(664.1)
Interest expense	154.6	104.1	161.3
Other expense (income), net	(273.3)	(264.6)	(193.2)
Earnings before income taxes and noncontrolling interest	(405.7)	(507.4)	(632.2)
Income tax (benefit) provision	(27.4)	(14)	(18.2)
Earnings of equity interest subsidiaries	328.8	886.4	1,360.2
Net earnings	(49.5)	393	746.2
Mylan Inc. | Other
Condensed Income Statements, Captions [Line Items]
Total revenues	0	0	0
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0
Total revenues	0	0	0
Cost of sales	0	0	0
Gross profit	0	0	0
Research and development	0	0	0
Selling, general and administrative	0	0	0
Litigation settlements and other contingencies, net	0	0	0
Total operating expenses	0	0	0
Earnings from operations	0	0	0
Interest expense	0	0	0
Other expense (income), net	0	0	0
Earnings before income taxes and noncontrolling interest	0	0	0
Income tax (benefit) provision	0	0	0
Earnings of equity interest subsidiaries	0	0	0
Net earnings	0	0	0
Guarantor Subsidiaries | Other
Condensed Income Statements, Captions [Line Items]
Total revenues	0	0	0
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net sales	11,268.7	11,760	10,967.1
Total revenues	11,433.9	11,907.7	11,076.9
Cost of sales	7,432.3	7,124.6	6,379.9
Gross profit	4,001.6	4,783.1	4,697
Research and development	704.5	783.3	826.8
Selling, general and administrative	1,883	1,879.3	1,762.8
Litigation settlements and other contingencies, net	(56.6)	(30.1)	672.5
Total operating expenses	2,530.9	2,632.5	3,262.1
Earnings from operations	1,470.7	2,150.6	1,434.9
Interest expense	38.7	52.5	95.1
Other expense (income), net	654.6	749.1	371.5
Earnings before income taxes and noncontrolling interest	777.4	1,349	968.3
Income tax (benefit) provision	2	242.1	(320.6)
Earnings of equity interest subsidiaries	0	0	0
Net earnings	775.4	1,106.9	1,288.9
Non-Guarantor Subsidiaries | Other
Condensed Income Statements, Captions [Line Items]
Total revenues	$ 165.2	$ 147.7	$ 109.8

Subsidiary Guarantors Condens_3

Subsidiary Guarantors Condensed Statement of Comprehensive Earnings (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Condensed Statement of Income Captions [Line Items]
Net earnings	$ 352.5	$ 696	$ 480
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(3.8)	3.8	21.4
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax (benefit) provision	(24.1)	12.8	5
Other comprehensive (loss) earnings, net of tax	(1,072.6)	1,902.5	(499.4)
Comprehensive earnings	(720.1)	2,598.5	(19.4)
Eliminations
Condensed Statement of Income Captions [Line Items]
Net earnings	(725.9)	(1,499.9)	(2,035.1)
Foreign currency translation adjustment	1,125.2	(2,103.9)	507.4
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	3.8	(3.8)	(21.4)
Net unrealized (loss) gain on marketable securities	0.1	6.7	(24.6)
Other comprehensive (loss) earnings, before tax	1,196.7	(2,153.7)	494.4
Income tax (benefit) provision	24.1	(12.8)	5
Other comprehensive (loss) earnings, net of tax	1,172.6	(2,140.9)	489.4
Comprehensive earnings	446.7	(3,640.8)	(1,545.7)
Mylan N.V.
Condensed Statement of Income Captions [Line Items]
Net earnings	352.5	696	480
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(3.8)	3.8	21.4
Net unrealized (loss) gain on marketable securities	(0.1)	(6.7)	24.6
Other comprehensive (loss) earnings, before tax	(1,096.7)	1,915.3	(494.4)
Income tax (benefit) provision	(24.1)	12.8	5
Other comprehensive (loss) earnings, net of tax	(1,072.6)	1,902.5	(499.4)
Comprehensive earnings	(720.1)	2,598.5	(19.4)
Mylan Inc.
Condensed Statement of Income Captions [Line Items]
Net earnings	(49.5)	393	746.2
Foreign currency translation adjustment	0	0	0
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	0.6	3	(1.1)
Net unrealized (loss) gain on marketable securities	0	(6.4)	24.6
Other comprehensive (loss) earnings, before tax	19.9	3.9	(24.2)
Income tax (benefit) provision	(4.7)	(1.6)	(9.1)
Other comprehensive (loss) earnings, net of tax	24.6	5.5	(15.1)
Comprehensive earnings	(24.9)	398.5	731.1
Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net earnings	0	0	0
Foreign currency translation adjustment	0	0	0
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	0	0	0
Net unrealized (loss) gain on marketable securities	0	0	0
Other comprehensive (loss) earnings, before tax	0	0	0
Income tax (benefit) provision	0	0	0
Other comprehensive (loss) earnings, net of tax	0	0	0
Comprehensive earnings	0	0	0
Non-Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net earnings	775.4	1,106.9	1,288.9
Foreign currency translation adjustment	(1,125.2)	2,103.9	(507.4)
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(4.4)	0.8	22.5
Net unrealized (loss) gain on marketable securities	(0.1)	(0.3)	0
Other comprehensive (loss) earnings, before tax	(1,216.6)	2,149.8	(470.2)
Income tax (benefit) provision	(19.4)	14.4	4.1
Other comprehensive (loss) earnings, net of tax	(1,197.2)	2,135.4	(474.3)
Comprehensive earnings	(421.8)	3,242.3	814.6
Cash Flow Hedging [Member]
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(79.2)	52.7	(31.2)
Cash Flow Hedging [Member] | Eliminations
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	79.2	(52.7)	31.2
Cash Flow Hedging [Member] | Mylan N.V.
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(79.2)	52.7	(31.2)
Cash Flow Hedging [Member] | Mylan Inc.
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	7.7	7.3	(47.7)
Cash Flow Hedging [Member] | Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	0	0	0
Cash Flow Hedging [Member] | Non-Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(86.9)	45.4	16.5
Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	111.6	(238.4)	(1.8)
Net Investment Hedging | Eliminations
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	(11.6)	0	1.8
Net Investment Hedging | Mylan N.V.
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	111.6	(238.4)	(1.8)
Net Investment Hedging | Mylan Inc.
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	11.6	0	0
Net Investment Hedging | Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships		0	0
Net Investment Hedging | Non-Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives in cash flow hedging relationships	$ 0	$ 0	$ (1.8)

Subsidiary Guarantors Condens_4

Subsidiary Guarantors Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	Aug. 05, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net cash provided by operating activities		$ 2,341.7	$ 2,064.8	$ 2,047.2
Cash flows from investing activities:
Capital expenditures		(252.1)	(275.9)	(390.4)
Cash paid for acquisitions, net		(65.9)	(167)	(6,481.9)
Proceeds from sale of assets and subsidiaries		29.3	86.7	0
Payments for non designated derivative instrument, investing activities		0	0	(128.6)
Cash paid for Meda's unconditional deferred payment	$ (308)	0	0	(308)
Purchase of marketable securities		(63.4)	(96.5)	(30.2)
Proceeds from sale of marketable securities		85.2	96.6	21.5
Payments to Acquire Other Investments		0	0	0
Payments to Acquire Notes Receivable		0	0	0
Proceeds from Dividends Received		0	0	0
Repayment of Notes Receivable from Related Parties		0	0	0
Payments for (Proceeds from) Other Investing Activities		(943.5)	(620.3)	(360.2)
Net cash used in investing activities		(1,210.4)	(976.4)	(7,677.8)
Cash flows from financing activities:
Payment of financing fees		(21.4)	(10.1)	(112.6)
Payments for Repurchase of Common Stock		(432)	(500.2)	0
Change in short-term borrowings, net		(44.4)	(2.9)	40.8
Proceeds from convertible note hedge				(35.5)
Proceeds from Issuance of Long-term Debt		2,577.9	876.1	11,752.2
Repayments of Long-term Debt		(3,165.2)	(2,232.7)	(6,296.3)
Proceeds from exercise of stock options		17.8	17.8	13.8
Taxes paid related to net share settlement of equity awards		(10.1)	(7.4)	(17.5)
Contingent consideration payments		(11.9)	(26.1)	(35.5)
Proceeds from Contributed Capital		0	0	0
Capital payments to affiliates		0	0	0
Payments on borrowings from affiliates		0	0	0
Repayments of Related Party Debt		0	0	0
Other items, net		(1)	(0.1)	0.8
Acquisition of noncontrolling interest		(0.6)	(7.5)	(1.1)
Net cash (used in) provided by financing activities		(1,090.9)	(1,893.1)	5,344.6
Effect on cash of changes in exchange rates		(21)	27.6	(9.6)
Net increase (decrease) in cash, cash equivalents and restricted cash		19.4	(777.1)	(295.6)
Cash, cash equivalents and restricted cash — beginning of period		369.9	1,147	1,442.6
Cash, cash equivalents and restricted cash — end of period		389.3	369.9	1,147
Contingent consideration			4	16
Ordinary shares issued for acquisition		0	0	1,281.7
Eliminations
Cash flows from operating activities:
Net cash provided by operating activities		0	0	0
Cash flows from investing activities:
Capital expenditures		0	0	0
Cash paid for acquisitions, net		0	0	0
Proceeds from sale of assets and subsidiaries		0	0
Payments for non designated derivative instrument, investing activities				0
Cash paid for Meda's unconditional deferred payment				0
Purchase of marketable securities		0	0	0
Proceeds from sale of marketable securities		0	0	0
Payments to Acquire Other Investments		28.8	30.2	49.6
Payments to Acquire Notes Receivable		6,180	3,914.4	17,788.7
Proceeds from Dividends Received		(118.6)	(261.3)	(135.6)
Repayment of Notes Receivable from Related Parties		(6,682.2)	(2,890)	(11,246.7)
Payments for (Proceeds from) Other Investing Activities		0	0	0
Net cash used in investing activities		(592)	793.3	6,456
Cash flows from financing activities:
Payment of financing fees		0	0	0
Payments for Repurchase of Common Stock		0	0
Change in short-term borrowings, net		0	0	0
Proceeds from convertible note hedge				0
Proceeds from Issuance of Long-term Debt		0	0	0
Repayments of Long-term Debt		0	0	0
Proceeds from exercise of stock options		0	0	0
Taxes paid related to net share settlement of equity awards		0	0	0
Contingent consideration payments		0	0
Proceeds from Contributed Capital		(28.8)	(30.2)	(49.6)
Capital payments to affiliates		118.6	261.3	135.6
Payments on borrowings from affiliates		6,682.2	2,890	(17,788.8)
Repayments of Related Party Debt		(6,180)	(3,914.4)	11,246.8
Other items, net		0	0	0
Acquisition of noncontrolling interest		0	0	0
Net cash (used in) provided by financing activities		592	(793.3)	(6,456)
Effect on cash of changes in exchange rates		0	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash		0	0	0
Cash, cash equivalents and restricted cash — beginning of period		0	0	0
Cash, cash equivalents and restricted cash — end of period		0	0	0
Contingent consideration			0	0
Ordinary shares issued for acquisition				0
Mylan N.V.
Cash flows from operating activities:
Net cash provided by operating activities		(230.4)	(326.6)	(0.3)
Cash flows from investing activities:
Capital expenditures		0	0	0
Cash paid for acquisitions, net		0	(71.6)	(5,608.8)
Proceeds from sale of assets and subsidiaries		0	0
Payments for non designated derivative instrument, investing activities				(128.6)
Cash paid for Meda's unconditional deferred payment				0
Purchase of marketable securities		0	0	0
Proceeds from sale of marketable securities		0	0	0
Payments to Acquire Other Investments		0	0	0
Payments to Acquire Notes Receivable		(492.2)	(322.7)	(14,073.5)
Proceeds from Dividends Received		118.6	261.3	135.6
Repayment of Notes Receivable from Related Parties		2,615.4	1,258.8	8,539.6
Payments for (Proceeds from) Other Investing Activities		0	0	0
Net cash used in investing activities		2,241.8	1,125.8	(11,135.7)
Cash flows from financing activities:
Payment of financing fees		(0.6)	(9.7)	(112.6)
Payments for Repurchase of Common Stock		(432)	(500.2)
Change in short-term borrowings, net		0	0	0
Proceeds from convertible note hedge				0
Proceeds from Issuance of Long-term Debt		496.5	874.5	11,652.6
Repayments of Long-term Debt		(2,012.5)	(1,820)	(400)
Proceeds from exercise of stock options		17.8	17.8	13.8
Taxes paid related to net share settlement of equity awards		(10.1)	(7.4)	(17.5)
Contingent consideration payments		0	0
Proceeds from Contributed Capital		0	0	0
Capital payments to affiliates		0	0	0
Payments on borrowings from affiliates		(1,454.2)	0	0
Repayments of Related Party Debt		1,383.7	645.5	0
Other items, net		0	0	0
Acquisition of noncontrolling interest		0	0	0
Net cash (used in) provided by financing activities		(2,011.4)	(799.5)	11,136.3
Effect on cash of changes in exchange rates		0	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash		0	(0.3)	0.3
Cash, cash equivalents and restricted cash — beginning of period		0	0.3	0
Cash, cash equivalents and restricted cash — end of period		0	0	0.3
Contingent consideration			0	0
Ordinary shares issued for acquisition				1,281.7
Mylan Inc.
Cash flows from operating activities:
Net cash provided by operating activities		(1,551.7)	(381.1)	(518.3)
Cash flows from investing activities:
Capital expenditures		(28.6)	(54.8)	(94.4)
Cash paid for acquisitions, net		0	0	(931.3)
Proceeds from sale of assets and subsidiaries		0	0
Payments for non designated derivative instrument, investing activities				0
Cash paid for Meda's unconditional deferred payment				0
Purchase of marketable securities		0	0	(4.3)
Proceeds from sale of marketable securities		36.3	0	0
Payments to Acquire Other Investments		(28.8)	(30.2)	(49.6)
Payments to Acquire Notes Receivable		0	(98)	(530.2)
Proceeds from Dividends Received		0	0	0
Repayment of Notes Receivable from Related Parties		0	0.3	793
Payments for (Proceeds from) Other Investing Activities		(0.5)	(0.9)	3.3
Net cash used in investing activities		(21.6)	(183.6)	(813.5)
Cash flows from financing activities:
Payment of financing fees		(20.8)	(0.4)	0
Payments for Repurchase of Common Stock		0	0
Change in short-term borrowings, net		0	0	0
Proceeds from convertible note hedge				0
Proceeds from Issuance of Long-term Debt		2,079.2	0	0
Repayments of Long-term Debt		(1,150)	0	(3,400)
Proceeds from exercise of stock options		0	0	0
Taxes paid related to net share settlement of equity awards		0	0	0
Contingent consideration payments		0	0
Proceeds from Contributed Capital		0	0	0
Capital payments to affiliates		0	0	0
Payments on borrowings from affiliates		(3,691.6)	(2,447.2)	6,961.2
Repayments of Related Party Debt		4,350.9	2,966.7	(3,021.9)
Other items, net		0	(16)	(16.2)
Acquisition of noncontrolling interest		0	0
Net cash (used in) provided by financing activities		1,567.7	503.1	523.1
Effect on cash of changes in exchange rates		0	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash		(5.6)	(61.6)	(808.7)
Cash, cash equivalents and restricted cash — beginning of period		23.8	85.4	894.1
Cash, cash equivalents and restricted cash — end of period		18.2	23.8	85.4
Contingent consideration			0	0
Ordinary shares issued for acquisition				0
Guarantor Subsidiaries
Cash flows from operating activities:
Net cash provided by operating activities		0	0	0
Cash flows from investing activities:
Capital expenditures		0	0	0
Cash paid for acquisitions, net		0	0	0
Proceeds from sale of assets and subsidiaries		0	0
Payments for non designated derivative instrument, investing activities				0
Cash paid for Meda's unconditional deferred payment				0
Purchase of marketable securities		0	0	0
Proceeds from sale of marketable securities		0	0	0
Payments to Acquire Other Investments		0	0	0
Payments to Acquire Notes Receivable		0	0	0
Proceeds from Dividends Received		0	0	0
Repayment of Notes Receivable from Related Parties		0	0	0
Payments for (Proceeds from) Other Investing Activities		0	0	0
Net cash used in investing activities		0	0	0
Cash flows from financing activities:
Payment of financing fees		0	0	0
Payments for Repurchase of Common Stock		0	0
Change in short-term borrowings, net		0	0	0
Proceeds from convertible note hedge				0
Proceeds from Issuance of Long-term Debt		0	0	0
Repayments of Long-term Debt		0	0	0
Proceeds from exercise of stock options		0	0	0
Taxes paid related to net share settlement of equity awards		0	0	0
Contingent consideration payments		0	0
Proceeds from Contributed Capital		0	0	0
Capital payments to affiliates		0	0	0
Payments on borrowings from affiliates		0	0	0
Repayments of Related Party Debt		0	0	0
Other items, net		0	0	0
Acquisition of noncontrolling interest		0	0	0
Net cash (used in) provided by financing activities		0	0	0
Effect on cash of changes in exchange rates		0	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash		0	0	0
Cash, cash equivalents and restricted cash — beginning of period		0	0	0
Cash, cash equivalents and restricted cash — end of period		0	0	0
Contingent consideration			0	0
Ordinary shares issued for acquisition				0
Non-Guarantor Subsidiaries
Cash flows from operating activities:
Net cash provided by operating activities		4,123.8	2,772.5	2,565.8
Cash flows from investing activities:
Capital expenditures		(223.5)	(221.1)	(296)
Cash paid for acquisitions, net		(65.9)	(95.4)	58.2
Proceeds from sale of assets and subsidiaries		29.3	86.7
Payments for non designated derivative instrument, investing activities				0
Cash paid for Meda's unconditional deferred payment				(308)
Purchase of marketable securities		(63.4)	(96.5)	(25.9)
Proceeds from sale of marketable securities		48.9	96.6	21.5
Payments to Acquire Other Investments		0	0	0
Payments to Acquire Notes Receivable		(5,687.8)	(3,493.7)	(3,185)
Proceeds from Dividends Received		0	0	0
Repayment of Notes Receivable from Related Parties		4,066.8	1,630.9	1,914.1
Payments for (Proceeds from) Other Investing Activities		(943)	(619.4)	(363.5)
Net cash used in investing activities		(2,838.6)	(2,711.9)	(2,184.6)
Cash flows from financing activities:
Payment of financing fees		0	0	0
Payments for Repurchase of Common Stock		0	0
Change in short-term borrowings, net		(44.4)	(2.9)	40.8
Proceeds from convertible note hedge				(35.5)
Proceeds from Issuance of Long-term Debt		2.2	1.6	99.6
Repayments of Long-term Debt		(2.7)	(412.7)	(2,496.3)
Proceeds from exercise of stock options		0	0	0
Taxes paid related to net share settlement of equity awards		0	0	0
Contingent consideration payments		(11.9)	(26.1)
Proceeds from Contributed Capital		28.8	30.2	49.6
Capital payments to affiliates		(118.6)	(261.3)	(135.6)
Payments on borrowings from affiliates		(1,536.4)	(442.8)	10,827.6
Repayments of Related Party Debt		445.4	302.2	(8,224.9)
Other items, net		(1)	15.9	17
Acquisition of noncontrolling interest		(0.6)	(7.5)	(1.1)
Net cash (used in) provided by financing activities		(1,239.2)	(803.4)	141.2
Effect on cash of changes in exchange rates		(21)	27.6	(9.6)
Net increase (decrease) in cash, cash equivalents and restricted cash		25	(715.2)	512.8
Cash, cash equivalents and restricted cash — beginning of period		346.1	1,061.3	548.5
Cash, cash equivalents and restricted cash — end of period		$ 371.1	346.1	1,061.3
Contingent consideration			$ 4	16
Ordinary shares issued for acquisition				$ 0

Subsidiary Guarantors Schedule

Subsidiary Guarantors Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	$ 388.1	$ 292.1
Restricted Cash	1.2	77.8
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	389.3	369.9	$ 1,147	$ 1,442.6
Mylan N.V.
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	0	0
Restricted Cash	0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	0	0	0.3	0
Mylan Inc.
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	18.2	0.2
Restricted Cash	0	23.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	18.2	23.8	85.4	894.1
Guarantor Subsidiaries
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	0	0
Restricted Cash	0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	0	0	0	0
Non-Guarantor Subsidiaries
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	369.9	291.9
Restricted Cash	1.2	54.2
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	371.1	346.1	1,061.3	548.5
Eliminations
Schedule of Cash, Cash Equivalents and Restricted Cash [Line Items]
Cash and cash equivalents	0	0
Restricted Cash	0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 0	$ 0	$ 0	$ 0

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring	$ (126.9)	$ (152.4)
Restructuring Reserve, Period Increase (Decrease)		0
Restructuring and Related Cost, Incurred Cost	(144.5)	(74.4)
Restructuring Reserve, Translation and Other Adjustment	(3.2)	5.6
Restructuring and Related Cost, Cost Incurred to Date	240.2	188	[1]
Restructuring Reserve	72.6	107		$ 140.2
Employee Severance
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring	(100.8)	(150)
Restructuring Reserve, Period Increase (Decrease)		(8.3)
Restructuring and Related Cost, Incurred Cost	0	0
Restructuring Reserve, Translation and Other Adjustment	(2.9)	5.2
Restructuring and Related Cost, Cost Incurred to Date	71.6	107.4	[1]
Restructuring Reserve	60.8	92.9		138.6
Other Restructuring
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring	(26.1)	(2.4)
Restructuring Reserve, Period Increase (Decrease)		8.3
Restructuring and Related Cost, Incurred Cost	(144.5)	(74.4)
Restructuring Reserve, Translation and Other Adjustment	(0.3)	0.4
Restructuring and Related Cost, Cost Incurred to Date	168.6	80.6	[1]
Restructuring Reserve	11.8	14.1		$ 1.6
North America Segment
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	129.1	48
Europe Segment
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	73.4	70.1
Rest of World Segment
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	16.2	36.5
Corporate (Other)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$ 21.5	$ 33.4
[1]	For the year ended December 31, 2018, total restructuring charges in North America, Europe, Rest of World and corporate were approximately $129.1 million, $73.4 million, $16.2 million and $21.5 million, respectively. For the year ended December 31, 2017, total restructuring charges in North America, Europe, Rest of World and corporate were approximately $48.0 million, $70.1 million, $36.5 million and $33.4 million respectively.

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Narrative) (Details) $ in Millions	Sep. 20, 2018USD ($)	Jan. 08, 2016USD ($)drugs	Jan. 30, 2015USD ($)	Feb. 12, 2013Product	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business Combination, Contingent Consideration, Liability					$ 355.3	$ 453.7	$ 564.6
Research and Development Expense					704.5	783.3	826.8
Momenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments					60
Number of drugs | drugs		6
Payments To Acquire Collaborative Agreement		$ 45
Research and Development Expense					13.4	$ 31.9	$ 29.2
Theravance Biopharma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments					30
FKB [Domain]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 10
Payments To Acquire Collaborative Agreement	$ 25
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments					425
Maximum | Theravance Biopharma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments			$ 220
Fiscal Year 2017 | Maximum | Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments					35
Generic Biologic Compounds Collaboration [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Insulin Analog Products | Product				3
Respiratory delivery platform [Member] | Fiscal Year 2017 | Maximum | Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments					60
Respiratory delivery platform [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business Combination, Contingent Consideration, Liability					$ 336.5

Litigation (Lorazepam and Clora

Litigation (Lorazepam and Clorazepate) (Narrative) (Details) - Lorazepam and Clorazepate $ in Millions	Aug. 30, 2017USD ($)	May 30, 2012USD ($)	Jun. 01, 2005USD ($)Insurer	Dec. 31, 2018
Loss Contingencies [Line Items]
Loss contingency accrual			$ 12
Damages awarded	$ 67
Other Current Liabilities [Table Text Block]				34.5
Health insurers
Loss Contingencies [Line Items]
Number of plaintiffs | Insurer			4
Bond
Loss Contingencies [Line Items]
Bond		$ 66.6

Litigation (Pricing and Medicai

Litigation (Pricing and Medicaid Litigation) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Payments for Legal Settlements	$ 472.7
Other current liabilities	2,147.6	$ 2,964.5
Pricing and Medicaid Litigation | Indemnification agreement | Mylan Specialty
Loss Contingencies [Line Items]
Other current liabilities	$ 65.7

Litigation (Modafinil Antitrust

Litigation (Modafinil Antitrust Litigation and FTC Inquiry) (Narrative) (Details) $ in Millions	Jul. 28, 2016	Jul. 10, 2015other_drug_manufacturers	Apr. 27, 2006other_drug_manufacturers	Dec. 31, 2016USD ($)	Dec. 31, 2018USD ($)
Loss Contingencies [Line Items]
Payments for Legal Settlements					$ 472.7
Modafinil Antitrust Litigation and FTC Inquiry
Loss Contingencies [Line Items]
Loss contingency accrual				$ 16	$ 16
Modafinil Antitrust Litigation and FTC Inquiry | Other drug manufacturers
Loss Contingencies [Line Items]
Number of defendants	4	3	4
Modafinil Antitrust Litigation Settlement
Loss Contingencies [Line Items]
Litigation Settlement, Amount (Deprecated 2017-01-31)				165
Payments for Legal Settlements				$ 89.2

Litigation (Medicare Drug Rebat

Litigation (Medicare Drug Rebate Program Settlement) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jun. 30, 2017
Other current liabilities
Loss Contingencies [Line Items]
Estimated Litigation Liability	$ 465	$ 10

Litigation (Drug Pricing Matter

Litigation (Drug Pricing Matters) (Details)	Dec. 14, 2016
Loss Contingencies [Line Items]
Number of states	20

Litigation (European Commission

Litigation (European Commission Proceedings) (Narrative) (Details) € in Millions, $ in Millions	Jul. 09, 2014EUR (€)	Jun. 19, 2013EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2018USD ($)
EU Commission Proceedings Perindorpril | Antitrust Proceedings | Mylan Laboratories Limited
Loss Contingencies [Line Items]
Loss contingency accrual	€ 17.2
EU Commission Proceedings Perindorpril | Antitrust Proceedings | Mylan
Loss Contingencies [Line Items]
Loss contingency accrual	€ 8		$ 21.7
EU Commission Proceedings Citalopram
Loss Contingencies [Line Items]
Damages awarded		€ 7.8
Loss contingency accrual | $				$ 7.4

Litigation (U.K. Competition an

Litigation (U.K. Competition and Markets Authority) (Narrative) (Details) - U.K. Competition and Markets Authority Proceedings Paroxetine £ in Millions	Feb. 12, 2016GBP (£)
Loss Contingencies [Line Items]
Damages awarded	£ 5.8
Mylan
Loss Contingencies [Line Items]
Damages awarded	£ 2.7

Litigation (Product Liability)

Litigation (Product Liability) (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Product Liability
Loss Contingencies [Line Items]
Loss contingency accrual	$ 10.9	$ 8.4

Litigation (Intellectual Proper

Litigation (Intellectual Property) (Narrative) (Details)	2 Months Ended	12 Months Ended
	Mar. 31, 2015patent	Dec. 31, 2018increase
Loss Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number | patent	3
Intellectual Property
Loss Contingencies [Line Items]
Number of times damages may be increased in cases of willful infringement | increase		3

Litigation (Other Litigation) (

Litigation (Other Litigation) (Narrative) (Details) $ in Millions	Jun. 30, 2017USD ($)
Other Foreign Operations
Loss Contingencies [Line Items]
Loss contingency accrual	$ 5.5

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance		$ 75.3	$ 59	$ 33.6
Additions Charged to Costs and Expenses		32.3	16.8	15.6
Additions Charged to Other Accounts	[1]	0.2	6	13
Deductions		(9.6)	(6.5)	(3.2)
Ending balance		98.2	75.3	59
Valuation allowance for deferred tax assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance		662.8	460.7	355.7
Additions Charged to Costs and Expenses		203.8	194.1	108.8
Additions Charged to Other Accounts	[1]	0	18.9	3.4
Deductions		(60.6)	(10.9)	(7.2)
Ending balance		$ 806	$ 662.8	$ 460.7
[1]	In 2016, this amount includes opening balances of businesses acquired in the period.